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Abstract 
   The work described in this thesis is an experimental study into the application 
of Electron Paramagnetic Resonance (EPR) Spectroscopy for the study of 
biological systems.  
   Using a variety of methods of site-directed spin-labelling (SDSL), this thesis 
aims to explore long range structure in an assortment of recombinant and native 
proteins, and complexes thereof. 
   The work described in this thesis covers all aspects of the work, from 
experimental design, molecular biology and cloning, protein expression and 
purification, as well as functional characterisation, and finally EPR distance 
measurements, data analysis and interpretation. Challenges and pitfalls will 
also be addressed. 
Chapters 1 and 2 introduce EPR spectroscopy, and its application in the study 
of long range structure in biological systems. The experimental techniques 
employed throughout this thesis are also introduced. 
Chapter 3 details an investigation into the complement C3b:factor H complex. 
This chapter addresses the challenges associated with the SDSL of cysteine 
rich proteins. Utilising hidden cysteine residues in native proteins for spin-
labelling purposes will also be addressed.  
Chapter 4 looks at the interactions of the human myosin regulatory light chain 
(RLC) with cardiac myosin binding protein C (cMyBP-C). Optimisation of 
expression and purification protocols will be the focus, as well as addressing 
issues with protein solubility and spin labelling efficiencies.  
Chapter 5 explores the development of new methods of SDSL, for the specific 
labelling of cysteine rich proteins. The ability of Escherichia coli to read through 
the amber stop codon will be exploited for the incorporation of unnatural amino 
acids for labelling purposes, and novel spin labels, specific for labelling cysteine 
pairs tested in several model systems. Furthermore, native paramagnetic 
centres in recombinant proteins will be explored as potential labelling sites.  
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Abbreviations 
A280                                                                                                               Absorbance at 280nm 
A412                                                                                                                                                                           Absorbance at 412nm 
AA                                                                                                                                  Amino Acid  
ADP                                                                                                         Adenosine Di-Phosphate 
AEC                                                                                           Anion Exchange Chromatography 
 aHUS                                                                               atypical Haemolytic Uraemic Syndrome 
Amp                                                                                                                                  Ampicillin 
AP                                                                                                                    Alternative Pathway 
AMD                                                                                        Age Related Macular Degeneration 
AOX                                                                                                                       Alcohol Oxidase 
ATP                                                                                                         Adenosine Tri-Phosphate  
BMG(Y)                                                       Buffered Minimal Glycerol (supplemented with yeast) 
BMM(Y)                                                          Buffered Minimal MeOH (supplemented with yeast) 
bp                                                                                                                                    base pairs 
BSA                                                                                                             Bovine Serum Albumin  
CaM                                                                                                                               Calmodulin 
C0                                                                                         (Myosin Binding Protein C) Domain 0  
CCP                                                                                                    Complement Control Protein 
CEC                                                                                          Cation Exchange Chromatography 
Cm                                                                                                                        Chloramphenicol 
CV                                                                                                                      Column Volume(s) 
CVFBb                                                                                    Cobra Venom Factor Bb convertase 
CW                                                                                                                      Continuous Wave 
DAB                                                                                                                  Di-amino Benzidine 
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ddH2O                                                                                                           double distilled Water 
ddNTP                                                                                  any deoxyribonucleotide triphosphate  
DEER                                                                                    Double Electron Electron Resonance  
DMSO                                                                                                               Di-methyl Sulfoxide 
DNA                                                                                                              Deoxyribonucleic Acid 
DTNB                                                                                         5,5’-dithiobis-(2-nitrobenzoic acid) 
DTT                                                                                                                             Dithiothreitol 
εACA                                                                                                             ε-Amino Caproic Acid 
E. coli                                                                                                                      Escherichia coli 
EDTA                                                                                            Ethylenediaminetetraacetic Acid  
ELC                                                                                                 Essential light chain of myosin 
ENDOR                                                                                 Electron Nuclear Double Resonance  
EPR                                                                                           Electron Paramagnetic resonance  
EtBr                                                                                                                     Ethidium Bromide 
EtOH                                                                                                                                    Ethanol 
fB                                                                                                                                        Factor B  
fH                                                                                                                                       Factor H 
fI                                                                                                                                          Factor I 
FPLC                                                                                      Fast Protein Liquid Chromatography 
FRET                                                                                      Forster Resonance Energy Transfer 
G            Gauss 
GAG                                                                                                                 Glycosaminoglycan 
HCM                                                                                                 Hypertrophic Cardiomyopathy 
HMM                                                                                                                Heavy Mero-Myosin  
HPLC                                                                            High Performance Liquid Chromatography 
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hr                                                                                                                                          hour(s) 
HRP                                                                                                        Horse Radish Peroxidase 
HYSCORE                                                                                      Hyperfine Sublevel Correlation 
IEC                                                                                                 Ion Exchange Chromatography 
IMAC                                                                           Immobilised Metal Affinity Chromatography 
IPA                                                                                                                                Isopropanol 
IPTG                                                                                   Isopropyl β-D-1-thiogalactopyranoside 
J                      Joules 
Kan                                                                                                                                Kanamycin 
kDa                                                                                                                                  kiloDalton 
LB                                                                                                           Luria Bertoni (Broth/Agar) 
LMM                                                                                                                   Light Mero-Myosin 
LSLB                                                                                        Low Salt Luria Bertoni (Broth/Agar) 
MAC                                                                                                     Membrane Attack Complex  
MCS                                                                                                                    Multi-Cloning Site 
MeOH                                                                                                                               Methanol 
min                                                                                                                                    minute(s) 
MMM                                                                 Multi-scale Modelling of Macromolecular Systems 
mRNA                                                                                                 messenger Ribonucleic Acid 
MS                                                                                                                    Mass Spectrometry 
MTSSL                          (1-Oxyl-2,2,5,5-tetramethyl-∆3-pyrroline-3-methyl) Methanethiosulfonate 
MW                                                                                                                      Molecular Weight  
MWCO                                                                                                     Molecular Weight Cut Off 
MyBP-C                                                                                                   Myosin Binding Protein C 
NaAc                                                                                                                      Sodium Acetate 
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NMR                                                                                                 Nuclear Magnetic Resonance 
NTB                                                                                                          2‐nitro‐5‐thiobenzoicacid 
OD600                                                                                                        Optical density at 600nm 
o/n                                                                                                                                     overnight 
pAcPhe                                                                                                        p-acetyl phenylalanine  
PBS                                                                                                      Phosphate Buffered Saline  
PCR                                                                                                    Polymerase Chain Reaction 
PDB                                                                                                                    Protein Data Bank 
PEG3350                                                                                                                                                           Polythylene Glycol 3350 
Pi                                                                                                                    Inorganic Phosphate 
pI                                                                                                                            Isoelectric Point  
pK                                                                                                                  propargyl lysine 
PMSF                                                                                               Phenylmethylsulfonyl Fluoride 
P. pastoris                                                                                                                Pichia pastoris 
PVDF                                                                                                       Polyvinylidene di-fluoride 
RLC                                                                                            Regulatory Light Chain of Myosin 
RNA                                                                                                                      Ribonucleic Acid  
rpm                                                                                                                 revolution per minute 
r.t.                                                                                                                     Room Temperature 
s                                                                                                                                       second(s)  
SAXS                                                                                                 Small Angle X-ray Scattering 
SDM                                                                                                      Site-Directed Mutagenesis 
SDSL                                                                                                   Site-Directed Spin Labelling  
SDS-PAGE                                          Sodium Dodecyl sulphate Polyacrylamide Electrophoresis 
SEC                                                                                              Size Exclusion Chromatography 
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s/n                                                                                                                                 supernatant  
SOB                                                                                                                Super Optimal Broth 
SOC                                                                    Super Optimal Broth (with catabolite repression) 
SPPS                                                                                              Solid Phase Peptide Synthesis 
T                                                                                                                                              Tesla 
TBE                                                                                                                     Tris-Borate EDTA 
TBTA                                                                                            Tris(benzyltriazolylmethyl)amine 
TCEP                                                                                             Tris(2-carboxyethyl) Phosphine   
TE                                                                                                                                     Thioester 
TED                                                                                                                     Thioester Domain 
TEMPO (2,2,6,6-TetraMethylPiperidin-1-yl)Oxyl – a small molecule containing a nitroxide radical 
Tet                                                                                                                                Tetracycline  
TEV                                                                                                                  Tobacco Etch Virus  
Tmelt                                                                                                      primer melting temperature  
TOAC                                         2,2,6,6-Tetramethylpiperidine-N-oxyl-4-amino-4-carboxylic Acid 
tRNA                                                                                                        transfer Ribonucleic Acid  
UAA                                                                                                              Unnatural Amino Acid 
UV-Vis                                                                                                                  Ultraviolet visible 
wt                                                                                                                                       wild type  
XRC                                                                                                             X-Ray Crystallography 
YNB                                                                                                                Yeast Nitrogen Base  
YPD                                                                           Yeast-Peptone Dextrose Media (broth/agar) 
YPDS                       Yeast-Peptone-Dextrose Media supplemented with 1M Sorbitol (broth/agar) 
Zeo                                                                                                                                    Zeocin
TM
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Amino Acids 
Alanine   (Ala)                                                                                                                               A 
Arginine   (Arg)                                                                                                                              R 
Asparagine   (Asn)                                                                                                                        N 
Aspartic Acid   (Asp)                                                                                                                     D   
Cysteine   (Cys)                                                                                                                            C 
Glutamine   (Gln)                                                                                                                          Q 
Glutamic Acid   (Glu)                                                                                                                     E 
Glycine   (Gly)                                                                                                                               G 
Histidine   (His)                                                                                                                              H 
Isoleucine   (Ile)                                                                                                                              I 
Leucine   (Leu)                                                                                                                              L 
Lysine   (Lys)                                                                                                                                 K 
Methionine   (Met)                                                                                                                         M 
Phenylalanine   (Phe)                                                                                                                    F 
Proline   (Pro)                                                                                                                                P 
Propargyl Lysine                                                                                                                         pK 
Serine   (Ser)                                                                                                                                 S 
Threonine   (Thr)                                                                                                                           T 
Tryptophan   (Trp)                                                                                                                        W 
Tyrosine   (Tyr)                                                                                                                              T 
Valine   (Val)                                                                                                                                  V 
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Chapter 1: An Introduction to Electron Paramagnetic 
Resonance Spectroscopy (EPR) and its Application in 
Measuring Nanometre (nm) Scale Distances in Proteins 
1 An Introduction to EPR Spectroscopy  
   Understanding how proteins and their complexes interact at a three dimensional, 
structural level is crucial in elucidating function. Obtaining distances between sites of 
interest in proteins and complexes thereof offers further insight into such interactions. 
   This thesis aims to explore the application of EPR Spectroscopy, in particular the use 
of Double Electron-Electron Resonance (DEER) Spectroscopy, in the study of protein-
protein interactions in large functional bio-macromolecular complexes.  
   The introduction to EPR spectroscopy is summarised by Atkins & de Paula, 2011, and 
Brustolon & Giamello, 2009. 
 
1.1 Distance Measurements in Proteins 
   Generally, spectroscopy can be defined as a measurement of the interaction of a given 
material with electromagnetic radiation. Molecules, or atoms, have discrete states, each 
of which has a corresponding energy. Spectroscopy can be used to measure and 
interpret the difference between these energy states (∆E), gaining further insight into the 
structural dynamics of the sample of interest. EPR is no exception, and involves the 
application of microwave frequency electromagnetic radiation to activate and 
specifically detect unpaired electrons.  
   Naturally occurring organic cofactors, e.g. flavin radicals, metal centres, e.g. copper, 
and metal clusters, e.g. ferric heme, in proteins are held in a fixed orientation with 
respect to the protein structure, and therefore are ideal spin probes, if paramagnetic. 
Very often, however, the EPR spectra of metal centres and naturally occurring radicals 
are too broad, and consequently very difficult to study by DEER (Bowen et al, 2013). 
Alternatively, spin labels containing radicals which are sensitive to their local 
environment can be incorporated site-specifically into proteins of interest, allowing 
indirect molecular observations of the protein/complex under study, at precisely defined 
locations within the protein structure. 
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   Due to the relationship between the coupling of unpaired electrons and the distance 
between them, one can collect several long range nm distance constraints between spin 
labels. This allows one to yield global structural elements from proteins of interest, and 
gain further insight into how the small pieces come together, and how this contributes to 
overall biological function. 
 
1.2 EPR Theory - The Static Spin Hamiltonian 
   These energy differences, ∆E, can be measured due to the relationship between ∆E 
and the absorbance of electromagnetic radiation, as shown in equation 1.1 
∆E = hν,  (EQUATION 1.1) 
where h is Plank’s constant (6.62607x10-34 Js) and ν is the frequency of the radiation. 
The EPR spectrum of an unpaired electron in an external magnetic field B0, can be 
described by a Hamiltonian of the form described in equation 1.2: 
 
H0 = HEZ + HHFS + HEE + HZFS + HQ + HNZ (EQUATION 1.2) 
     
where the above terms stand for the Electronic Zeeman Interaction (EZ), Hyper-Fine 
Splitting (HFS), the Electron-Electron Interaction (EE), Zero-Field Splitting (ZFS), the 
Quadrupolar Interaction(Q), and the Nuclear Zeeman Interaction (NZ), respectively.  
   The greater majority of the work undertaken in this thesis has been done so using spin 
labels containing the nitroxide radical (NO
.
), with spin ½. For such spin systems the 
HEZ, HZFS and HEE contributions are the most significant, although all contributions to 
the spin Hamiltonian will be discussed. 
 
1.2.1 The Electronic Zeeman Splitting Effect 
   Each unpaired electron has an intrinsic angular momentum, or ‘spin’, denoted S. Due 
to the charge carried by each unpaired electron, the angular motion of this particle 
generates a magnetic field, resulting in each unpaired electron displaying 
paramagnetism when aligned with an external magnetic field (B0). The magnetic field, 
B0, produces two energy levels for the magnetic moment, µ , of the electron, causing a 
splitting of the otherwise degenerate spin energy levels.  
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   A single electron has a spin, S of ½, with magnetic components of ms ± ½, making it 
doubly degenerate, and restricted to two positions, referred to as up and down. When an 
external magnetic field is applied there is an absorption of energy, causing an EPR 
transition from the lower energy state (when aligned in the same direction as the field 
(ms= - ½)) to the higher energy state (when aligned against the magnetic field direction 
(ms = +½)). This movement between energy levels is the Zeeman Splitting Effect, which 
is illustrated in Figure 1.1. 
 
 
 
 
 
 
Figure 1.1: The Electronic Zeeman Splitting Effect. Divergence of energy levels of discrete spin states 
with application of magnetic field for a S= ½ system.  
The energies for an electron with magnetic moments ms ± ½ are given by equations 1.3 
and 1.4, respectively 
                                                 E +½ =   ½ geβB0   (EQUATION 1.3).  
                                       and    E -½ = - ½ geβB0     (EQUATION 1.4). 
for each electron, µ = msgeβ, where β is a conversion constant called the Bohr magneton 
(9.27401 x10
-24
 J x T
-1
) and ge is the spectroscopic g-factor of the electron. The g factor 
is a constant of proportionality, whose value is the property of the electron in a certain 
environment.  
 
1.2.1.1 The Spectroscopic g-factor 
   In order to interpret EPR spectra of radicals incorporated into proteins, one must first 
be able to compare the spectrum of the sample of interest with that of a free electron. 
The g-factor of a dimensionless electron in space is 2.003192778 (~2.00). Combining 
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equations 1.3 and 1.4, in a magnetic field (B0) the energy levels of a free electron are 
split by the following, equation 1.5: 
∆E = hν = ge.β.B0   (EQUATION 1.5). 
however, the magnetic moment of the nitroxide radical interacts with the external 
magnetic field in a different manner than that of a free electron.  
   Therefore, on account of local magnetic fields induced in the specific molecular 
framework of the nitroxide radical, the resonance condition is normally denoted by that 
described in equation 1.6: 
∆E = hν = g.β.B0   (EQUATION 1.6), 
where g is equal to the g-value of the specific radical under study.  
   Typically, organic radicals have g-values of ~ 2.0027, inorganic radicals between 
1.9-2.1, and paramagnetic d-metal complexes anywhere between 0 and 6. A 
measurement of a system’s g factor yields some level of information about electronic 
structure, although it does not give much in way of structural dynamics. 
 
1.2.1.2 Resonance and the CW EPR Experiment 
   By keeping the electromagnetic radiation frequency constant and scanning the 
magnetic field, a peak in absorption will occur when the magnetic field tunes the two 
spin states, so that the difference in energy, ∆E, matches the energy of the radiation. 
This is called the field for resonance and is the technique used in Continuous Wave 
(CW) EPR Spectroscopy. Typically for such experiments, in a 0.3 T static field, the 
frequency, ν, of electromagnetic radiation required to cause an inversion of the 
unpaired electron spin is about 9 GHz. This is often referred to as X-band frequency.  
   The application of a resonant microwave frequency magnetic field induces the 
transitions between energy states, and is how CW EPR can be used to measure the 
resonance. Electrons are not isolated, and can exchange energy with their 
surroundings and with other spins in the system. Relaxation of the electron to its 
ground state is crucial in understanding magnetic resonance, as the shape of the EPR 
spectra obtained is determined by both the spin-lattice (T1) and spin-spin (T2) 
relaxation rates.  
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Table 2.1 Microwave bands found in commercial EPR spectrometers, with the static magnetic field 
required for resonance of a free electron 
Designation (band) ν (GHz) Field (T) 
   
X-Band 9 0.3 
Q-Band 35 1.0 
W-Band 95 3.4 
  
Historically, microwave frequencies are divided into bands, with most commercially 
available EPR spectrometers operating at X, Q and W band, which are outlined in Table 
1.1 with the corresponding magnetic field required for the resonance of a free electron. 
At higher field, the spectral resolution of the nitroxide radical improves since the 
Zeeman splitting increases with the applied magnetic field.   
 
1.2.2   The Hyperfine Splitting   
   In order to interpret EPR spectra, one must take into account the effect that magnetic 
nuclei have on the energy of the unpaired electron. In EPR, the hyperfine structure is the 
result of the magnetic interaction between the electron spin, and the magnetic dipole 
moments of the nuclei, in the radical under study. Generally a nucleus with spin, I, splits 
the EPR spectrum into 2I+1 hyperfine lines. For a nitroxide radical (I=1), the EPR 
spectrum consists of three lines of equal intensity (Figure 1.2), due to the three possible 
spin orientations of the 
14
N nucleus.  
 
 
 
 
 
 
 
 
   
Figure 1.2: Near Isotropic 3 line Spectrum of 4-amino-TEMPO. The nitroxide containing small 
molecule TEMPO is in double distilled H2O (ddH2O) (spectrum normalised to maxima). 
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   In theory, the total energy absorbed by a sample is measurable, however, in practice 
the noise component significantly obscures the resonance signal. For this reason, the 
static magnetic field is modulated, and only the modulated part of the output voltage 
detected. The output is therefore the detection of the first derivative of the absorption, 
rather than the absorption itself, but with an enhanced signal to noise ratio. The 
hyperfine structure of the EPR spectra is a basic fingerprint of this interaction from 
which it is possible to gleam a host of information. Figure 1.2 shows the near isotropic 
CW spectra of the nitroxide containing 4-amino TEMPO. 
  The hyperfine coupling has anisotropic components which influence the CW EPR line-
shape. A small molecule containing a nitroxide radical, such as TEMPO – see Figure 
1.2, tumbling rapidly in solution has an average hyperfine splitting, typically of about 
15G. The hyperfine anisotropy is due to the majority of the electron density being 
distributed in molecular orbitals (p orbitals of the nitrogen lone pair), aligned parallel to 
the molecular z axis of the paramagnetic moiety. Typically therefore Azz>Ayy,Axx and 
this becomes evident for crystal or powdered samples.  
   Furthermore the hyperfine coupling, and consequently the CW EPR linewidth is 
sensitive to variation from the spin label side chain sampling different water, protein 
and lipid environments.  Bordignon & Steinhoff, 2007 confirmed this with their studies 
on solvent accessibility in membranes.  
   Generally as the polarity and proticity of the environment increases, so does the 
hyperfine coupling, showing the potential for defining the topology of the spin label 
side chain with respect to other proteins, as well as the identification of water-
membrane boundaries.        
   Characterising specific regions of proteins in terms of their polarity/proticity profiles, 
as well as identifying hydrophobic barriers by monitoring changes in hyperfine 
coupling, may provide means to obtain structural and topological detail of proteins, and 
help elucidate further specific biological process. 
 
1.2.2.1 Spin Label Dynamics 
   The appearance of the EPR spectrum changes as the motion of the radical is restricted, 
and rotational correlation time increases due to the anisotropic nature of the hyperfine 
tensor. Figure 1.3 shows the effect of an increased rotational correlation time on the 
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EPR line-shape, as well as the effect of freezing. Restricted motion may be as a result of 
a reduced tumbling rate due to attachment of the spin label to a particularly large 
protein, or restriction of the label’s rotation through binding position, temperature 
reduction or an increase in viscosity (Beier & Steinhoff, 2006). 
 
 
Figure 1.3: Spectral Simulations of a nitroxide radical (such as TEMPO), at X-band. Shows 
increasing correlation times, as simulated using the Easyspin Spectral Simulation Software (Chili and 
Pepper Functions) for MatLab® (spectra normalised to maxima). (A) correlation time of 0.1x10
-9
s, (B) 
correlation time of 1x10
-9
s, (C) correlation time of 10x10
-9
s, (D) simulated powder spectrum of a 
nitroxide (e.g. frozen). 
 
   Ideally, spin labels should produce an EPR spectrum that significantly broadens as its 
motion is even slightly restricted. This is true for nitroxide spin labels, as we can see an 
increased rotational correlation time from Figures 1.3A to 1.3C. Assuming total 
intensities are the same across all simulated spectra, it is clear that an increase in 
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correlation time results in a broadening of the spectral lines due to an increased rigidity, 
and more restricted motion of the spin label.  
1.2.3 The Electron-Electron Interaction 
   The interaction of two (or more) electrons results in a coupling of spin states. There 
are two magnetic interactions that operate between two interacting unpaired electrons, 
one being the isotropic exchange coupling interaction and the second the anisotropic 
through space dipole-dipole interaction. 
 
1.2.3.1 Exchange Coupling 
   The exchange interaction, characterised by the exchange coupling tensor, J, is 
dependent upon the electric interaction between electrons, from a combination of 
repulsion and overlapping of orbital densities. This interaction falls off exponentially as 
the distance between interacting centres increases, assuming no orbital overlap. 
 
1.2.3.2 Dipolar Coupling 
   The dipolar coupling interaction will be discussed in greater detail in 1.4. Briefly, the 
dipolar coupling is the interaction between two magnetic moments, which for the 
purpose of this thesis will be the magnetic moments between two interacting electrons 
separated in space. 
 
1.2.4 Zero-Field Splitting 
   The ZFS interaction is only relevant when applied to high spin systems, i.e. S > ½. 
Zero-field splitting describes various interactions of the energy levels of an electron spin 
in the absence of an applied magnetic field. The electrons couple to one another, 
causing an energy level splitting called the ZFS. This can be very large, e.g. common 
transition metal ions in biological systems, such as iron, have such large ZFS energies 
that their spectra have still to be fully measured even at very high magnetic fields 
(Bowen et al, 2013). 
 
1.2.5 Nuclear Quadrupole Interaction 
   The Nuclear quadrupole interaction is analogous to the zero-field interaction, as these 
transitions can be detected in the absence of an applied external field. Nuclei with I ≥ 1, 
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possess an electrical quadrupole moment Q, arising from their non-spherical charge 
distribution. This charge distribution then interacts with the electric-field gradient 
produced by the electrons in the vicinity.  
   In EPR spectra, nuclear quadrupole interactions can cause a shift in resonance, and the 
appearance of forbidden transitions, however, such effects are usually of the second 
order and difficult to observe.  
 
1.2.6 Nuclear Zeeman Interaction 
   This contribution is analogous to the electronic Zeeman, but addresses the coupling of 
nuclear spins to the external magnetic field. For the most part, this can be considered 
isotropic. This small energy contribution has little influence on EPR spectra, however, 
may affect nuclear frequency spectra measured by EPR techniques, such as Electron-
Nuclear Double Resonance (ENDOR) Spectroscopy. 
 
1.3   Obtaining Distances Between Paramagnetic Centres Using EPR  
   Distance determination across all methods of EPR relies upon the magnetic dipole-
dipole interaction between the magnetic moments µA and  µB, of two spins A and B. For 
the purpose of this thesis, the focus will be on dipolar interactions between pairs of 
electrons, from which the distance between them can be resolved. 
   The energy of the dipolar interaction is a result of the change in Zeeman energy of the 
observed spin A, due to the presence of the second spin, B. In the high field 
approximation, the dipolar coupling to the external magnetic field dominates all other 
contributions. Hence the dipoles align parallel to B0. The energy of the dipolar coupling 
interaction is simplified to that shown in equation 1.7: 
E= 
𝜇0
4𝜋
 
1
𝑟3
 (1 - 3cos
2 θ)    (EQUATION 1.7) 
where µ0 is equal to the vacuum  permeability constant, r is the distance between the 
two unpaired electrons and θ is the angle formed by the applied field and the vector 
connecting the unpaired electrons.  
   The θ value can give information on the orientation, (Prisner et al, 2015, Gophane et 
al, 2014) however, this is not of interest for the work described in this thesis, where the 
focus is nitroxide spin labels at X and Q bands, which, due to conformational freedom, 
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and limited g-value splitting at X and Q band, do not give much away in terms of 
orientation. 
 
1.3.1 Distance Measurements Using CW EPR Spectroscopy 
   CW EPR is most often applied to nitroxides whose powder spectra (i.e. static, e.g. 
frozen) are dominated by the (inhomogeneous) broadenings from nitrogen hyperfine 
interactions and g tensors (Bowen et al, 2013). The effect of dipolar coupling is a small 
broadening effect, which can be extracted using deconvolution methods,  (Rabenstein & 
Shin, 1995) or multi-parameter fits (Hustedt et al,  1997) and from the dipolar coupling 
interaction, distances can be determined. 
   CW EPR is practical for the measurement of short distances of ~ 0.8nm up to a 
maximum of 1.5-2.0nm, with those distances less than 1.5nm being the most reliable 
(Banham et al, 2008). For protonated spin labels, the inhomogeneous line broadening 
(in part due to unresolved hyperfine coupling) obscures dipolar broadening for distances 
in the 1.5-1.7nm range resulting in lower distance resolution.  
   With increasing distance between paramagnetic centres, it becomes progressively 
more difficult to measure the dipolar interaction with CW EPR as an effect on line 
broadening, as the coupling strength becomes comparable to the linewidth. To extend 
this limit, with respect to CW EPR, the spin label can be deuterated (de Vira et al, 2015) 
or trityl spin labels may be used as an alternative to nitroxides.  Due to the  much 
narrower line-shape of trityl radicals (Kunjir et al, 2013) inter-spin distances can be 
accurately measured from the CW EPR spectrum up to ~2.4nm (Reginsson et al, 2012). 
 
  1.4   Pulsed Methods of EPR Spectroscopy 
   Unlike CW EPR spectroscopy, where the microwave frequency is kept constant 
throughout, pulsed methods of EPR spectroscopy apply a series of microwave pulses, in 
order to refocus the broadening that occurs in spectra obtained from CW EPR, and 
collect more high resolution data. The Hahn echo pulse set (π/2-τ-π-τ) is the basis for 
the majority of pulse sequences used in such techniques (Figure 1.4). 
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Figure 1.4: The Principle of the Hahn Spin Echo. (A) The vertical red arrow is the average magnetic 
moment of a group of spins. All are vertical in the vertical magnetic field and spinning on their long axis, 
but this illustration is in a rotating reference frame where the spins are stationary on average. (B) A 90° 
(π/2) pulse is applied that flips the arrow into the horizontal plane. (C) Due to local magnetic field 
inhomogeneity some spins slow due to lower local field strength while some speed up due to higher field 
strength. This makes the signal decay. (D) A 180° (π) pulse is applied so that the slower spins lead ahead 
of the main moment and the fast ones trail behind. (E) The fast moments catch up with the main moment 
and the slow moments drift back toward the main moment. (F) Complete refocusing has occurred and at 
this time, an accurate T2 echo can be measured. 
 
   Pulsed methods of EPR spectroscopy come in many flavours. Electron Nuclear 
Double Resonance (ENDOR) and Hyperfine Sublevel Correlation Spectroscopies 
(HySCORE) are just two pulsed methods of EPR spectroscopy that can be used to probe 
the environment surrounding paramagnetic centres.  
   For more on other pulsed EPR methods see Borbat & Freed, 2013. However, the 
focus of this thesis is the use of DEER spectroscopy in obtaining nm scale distance 
measurements between paramagnetic centres, based on the dipolar interactions between 
them.  
 
  1.4.1   Distance Measurements Using Pulsed EPR Techniques - DEER 
   Whilst CW EPR is used for accurate distance determination of the shortest distances, 
it is the pulse techniques which allow access to long range distance distributions, more 
synonymous with large functional biological complexes. The focus of this thesis is the 
A                                                B                                             C 
 
 
 
 
 
 
 
 
 
 
 
 
D                                                E                                             F 
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use of DEER for studying the structure of biomolecules on the nanoscale, by measuring 
the dipolar coupling between paramagnetic centres.  
   Using DEER, the dipolar couplings are isolated by suppression of the hyperfine 
couplings, allowing longer range distance measurements to be obtained. Until recently 
the often quoted range for DEER distance measurements was 1.5-8nm (Tsvetkov & 
Grishin, 2009) (Gunnar Jeschke, 2012), however recent work by El Mkami (2014) and 
co-workers have pushed the limits to a theoretical maximum of 13nm. 
 
1.4.1.1   3-Pulse DEER 
   The constant time 3-Pulse DEER sequence (shown in Figure 1.5) was initially used to 
gain further insight into molecular distribution by Milov et al, 1981. 
 
 
 
 
 
 
 
 
 
Figure 1.5: Schematic representation of the 3-pulse DEER sequence. Observer and pump pulses 
shown at frequencies A and B (νA, νB). 
 
   Application of the π pulse at νB, between the Hahn Echo pulse sequence (π/2, π) 
causes a focusing of the electrons coupled to the observer spins. At time T, the local 
field at the A spins (in resonance with νA) is altered. T is incremented, and the extent of 
coupling determines the modulation period.  
   However, the start of the DEER time trace is usually distorted due to application of 
the pump pulse, at νB, at the same time as the first observer pulse, π/2, at νA. 
Consequently, the complete shape of the dipolar spectrum is not recovered, leading to a 
‘dead-time’, which proves detrimental if distance distributions are broad (Lovett et al, 
2012).  
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   4-Pulse DEER, although less sensitive than 3-pulse DEER, is commonly used in 
measuring distance distributions in structural biology investigations, where broad 
distance distributions are more commonplace. 
 
1.4.1.2   4-Pulse DEER 
   The four pulse DEER technique provides a dead-time-free method for measuring the 
frequency of the dipolar coupling interactions and is the chosen method used in this 
thesis.  
   For a two spin system containing spins A and spin B, both from nitroxide radicals, the 
spins are differentiated by exciting different parts of the nitroxide spectrum, using two 
very different microwave frequencies (νA and νB), as illustrated in Figure 1.6B and 1.6C.  
   A two-pulse Hahn echo sequence is employed to selectively monitor the intensity of 
the echo (Figure 1.6C), ν(T), of the paramagnetic species A, at frequency νA, in 
resonance with spins A. This particular pulsed sequence generates a refocused echo 
after the last delay, τ2, which is the measurable DEER signal. The π pulse at microwave 
frequency νB, applied during the time interval T, often referred to as the pump pulse, 
then excites spins B, in resonance with frequency B, νB. This introduces a coupling 
between spins A and B. 
   Using the two microwave frequencies νA and νB, and keeping the refocused echo at a 
fixed position in the time domain, strongly suppresses the hyperfine interactions. The 
time T, at which the pump pulse is applied, is incremented, resulting in an increase or 
decrease in the intensity of the refocused echo. The frequency of this oscillation, νAB, 
can be used to obtain the dipolar coupling.  
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Figure 1.6: Schematic representation of the 4-Pulse DEER Experiment. (A) For a two spin system, 
the distance between Spin A (green sphere) and Spin B (purple sphere) is denoted rAB. (B) Field sweep 
spectrum of a nitroxide at X-band, illustrating where in the spectrum Spins A and Spins B are excited 
(green and purple respectively). (C) The dead-time free 4 pulse DEER sequence. (D) The four pulse 
DEER time trace (black line) together with the fitted intermolecular background decay (red line). (E) 
Background corrected distance distributions rAB obtained following Tikhonov regularisation of the DEER 
time trace (Jeschke 2006).  
 
   Due to potential intermolecular spin-spin interactions, there may be an exponential 
decay of the DEER signal. These interactions are the background contribution (as 
shown in Figure 1.6D), and so the DEER trace obtained must first be background 
corrected, in order to obtain an accurate representation of the intramolecular spin-spin 
distance distribution (as shown in Figure 1.6E). A spin concentration of between 50µM 
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and 200µM will minimise this contribution, whilst ensuring sensitivity. For the 
experiments performed throughout, a final sample of ~80µL is required. 
 
1.4.2 Enhancing DEER Sensitivity - Solvent, Temperature and Deuteration Effects     
   Typically, DEER experiments are conducted at temperatures in the range of 50K, with 
the protein solution forming a frozen glass. At 50K, one of the major factors 
contributing to the persistence of an echo, and therefore the sensitivity and measureable 
distances between spin labels, is the electron spin echo dephasing time, TM.  
   Due to the cryogenic temperatures involved, cryo-protectants are required to prevent 
ice crystal formation and protein aggregation, which can leads to a dramatic decrease in 
the TM, therefore seriously compromising the signal to noise ratio (S de Vera et al, 
2015).  
   Due to relatively short TM (Ward et al, 2010) when measuring proteins, it is standard  
practice to deuterate the solvent in which the proteins are present, which slows 
relaxation and extends the range of distance measurements and level of sensitivity 
(Huber et al, 2001). 
   In a non-deuterated environment, short spin echo dephasing times – between 2-4µs-
would only allow for distances in the 3-4nm range, with limited sensitivity (El Mkami 
et al, 2014), however, deuteration of the solvent can significantly increase the TM in the 
5-6µs range (El Mkami et al, 2014). This was demonstrated by Banham et al, 2006, in 
the study of a von Willebrand factor  domain, where deuteration of the solvent matrix 
(60% D2O, 40% deuterated glycerol), doubled the TM, compared to the protonated 
sample, extending the dipolar evolution time to 6µs, allowing distances in the 6.8nm 
range.  
   It is quoted throughout the literature that the upper distance limit for measuring using 
EPR spectroscopy is 8nm (Gunnar Jeschke, 2012). However, full deuteration of not 
only the sample, but the protein itself (if expressed in deuterated conditions) has the 
potential to increase TMs, therefore allowing access to longer distances. This was 
demonstrated beautifully by Bowman et al, 2014 in their work on the histone chaperone 
proteins Vps75 and NapI.  
   Using entirely deuterated samples, a distance of 10.2nm was obtained, a record for 
distances obtained using 4-pulse DEER. As stated above, DEER measurements are 
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typically taken at 50K, as at this temperature, TMs are increased. It is generally accepted 
that at higher temperatures, a decreased TM limits the distance range that can be 
measured, however entire deuteration of the protein could circumvent this. As 
demonstrated by Ward et al., 2010, the TM of an entirely deuterated protein at 100K was 
comparable to a non-deuterated protein at 50K, highlighting the potential to measure at 
higher temperatures which previously were not possible. 
 
1.4.3   DeerAnalysis 
   The initial time trace (Figure 1.6D) represents both inter and intra molecular 
contributions as a function of time. The desired intra-molecular signal is obtained 
following division of the original time trace (D) by the intermolecular contribution. 
Fourier transformation of the intra molecular interaction trace generates a Pake pattern 
(as reviewed in Jeschke, 2012). 
   Small distortions in the DEER signal such as noise or some orientation selection, as 
well as the measurement of a distribution of distances, will make reading distances from 
the Pake spectrum difficult. Tikhonov regularisation of the intramolecular time trace is 
carried out to yield distance distributions, using the software package DeerAnalysis2015 
(G. Jeschke et al, 2006). DeerAnalysis will take the experimental DEER data, 
background fit and then use Tikhonov regularisation, or models such as Gaussian 
lineshapes, to extract distances and distance distributions. 
 
1.5 Site-Directed Spin Labelling (SDSL) – Cysteine Substitution 
Mutagenesis 
   As stated before, EPR spectroscopy specifically detects unpaired electrons within a 
system. These unpaired electrons, or radicals, can be naturally occurring, or are more 
commonly specifically introduced. Consequently, this allows one to look at many 
different proteins, regardless of cofactors, precisely where desired within the protein 
structure.  
   When studying biological complexes, radicals are specifically introduced at specific 
sites of interest within recombinant proteins, in a process known as site-directed spin 
labelling (SDSL). 
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1.5.1 Cysteine Chemistry 
   The chemical versatility of the thiol group of a cysteine residue is commonly 
exploited for a wide range of chemical transformations of proteins. Illustrated in Figure 
1.7 is the chemical structure of cysteine.  
   Cysteine is usually the most powerful nucleophile in a protein, and, as a result, is 
frequently the easiest to selectively modify with a variety of reagents, including the site 
specific incorporation of spectroscopic probes, allowing one to obtain precise structural 
detail on proteins of interest.  
 
 
 
 
 
Figure 1.7: Chemical structure of the amino acid cysteine. Visualised using ChemDraw
TM
. The highly 
reactive thiol group of the cysteine residue is circled. 
   Native cysteine residues can be used as a chemical handle for the incorporation of 
spin labels, or, alternatively, as demonstrated in pioneering work by Hubbell et al, 1994, 
reactive native cysteine residues can be replaced by a non-reactive amino acid, and 
further cysteine residues introduced at sites of interest, creating a specific labelling site. 
1.5.2 Nitroxide-Radical Spin Labels 
 
   The first attempt to introduce a paramagnetic reporter group into an otherwise EPR 
silent macromolecule, was carried out by Stone et al, 1965, where a nitroxide radical 
was introduced into Bovine Serum Albumin (BSA), in order to obtain conformational 
information about the biomolecule via EPR spectra.  
   Since then, the technique has evolved, and is now used to gain insight into dynamics 
(Abdullin et al, 2014), orientation selection (Lovett et al, 2009), conformational 
transitions and protein folding in real time (Steinhoff et al, 1994), whilst not being 
limited to the size of the biological complex under study (Hubbell et al, 1996).  
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   The process of SDSL incorporates a stable radical into the protein structure. Many 
commercially available spin labels contain thiol-reactive functionalities including 
methanethiosulfonate, maleimide, and iodoacetamide, which all form a covalent bond 
with the thiol of cysteine residues, however, the most commonly used spin label is 
MTSSL (1-Oxyl-2,2,5,5-tetramethylpyrroline-3- methyl) Methanethiosulfonate), the 
chemical structure for which is shown in Figure 1.8. 
   MTSSL contains a nitroxide radical, protected by bulky methyl groups, which 
function to sterically hinder the radical, preventing collisions, and therefore limiting its 
reactivity (Brown et al, 2002). Unlike the vast majority of free radicals that are highly 
unstable, the nitroxide radical is stable under a variety of physicochemical conditions, 
including different solvents, pH and temperatures (Schreier et al, 2012), which proves 
desirable when working with biological systems. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: Structural composition of Pyrrolinoxyls, and SDSL of Cysteine Residues with MTSSL. 
(A) General structure of pyrrolinoxyls, highlighting key features which make them amenable, and 
therefore more commonly used for protein labelling. (B) Schematic representation of any given protein, 
with the thiol group (-SH) of a given cysteine residue (be it naturally occurring, or incorporated via site 
directed mutagenesis) shown. (C) Chemical structure of the commercially available MTSSL. (D) 
Illustrates the MTSSL covalently bound to the thiol group of the cysteine residue, forming a disulphide 
bond (Visualised using ChemDraw
TM
). 
functional group  
pyrrolinoxyl 
important for stability 
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MTSSL 
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   MTSSL is highly selective in its reactivity for cysteine, and undergoes covalent 
attachment to the thiol group of the incorporated cysteine residue, forming a disulphide 
bond, and sidechain designated R1 (Hubbell et al, 1996). Due to its notably smaller 
molecular weight compared to other commercially available spin labels, and the degree 
of flexibility it exhibits around single bonds, the MTSSL should not interfere with the 
native fold of the protein (Longhi et al, 2011), therefore resulting in minimal structural 
and functional perturbation. 
1.6 SDSL – Incorporation of Unnatural Amino Acids (UAAs)  
   SDSL using cysteine substitution mutagenesis proves difficult when the protein of 
interest is cysteine rich and there is a driving force to be able to tag or label proteins in 
cell using unique chemistries. Both these aspects can be tackled by the site-specific 
incorporation of non-canonical UAAs with novel functional groups into peptides and 
recombinant proteins, with a subset containing chemically reactive functional groups for 
the selective incorporation of biophysical probes (see Lang & Chin, 2014, and 
references therein). 
 
1.6.1 Solid Phase Peptide Synthesis (Merrifield Coupling) and Semi- Synthesis 
   Several methods have been established for UAA incorporation in both peptides and 
recombinant proteins. The spin label amino acid TOAC ( 2,2,6,6-tetramethyl-N-oxyl-4-
amino-4-carboxylic acid) was the first spin label probe incorporated into the peptide 
backbone by means of a peptide bond (as reviewed in Schreier et al, 2012), allowing 
one to study backbone dynamics and peptide secondary structure. However, due to its 
rigidity, TOAC has a limited range of backbone dihedral angles, resulting in a 
significant distortion of the secondary structure of proteins. Consequently it currently 
can only be incorporated into small peptides and proteins by total solid phase synthesis 
(Fielding et al, 2014).  
   Work carried out by Becker et al, (2005) has tried to overcome such obstacles, by 
combining  SPPS with recombinant techniques, providing the tool for introduction of 
UAAs at specific sites of interest in large proteins, and even membrane proteins. Using 
SPPS, paramagnetic UAAs can be incorporated into short peptides via protected lysine 
residues. Using chemical ligation, the peptide can then be incorporated into recombinant 
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proteins of interest, which in this case is the kinase, cRaf1. The combination of 
chemically synthesised peptides with recombinant polypeptides greatly increases the 
versatility and applicability of chemical synthesis of labelled proteins. 
 
1.6.2 Expanding the Genetic Lexicon  
   Continuous Exchange Cell Free Systems allow incorporation of unnatural amino acids 
at multiple sites within the same protein. Using S30 extracts is an effective tool for the 
complete cell free synthesis of recombinant proteins (Loscha et al, 2012) (Kanda et al, 
2000) (Cornish et al, 1994). S30 extracts are named as such, due to their sedimentation 
rate by ultracentrifugation (30,000 x g) (Meyers, 1995). The expense of the systems, the 
degradation of essential components, and the comparatively poor protein yields 
associated, mean that methods for UAA incorporation in recombinant proteins are 
continuously evolving.  
   Pioneering work by Peter Schultz (Scripps Institute) and Jason Chin (Medical 
Research Council Centre, Cambridge) aims at expanding the genetic lexicon by 
engineering the translational machinery of cells, for the in vivo incorporation of novel 
amino acids (Young & Schultz, 2010) (Chin, 2011). 
 
1.6.2.1 Reprogramming Translation Using Orthogonal Ribosomes 
   The engine of translation and where mRNA is ultimately decoded into protein is the 
ribosome. Engineering orthogonal ribosomes, uncoupled from the requirement to 
synthesise the cellular proteome, results in a non-essential cellular ribosome with the 
potential for the incorporation of specific UAAs, in response to unique codons. To 
exemplify this approach, Neumann et al, 2010, evolved an orthogonal ribosome, Ribo-
Q,  that was able to efficiently decode a series of quadruplet codons using extended 
tRNA anti-codons. These codons were not read by endogenous ribosomes, and so 
corresponding tRNAs can be loaded with new amino acids, and these incorporated into 
proteins in response to the quadruplet codon at the orthogonal ribosome.  
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1.6.2.2 Orthogonal Amino-acyl tRNA Synthetase/ tRNA Pairs 
   Whilst there are no blank codons in the genetic code, Schultz took advantage of the 
amber stop codon, and its ability to be decoded, using amber suppressor tRNAs, for the 
incorporation of UAAs. Amber suppression provides a codon TAG, that can be used as 
an initial insertion signal for UAA incorporation into recombinant proteins in 
Escherichia coli (E. coli). By employing tRNA synthetase and tRNA pairs from other 
organisms, UAAs can be incorporated in response to the amber stop codon TAG, as 
long as no cross talk exists between the orthogonal tRNA synthetase/tRNA and 
exogenous pairs. 
 
1.6.2.3   Incorporation of the UAA p-acetyl Phenylalanine (pAcPhe) in response to 
the amber Stop Codon  
   The chemical structure of the UAA pAcPhe is shown in Figure 1.9. This UAA 
contains the chemically versatile keto functional group that is not present in any of the 
common amino acids, and readily reacts with hydroxylamines in aqueous solution, due 
to the accessibility of the ketone functionality to the nucleophile. 
 
 
 
 
 
 
 
 
Figure 1.9: Chemical Structure of the unnatural amino acid p-acetyl-phenylalanine (pAcPhe). 
Visualised using ChemDraw
TM
 
   Work carried out by Fleissner et al, 2009 incorporated the pAcPhe into T4 lysozyme, 
forming a keto linked spin label when reacted with hydroxylamine-nitroxide. In this 
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strategy, a non-native suppressor tRNA and aminoacyl tRNA synthetase pair is used to 
incorporate the UAA into the protein site specifically, in response to the unique amber 
stop codon TAG. The conditions of such reactions are perhaps not favourable for most 
protein systems (pH 4, 37
o
C). Recent modification of protocols (Hahn et al, 2014) has 
shown that the pAcPhe can be labelled at physiological pH, which is more amenable to 
the study of bio-molecules, however now the caveat is that organic solvents are 
necessary.    
1.7 Simulation of DEER Data 
   Having a fast and reliable approach for the prediction of spin label conformations in 
bio-macromolecular complexes facilitates the application of SDSL-EPR methods in the 
study of protein structure and function. In order to obtain global structural elements of a 
protein from DEER, one must first have an understanding of the environment in which 
the spin-label resides, so as to obtain distance distributions which can be critically 
interpreted.  
   Comparison of the simulations with the experimental DEER distance distribution can 
be used to validate structures in solution, or indeed differentiate between different 
conformational states of a protein. If two or more potential models for a particular 
structure exist, comparison of the experimental data obtained with the in silico can often 
help decide which model is in in best agreement. 
 Modelling programmes such as Multiscale Modelling of Macromolecules (MMM) 
(Polyhach et al, 2011) and MtsslWizard (Hagelueken et al, 2012) can be used to 
generate a model distance distribution between spin labels.  
 
1.7.1   Multiscale Modeling of Macromolecules (MMM) 
   MMM is a freely available tool for predicting spin label orientations and the resultant 
DEER, and can be used within Matlab. MMM is based on a rotamer library of 
computationally-calculated likely conformations of the MTSSL in relation to a protein 
of interest, which then simulates the resulting DEER. The MMM simulation is 
calculated at 175K – the water/glass transition temperature. 
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1.7.2   Mtssl Wizard 
   The wizard operates as a plugin for the PyMOL molecular graphics system and works 
by estimating distances between spin labels on proteins quickly, and with user 
configurable options, searching for MTSSL conformations that do not clash with a static 
model of the protein of interest. 
These particular programmes work by modelling the MTSSL onto user-specified 
positions with the protein structure, therefore allowing the spin label to sample different 
conformations in relation to the protein.  
    
1.8 Advancing the Field of Structural Biology 
   Established biophysical techniques applicable for the study of biological systems, 
such as high resolution Nuclear Magnetic Resonance (NMR) Spectroscopy and X-Ray 
Crystallography (XRC), have contributed significantly to advancement in the field of 
structural biology (as reviewed by Maslennikov & Choe, 2013, Zheng et al, 2014, 
Malito et al, 2015), and have made it possible to visualise individual biological 
molecules, as well as their bio-macromolecular complexes at an atomic level.     
   Fluorescence based methods such as FRET, are also very powerful methods for 
exploring long range structure, and can be used to obtain nanometre length distance 
restraints in biological systems. FRET is a technique, that can be applied at the single 
molecule level providing real time dynamics over several time scales (Reginsson & 
Schiemann, 2011), however, it is not without its caveats. There is a lack of precision 
when it comes to quantifying distances and distance distributions, and the labels used 
for FRET are significantly bigger than those used for EPR, and may affect the structural 
integrity and conformation of the protein complexes.  
   Employing EPR spectroscopy in place of, or indeed in collaboration with such 
techniques, allows structural resolution at the level of the backbone fold, and allows one 
to monitor changes in equilibria, as well as check conflicting interpretations.  
 
1.8.1 EPR Spectroscopy in the Study of Large and Flexible Soluble Proteins 
   Using EPR as a tool for measuring nm length distances in proteins, and complexes 
thereof, is a useful tool in the study of protein structure, and protein-protein interactions, 
and how such interactions contribute to overall function. The application of EPR 
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spectroscopy has resulted in the structures of many large and complex biologically 
significant proteins being elucidated.  
   The combined use of NMR and EPR proved to be a powerful approach in the study of 
the cytoskeletal complex, talin and vinculin, due to the large nature of both proteins 
involved in the complex, coupled with the high degree of flexibility exhibited in the 
extended talin rod (Gingras et al, 2006).  These variables would deem this complex 
unsuitable to be studied by NMR alone, and so in collaboration with EPR, one can gain 
insight into such interactions, which otherwise would be inaccessible. 
 
1.8.2 EPR in the Study of Membrane Proteins 
   Membrane proteins account for ~25% of all proteins within the cell. Structural 
determination of membrane proteins by X-Ray diffraction (Bai, Yan et al, 2015), 
solution NMR (Mineev et al, 2015) and more recently single-particle electron cryo-
microscopy (cryo-EM) (Schmidt-Krey et al, 2011) has resulted in more than 2,000 
structures deposited (Rodriguez et al, 2014).  
   However in the majority of cases, determination by such means does not reveal the 
structure of the protein in a membrane, but rather in a crystal lattice or in a 
micelle/bicelle. Using EPR to obtain some simple distance restraints, it is possible to 
check for potential crystallisation artefacts. 
   Work carried out by Pliotas et al, 2012 looks at the different conformational states of 
the membrane protein MscS, a mechanosensitive ion channel, composed of 7 monomers 
made up of 21 transmembrane helices. This particular multi-domain protein has been 
crystalized, although the crystal repeatedly challenged, with three mutually 
incompatible models hypothesised, which proves detrimental to the field.      
   Using SDSL in collaboration with XRC, Pliotas et al, 2012 demonstrated the wider 
utility of EPR, and showed it to be a reliable technique when studying such a complex 
system. Similarly, Endeward et al, 2009 and  Padmavathi & Steinhoff, 2008  used 
SDSL to study the tetrameric potassium ion channel KcsA, and the closed channel of 
Colicin A, respectively.  
   Using EPR, it was possible to gain information on side chain mobility, solvent 
accessibility, and the orientation of specific regions, and follow dramatic 
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conformational changes (as a function of time), which had been disputed in the 
literature.  
 
   1.8.3 EPR as a Stand Alone Technique 
   Although using EPR in collaboration with other higher resolution structural 
techniques has proven successful in elucidating the structures of previously disputed 
complexes, EPR stands alone as a powerful structural technique. Many transporter and 
importer structures have been solved using EPR and SDSL (see Joseph et al, 2011, and 
Borbat et al, 2007) as many of these systems are important pharmaceutical targets. 
   Hilger et al, 2009, used ab initio protein modelling to build a three dimensional model 
of the Na
+
/Proline transporter PutP of E. coli from scratch, solving the backbone 
structure by obtaining distances between spin labelled mutants at 2Å resolution, 
allowing insight into the structural and functional relationship. The crystal structure was 
later solved, verifying the original model. 
 
1.9 Beyond in vitro EPR, and towards physiological conditions 
   The next level in elucidating protein structure and ultimately function, requires one to 
consider the natural cellular environment in which the protein of interest resides. 
The use of DEER for obtaining nm distance restraints is typically done in frozen 
solutions at cryogenic temperatures, in order to reduce the rapid electron spin relaxation 
rates. Also, the matrix in which the proteins are present must be carefully considered, in 
order to stop tumbling of the protein averaging the dipolar interaction to zero. 
Measurements cannot be taken in an aqueous matrix, as the high dielectric constant of 
liquid water absorbs microwaves. 
    However, using EPR spectroscopy at ambient temperatures would allow for a more 
direct comparison of the experimental environment with how proteins interact in 
physiological environments. The process of SDSL and the pulsed EPR techniques 
themselves have evolved considerably from when the techniques were in their infancy, 
however, comparatively, the labelling process, and evolution of the labels themselves 
has lagged somewhat behind.  
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1.9.1 Trityl and Spiro Radical Spin Labels 
   In order to obtain measurements in liquid solution without the need for cryogenic 
temperatures, a number of groups have successfully incorporated trityl spin labels into 
proteins such as T4 lyzosyme (Yang et al, 2012) and into nucleic acids (Shevelev et al, 
2014). Due to the relatively long relaxation times exhibited by these labels, using pulsed 
methods, namely Double Quantum Coherence (DQC), these bio-macromolecules could 
be measured in solution. Shown in Figure 1.10 is an example of a cysteine specific trityl 
radical such as that used in the study of T4 lyzosyme. 
 
 
 
 
 
 
 
 
 
Figure 1.10: Chemical structure of a cysteine-specific trityl radical. 
  
   Using trityl radicals in these model systems, distances of up to approximately 4.6nm 
at 310K (37
o
C) have been measured (Shevelev et al, 2014), demonstrating the potential, 
with significant improvement to the overall size and hydrophobicity of the label, for the 
future application of trityls as spin labels, at temperatures comparable to physiological.     
   Studies by Eaton et al, 2015, have shown that the incorporation of spiro-cyclohexyl 
radical labels using SDSL to sites on T4 lysozyme resulted in inter-spin distances of up 
to ~4nm being measured by DEER at 160K, however, when in a trehalose matrix, an 
extended TM allowed a distance of ~3.2nm to be measured at room temperature (r.t).     
   These distances could not be measured using the conventional MTSSL label, and so 
evolution of labelling and labels themselves, will allow long range distances to be 
obtained at temperatures and in environments which are closer to the physiological 
environment in which the proteins natively reside.  
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1.9.2 in vivo EPR Studies  
 
   Ultimately, in order to truly elucidate protein structure and function, one must be able 
to mimic, as closely as possible the natural cellular environment. The in-cell 
environment is characterised by thousands of cellular components that can interfere 
with the biomolecule under study. Due to the sensitivity of DEER for paramagnetic 
systems, background interference is negligible and so DEER could be adapted for in 
vivo structural studies. 
   Schmidt et al, (2014) have successfully encoded an UAA in E. coli, in response to the 
amber stop codon, TAG. Direct incorporation of the nitroxide radical with the 2,2,5,5-
tetramethyl-pyrrolin-1-oxyl moiety enables intracellular biosynthesis of spin labelled 
proteins in vivo. The chemical structure of the radical is shown in Figure 1.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: Chemical structure of the UAA containing the 2,2,5,5-tetramethyl-pyrrolin-1-oxyl 
moiety. (Visualised using Chemdraw ®) (Schmidt 2014). 
 
   The higher stability of the nitroxide radical in E. coli than other intracellular 
environments enabled cells expressing thioredoxin with two of the nitroxide containing 
UAAs to be frozen and a DEER measurement taken. Furthermore, using specific E. coli 
cell lines, such as Origami, which are deficient in specific reducing agents, it is possible 
to extend the lifetime of the nitroxide radical in cell (Dunkel et al, 2015).  
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   In human cells, nitroxide radicals are reduced and converted into a diamagnetic 
hydroxylamine with a half-life of approximately 50min (Martorana et al, 2014) 
however, it is also possible to adapt the nitroxide spin label itself to one that is more 
resistant to reduction. Studies by Jagtap et al, 2015 and  Kinoshita et al, 2010 have 
found that sterically shielded spin labels, such as tetraethyl substituted nitroxides 
(pyrrolidine and piperidine derivatives) are more resistant to reduction by ascorbic acid, 
and in the presence of cellular extracts and oocytes.  
   Furthermore, reduction resistant Gd
3+
 chelates have been proposed as a potential 
alternative for in-cell DEER distance measurements in human cells (Martorana, 2014).  
Building on adapting nitroxide spin labelling in vivo, and labelling with Gd
3+
 chelates 
will broaden the application of SDSL EPR, allowing one to further characterise proteins 
which before were not suited to study by DEER. 
 
1.10 Application of EPR in this Thesis 
   Following thorough exploration of the literature, it is clear than EPR has advanced 
from a technique that was once used by few, in complement with high resolution 
structural biology techniques, to a powerful technique in its own right. Using a variety 
of methods of SDSL, this thesis aims to explore long range structure in an assortment of 
recombinant and native proteins, and complexes thereof.  
   Using various expression systems, different methods of SDSL will be explored in the 
study of various protein complexes, in hopes of confirming proposed structural 
hypotheses. This will include the SDSL of highly flexible, cysteine rich recombinant 
proteins, and the manipulation of native plasma proteins for SDSL purposes. 
   New methods for the specific labelling of cysteine rich proteins will be explored. The 
ability of E. coli to read through the amber stop codon will be exploited for the 
incorporation of UAAs for SDSL, and novel spin labels, specific for labelling cysteine 
pairs tested in several model systems. Furthermore, native paramagnetic centres of 
recombinant proteins will be explored as potential labelling sites.  
   The work described in this thesis covers experimental design, molecular biology and 
cloning, protein expression and purification, as well as functional characterisation, and 
finally EPR distance measurements, data analysis and interpretation. Challenges and 
pitfalls will also be addressed. 
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Chapter 2: Materials & Methods 
   All chemicals, unless otherwise stated, were purchased from Sigma Aldrich 
(Gillingham, UK). All buffers, stock solutions and media recipes are included in 
Appendix A. Primers were ordered from Sigma Aldrich and stored at -20
o
C as 100µM 
stocks, and a 10µM working stock concentration of each primer used for each PCR 
reaction. All primer sequences are included in Appendix A. 
2.1 Mutagenesis, Purification, and Manipulation of DNA for 
Transformation into Chemically Competent E. coli 
2.1.1 Site – Directed Mutagenesis (SDM)  
    In vitro SDM is a commonly used technique in molecular biology for generating 
point mutations in DNA coding genes of interest. It is possible to alter the primary 
amino acid sequence by replacing, inserting or deleting specific residues. All 
mutagenesis was carried out following the protocols set out in the Quikchange© site-
directed mutagenesis manual (Stratagene, California, USA). Reactions were carried out 
(Eppendorf Mastercycler personal, Eppendorf, Hamburg, Germany) according to the 
pipetting scheme and PCR programme detailed in Tables 2.1 and 2.2, using the 
mutagenic primers, and thermo-stable PfuTurbo® DNA polymerase as it exhibits high 
fidelity 3’-5’ proof reading capability, thus minimizing the number of PCR induced 
mutations. 
Each PCR reaction mixture (Table 2.1) underwent the following cycle for mutagenesis. 
Table 2.1: PCR Reaction Mixture for SDM 
               5.0µL    Pfu-buffer (10x) 
               1.0µL ddNTPs 
               1.0µL Primer 5’ 
               1.0µL Primer 3’ 
               3.0µL DMSO (dimethyl sulfoxide) 
               1.0µL Template (125ng) 
               1.0µL PfuTurbo® 
polymerase 
             37.0µL ddH2O* ( to 50µL) 
*double distilled H2O  
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Table 2.2: Programme used for Site-Directed Mutagenesis PCR 
Step Temperature (
o
C) Time (s) Cycles 
INITIATION 95 30 1 
DENATURATION 95 30 12-18
*
 
ANNEALING 55 30  
ELONGATION 68 60/kb plasmid length  
HOLD 4 ∞  
 
* = 12 for point mutation, 16 for single amino acid change, 18 for multiple amino acid deletion/insertion 
 
   Immediately following the reaction, the PCR product was treated with 2µL of the 
restriction endonuclease DpnI which promotes the specific digestion of methylated 
template (parental) DNA (target sequence: 5’-GM6ATC-3’). The PCR product was 
incubated with the DpnI enzyme at 37
o
C for 2hr, before 3µL of the digested mutated 
DNA-plasmid was transformed into XL1 Blue or Top 10 (homemade cells cultured 
from Life Technologies stocks – see Appendix B) chemically competent E. coli cells, as 
described in 2.1.2.  
 
2.1.1.1 Designing Mutants Suitable for EPR 
   Generally, to be considered a suitable candidate for SDSL, mutations are made in 
non-conserved, hydrophilic, surface exposed regions, usually alpha helices, to facilitate 
efficient incorporation of spin labels into proteins of interest, whilst maintaining 
stability.  
   When making mutations, one must take into consideration which amino acids are 
being substituted, and opt for substitutions which are conservative, with amino acids 
possessing similar characteristics. For example, serine, glutamate and asparagine are all 
uncharged residues, as is cysteine, which makes substitution to cysteine for SDSL less 
drastic.  
 
2.1.1.2 Primer Design 
   Following guidelines set out in the Stratagene Quikchange © SDM manual, primers 
were designed to facilitate directional cloning. Generally, both forward and reverse 
mutagenic primers were designed to contain the desired mutation, and anneal 
complementarily to the plasmid. Primers should be between 25 and 45 bases in length, 
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with a melting temperature (Tmelt), higher than, or equal to 78
o
C. The Tmelt for each 
primer was determined using equation 2.1: 
 
Tmelt = 81.5 + 0.41 (%GC) – 675/N - % mismatch (EQUATION 2.1), 
 
where N is the primer length in bases and % GC and % mismatch are whole numbers. 
The mutation was designed to be in the centre of the mutagenic primer, flanked on 
either side by 10 – 15 bases homologous to the plasmid. The overall GC content of the 
primer did not exceed 40%, and the primer terminated in one or more C or G bases. 
 
2.1.2 Transformation of Plasmid DNA into Chemically Competent E. coli Cells 
   For each transformation reaction, 50µL of XL1 blue or Top 10 (for high efficiency 
cloning) chemically competent cells were thawed on ice before being transferred to 
chilled, round bottomed 15mL Falcon© tubes. The cells were mixed with 3µL of DpnI 
digested DNA following the mutagenesis PCR. Following heat shock at 42
o
C in a 
circulating water-bath for 30s (Top 10) or 45s (XL1 Blue), cells were cooled on ice for 
2min, before 300µL of pre-warmed (37
o
C) super optimal broth (SOB) with catabolite 
repression (SOC, Life Technologies) was added to each transformation reaction to allow 
cell recovery. Cells were then incubated with shaking at 200rpm at 37
o
C.  
   This outgrowth step allows the bacteria time to generate the antibiotic resistance 
proteins encoded on the plasmid backbone so that they are able to grow once plated on 
the antibiotic containing agar plates. Following outgrowth, cells were spun down at 
13,000rpm, and pelleted cells re-suspended in 200µL SOC, before being plated onto LB 
or LSLB (Zeocin
TM
 only) agar plates containing the appropriate antibiotics for selection 
(Table 2.3) (50 and 150µL). 
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Table 2.3: Final concentration of antibiotics for selection following E. coli transformation 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.3 Isolation and Purification of Plasmid DNA 
 
   To prepare plasmid DNA from bacterial cultures, a QIAprep Spin MiniPrep kit was 
used for the preparation and purification of plasmid DNA on a small-scale (up to 20µg 
of high copy plasmid DNA from 5mL of E. coli culture grown overnight in LB broth) 
and the HiSpeed Plasmid Maxi (QIAgen, Hilden, Germany) kit for large-scale isolation 
(up to 500µg from up to 500mL of culture). The QIAquick Gel extraction kit (QIAgen) 
was used to recover and purify DNA from agarose gels. All buffers used in 2.1.3.1, 
2.1.3.2, and 2.1.3.3 were provided with, and used according to the manufacturer’s 
instructions (Qiagen, Hilden, Germany). Purified DNA was stored at -20°C.  
 
2.1.3.1 Mini-Prep  
 
   A single colony from a freshly streaked transformation plate was used to inoculate 
5mL of LB/LSLB medium containing the appropriate antibiotic for selection. The 
cultures were incubated with shaking at 200rpm at 37
o
C for 16hr before cells were 
harvested by centrifugation at 4,500rpm, for 10min at 4
o
C. Pelleted bacterial cells were 
re-suspended in 250µL of Buffer P1, followed by the addition of 250µL of P2 to initiate 
cell lysis.  
Kanamycin (Kan.) 
A 
100µg/mL 
 
 
 
 
 
Ampicillin (Amp.) 
T 
100µg/mL 
 
 
 
 
Tetracycline (Tet.) 25µg/mL 
Chloramphenicol (Cm.) 100µg/mL 
Zeocin
TM 
(Zeo.) 25µg/mL 
Amp. & Kan. 50 & 50µg/mL 
Amp. & Cm. 50 & 50µg/mL 
Kan. & Cm. 50 & 50µg/mL 
Kan. & Tet. 50 & 25µg/mL 
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   Buffer N3 was then added at a volume of 350µL to neutralise the lysis reaction, and 
the reaction mixture was spun at 13,000rpm at 4
o
C for 10min. The resulting supernatant 
was then loaded onto the QIAprep® spin column. The column was spun at 13,000rpm 
for 1min, discarding the flow-through. The column was washed with 500µL of PB 
Buffer and 750µL PR Buffer, spinning between washes to remove residual buffer. DNA 
was eluted by the addition of 50µL of EB buffer to the column, followed by spinning at 
13,000rpm for 1min, and the plasmid DNA concentration checked by UV spectrometry.  
 
2.1.3.2 Maxi-Prep 
 
   A single colony grown on selective media was used to inoculate 5mL of LB/LSLB 
containing the same antibiotic. The culture was incubated by shaking at 200rpm at 37
o
C 
for 9hr, before being used to seed a fresh 250mL of LB/LSLB, again with the same 
antibiotic concentrations. This culture was incubated by shaking for 16hr at 37
o
C before 
being harvested by centrifugation at 4,500rpm for 10min at 4
o
C.  
   Pelleted cells were re-suspended in 10mL of Buffer P1 before the addition of 10mL of 
Buffer P2. Cells were mixed gently by inverting, and incubated at r.t for 5min. To the 
lysed cells, 10mL of chilled Buffer P3 was added, and the mixture was allowed to 
separate into two distinct layers. The aqueous layer was applied to a QIAgen-HiSpeed 
Maxi tip, equilibrated in 10mL QBT Buffer, and allowed to enter the resin by gravity 
flow. The tip was washed with 60mL of Buffer QC, and DNA eluted from the tip by 
applying 15mL of Buffer QF by syringe, and collecting the DNA in the flow through. 
DNA was precipitated by the addition of 10.5mL of r.t isopropanol (IPA) and incubated 
at r.t for 5min after mixing. The mix was applied to the QIAprecipitator. Using a 
syringe, 2mL of 70% ethanol (EtOH) was added to the precipitator.  
   The DNA (contained within the precipitator) was eluted by adding 1mL of Elution 
Buffer (EB) to the precipitator with a syringe. The concentration of the DNA in the 
flow-through was determined by UV spectrometry.  
 
2.1.3.3 Gel Extraction 
 
   For isolation of plasmid DNA from agarose gels following DNA agarose gel 
electrophoresis (described in 2.2.2), all extractions were carried out using the QIAquick 
Gel Extraction Kit (QIAgen). The desired DNA fragment was excised from the agarose 
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gel, with a clean, sharp scalpel, taking care to avoid the inclusion of excess agarose. The 
gel slices were then weighed, and 300µL of Buffer QG added per 100mg of gel slice, 
before incubation at 50
o
C for 10min, or until gel slices dissolved. One gel volume (e.g. 
100µL to 100mg of gel) of r.t IPA was added. The mixed sample was placed in the 
QIAquick spin column and the column placed in a 2mL collection tube. The sample was 
spun at 13,000rpm for 1min and flow-through discarded. Buffer QG (500µL) was then 
added to the column, followed by spinning at 13,000rpm for 1min, discarding the flow-
through.  
   The bound DNA was washed by applying 750µL of PE Buffer to the column, 
spinning at 13,000rpm for 1min, discarding the flow-through. The column was spun 
once more to remove residual buffer, before the column was placed in a clean 2mL 
collection tube. DNA was eluted by the addition of 30µL of EB Buffer to the centre of 
the column membrane. The column was left at r.t for 3min, before being spun at 
13,000rpm for 1min to elute the now unbound DNA. Concentrations of recovered DNA 
were determined by UV spectroscopy. 
2.1.4 Sequencing of Plasmid DNA   
   In order to confirm whether mutagenesis or cloning have been successful, the plasmid 
DNA was screened using the automated service GenePool (University of Edinburgh). 
DNA sequencing for all fH constructs cloned into the pPICZα vector used primers 
targeting the alpha secretion factor, the sequences for which are shown in Table 2.4. 
Table 2.4: Sequencing primers for pPICZα 
Primer Sequence 
5’α-factor 5’-TACTATTGCCAGCATTGCTGC-3’ 
3’α-factor 5’-GCAAATGGCATTCTGACATCC-3’ 
 
   DNA sequencing for all constructs cloned into vectors carrying the T7 promoter and 
terminator (common in IPTG inducible proteins) was carried out at Genepool, 
University of Edinburgh. Primers used for targeting the T7 promoter and terminator are 
shown in Table 2.5. 
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Table 2.5: Sequencing primers for T7 promotor and terminator 
 
 
 
   For each sequencing reaction, 250-300ng of template DNA was added to 1µL of 
forward or reverse primer, and 4µL of prism BigDye Terminator Mix (Applied 
Biosystems, California, USA), and the reaction mixture  made up to 20µL with the 
addition of ddH2O. The BigDye Reagent is necessary for the dideoxy method for 
sequencing as developed by Sanger et al, 1977, which utilizes the ability of DNA-
polymerases to incorporate nucleotide analogues such as 2’,3’-dideoxynucleotides 
(ddNTPs).   
   When a dideoxynucleotide is incorporated at the 3’-end of the growing chain, chain 
elongation is terminated selectively at A, C, G, or T because the ddNTP lacks a 3-
hydroxyl group. The BigDye terminator mix contains four different fluorescently 
labelled ddNTPs, which are added sequentially to the primer through cycled sequencing 
reactions. The outcome is a mixture of fragments with different ddNTP residues at the 
3’-end which can be separated by polyacrylamide gel electrophoresis, where a pattern of 
bands is obtained from which the sequence can be read off. Table 2.6 outlines the 
parameters for the PCR reaction for these sequencing reactions. 
 
 
                                Table 2.6: Programme used for Sequencing PCR 
Step Temperature (
o
C) Time (s) Cycles 
INITIATION 95 30 1 
DENATURATION 96 30 24 
ANNEALING 50 30 24 
ELONGATION 60 240 
plasmid 
length 
24 
HOLD 4 ∞ - 
 
 
Primer Sequence 
5’α-factor 5’-TACTATTGCCAGCATTGCTGC-3’ 
3’α-factor 5’-GCAAATGGCATTCTGACATCC-3’ 
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2.2 Mutagenesis, Purification, and Manipulation of DNA for 
Transformation into Electro-Competent Pichia pastoris (P. pastoris) 
2.2.1 Amplification of specific CCPs from the full length codon optimised fH gene 
using PCR 
   The gene encoding full length fH, codon optimised for expression in P. pastoris, was 
purchased from GeneArt® (California, USA). This served as the template DNA from 
which both of the fH fragments used in this study were amplified. Primers were 
designed to match the first 25 bases of the desired CCP fragment for the 5’ annealing, 
and the last 25 bases of the fragment for 3’ annealing. Designing primers would result 
in amplification of just the desired fragment, either fH1-4 or fH19-20, from the full 
length gene. The following pipetting scheme and PCR programme were used to 
facilitate this (Tables 2.7 and 2.8). 
 
 
Table 2.7: PCR Reaction Mixture for CCP Amplification 
 
 
 
 
Table 2.8: Programme used for fH CCP Amplification PCR 
 
 
 
 
 
 
             5.0 µL    Pfu-buffer (10x) 
             1.0 µL ddNTPs 
             1.0 µL Primer 5’ 
             1.0 µL Primer 3’ 
             1.5 µL DMSO 
             1.0 µL Template DNA (fH gene) 
             1.0 µL Pfu Turbo® polymerase 
            38.5 µL ddH2O (final volume 50µL) 
Stage Temperature (
o
C) Time (s) Cycles 
    
INITIATION 95 300 1 
DENATURATION 95 30 35 
ANNEALING Tmelt  -5
o
C 30 35 
ELONGATION 68 120 (60/kb plasmid) 35 
EXTENSION 72 600 1 
HOLD 4 - - 
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2.2.2 DNA Agarose Gel Electrophoresis 
 
   Agarose gel electrophoresis is a well-established method for separation of DNA 
molecules according to their size. Following amplification of the fH fragments by PCR, 
the resulting PCR product was run on an agarose gel to confirm the size. Upon 
application of an external electrical field, DNA molecules migrate through the gel due 
to the nature of the negatively charged nucleic acids. DNA fragments of smaller size 
migrate readily and more quickly through the agarose gel matrix than those of larger 
size, and so are resolved further down the gel.   
   To prepare a 1% gel, 1g of agarose was added to 100mL of TBE Buffer, and the 
mixture heated in a microwave oven until the agarose was fully dissolved and the 
mixture molten. The mixture was allowed to cool to 55
o
C, before either 10µL of EtBr 
(10mg/mL stock) or 10µL of SYBR®Safe (Life Technologies, California, USA) 
(1:10,000 dilution) was added. The gel was cast with combs to create wells, and allowed 
to set.  
   Dependent on the size of construct being resolved, either a 100bp or 1kbp DNA 
ladder (2µL) was used as a size standard (New England BioLabs (NEB), Massachusetts, 
USA). Samples were prepared by the addition of sample DNA (2µL) to (5x) DNA 
loading buffer (8µL) (New England BioLabs (NEB), Massachusetts, USA). The gel 
tank was filled with TBE buffer and samples run at 90V for 30min, or until bands were 
nicely separated. EtBr and SYBR®Safe are hydrophobic molecules that work by 
intercalating DNA between the stacked bases which can then be visualised using UV 
light and a trans-illuminator (Benchtop 3 UV transilluminator, UVP, Cambridge, UK).  
 
2.2.3 Cloning of fH Fragments into pPICZαB Vector, Using Restriction Enzymes  
   Once fragment size was confirmed, SDM was carried out, as detailed in 2.1.1, to 
incorporate cysteine residues for SDSL purposes, and the restriction sites PstI and XbaI 
at the N’ and C’ termini of each fragment, respectively. Incorporation of these 
restriction sites allows for ligation of the DNA fragments into the Multiple Cloning Site 
(MCS) of the pPICZαB vector. The chosen mutations in each fragment were K247C 
and G1107C for the fH1-4 and fH19-20 fragments, respectively. Following 
unsuccessful expression tests of the fH1-4 fragment, the fH1-4 fragment was further 
mutated by the inclusion of a C’ terminal hexa-histidine tag. 
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2.2.3.1 Double Digest   
   The remainder of the PCR products of the amplified fH fragments were run on an 
agarose gel, alongside some of the empty pPICZαB vector, as detailed in 2.2.2, and gel 
extraction carried out, as detailed in 2.1.3, in order to purify the DNA. Once eluted from 
the gel extraction columns, the DNA was treated with 1µL each of the restriction 
enzymes PstI and XbaI, 1µL of Bovine Serum Albumin (BSA), and 60µL of Buffer 3.1 
(all NEB). Each fragment, and the empty vector, was incubated with the restriction 
enzymes for 2hr at 37
o
C before the enzymes were heat inactivated at 80
o
C for 20min. 
2.2.3.2 Ligation of Digested Fragments into pPICZαB   
    Following digestion with the restriction enzymes, 50ng of the cut vector was 
combined with 150ng of the relevant fragment, 2µL of 10x ligation buffer (NEB) and 
the reaction left at r.t for 10min, before 1µL of T4 DNA ligase (NEB) was added, and 
the reaction mixture adjusted to a final volume of 20µL with the addition of ddH2O. The 
reaction was left at r.t for 3 hr, before 5µL of the ligation reaction was transformed into 
Top 10 chemically competent E. coli cells, as described in 2.1.2, using Zeocin
TM
 for 
selection. 
2.2.3.3 PCR Colony Screen 
   In order to confirm whether a ligation reaction has been successful following 
transformation, it is possible to screen any colonies that form and differentiate between 
those which contain the plasmid with insert, or those that contain the empty plasmid 
vector. From fresh ligation transformation plates, several colonies were re-streaked onto 
relevant agar media with appropriate antibiotic to give more working material. After a 
20hr period, a scraping from each colony restreak was used to inoculate a separate 20µL 
of EB Buffer (QIA Prep MiniPrep Kit), until the reaction mixture was cloudy. The 
samples were heated at 95
o
C for 5min to lyse the bacteria and solubilize the plasmid 
DNA. To 5µL of PCR MasterMix (Promega), 2µL of both the forward and reverse 
sequencing primers (Tables 2.4 and 2.5) were added, alongside 2µL of the lysed 
bacteria. The programme used for thermal cycling is outlined in Table 2.9. 
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Table 2.9: Programme used for PCR Colony Screen 
Step Temperature (
o
C) Time (s) Cycles 
INITIATION 95 120 1 
DENATURATION 95 45 39 
ANNEALING 55 45 39 
ELONGATION 72 120 39 
EXTENSION 72 300 39 
HOLD 4 ∞ - 
 
   Immediately following the PCR reaction, each colony was tested for successful 
ligation by analysing each PCR product by DNA agarose gel electrophoresis (2.2.2). 
This procedure distinguishes between those colonies carrying the relevant insert and 
those which contained empty plasmid vector, which still contains the relevant antibiotic 
resistance markers. Those clones which appear at the expected size for the fragment 
successfully ligated into the vector were confirmed by sequencing (2.1.4), before maxi-
preps (2.1.3) were carried out to yield more DNA. 
2.2.4 Preparation of DNA for Transformation into P.  pastoris                                     
   Purified plasmid DNA that had been previously transformed into E. coli required 
linearization before it could be successfully incorporated into P. pastoris via 
homologous recombination. Therefore, 25µg of plasmid DNA (from maxiprep), was 
incubated with 5µL of the restriction enzyme SacI (plus 6µL BSA and 60µL Buffer I, 
NEB) which cuts at a specific recognition site in pPICZαB. Consequently, it is vital that 
the gene of interest does not contain this restriction site. Successful linearization was 
confirmed by agarose gel electrophoresis (2.2.2) and the enzyme heat-inactivated by 
incubating at 62
o
C for 30min. 
2.2.4.1 Phenol-Chloroform Extraction              
   To clean the DNA and eliminate any residual enzyme, a phenol-chloroform extraction 
was performed using a phenol:chloroform:isoamyl alcohol mixture (25:24:1) saturated 
with 10mM Tris, pH 8.0, 1mM EDTA. Briefly, the DNA was washed with an equal 
volume of phenol:chloroform before being spun for 1min at 13,000rpm (4
o
C). The 
aqueous layer was then washed in the same manner. Finally, an equal volume of 
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chloroform was added to the aqueous layer, the mixture spun, and the aqueous layer 
taken off. A 10% solution (v/v) of sodium acetate (NaAc) was added (3M, pH 5.2) as 
well as 2.5mL of ice cold 100% EtOH. The mixture was then kept at -20
o
C overnight 
before undergoing EtOH precipitation. 
2.2.4.2 EtOH Precipitation 
   Following overnight incubation at -20
o
C, the DNA sample was spun at 13,000rpm for 
30min at 4
o
C. The supernatant was discarded and 400µL of ice cold 70% EtOH added. 
Further spinning at 13,000rpm for 10min at 4
o
C followed. The supernatant was 
removed and the pellet allowed to air dry, before being re-suspended in 11µL of ddH2O. 
DNA was stored at -20
o
C. 
2.2.5 Preparation of electro-competent P. pastoris cells 
   From a stab culture (Invitrogen) of P. pastoris strain KM71H, YPD agar plates were 
streaked to obtain single colonies. A single colony was used to inoculate 5mL of YPD 
medium and this was left shaking overnight at 30
o
C. The overnight culture was then 
used in volumes of 20,40 and 80µL to inoculate a fresh 100mL of YPD medium (in 
3x1L baffled flasks), and left overnight at 30
o
C until an OD600 of between 1.3 and 1.5 
was achieved. Three different inoculation volumes were used to ensure there were cells 
available should one culture overgrow.  
   Cells were harvested by centrifugation at 1,500 x g for 5min at 4
o
C and the pellet re-
suspended in 100mL of ice-cold ddH2O (sterilized by autoclaving). Spinning was 
repeated, and cells re-suspended in 50mL of ice-cold ddH2O. Following another spin 
the cells were re-suspended in 4mL of ice cold IM sorbitol (sterilized by autoclaving) 
before the final spin and re-suspension in 200µL of ice-cold 1M sorbitol. Cells were 
kept on ice for use that day as they cannot be stored. 
2.2.6 Electro-transformation of P. pastoris 
   Linearised DNA (~30µg in no more than 10µL) was added to the wall of a pre-chilled 
electroporation cuvette (Gene Pulser Cuvettes 0.2cm gap, BioRad, Hemel Hempstead, 
UK) and 80µL of the electro-competent P. pastoris cells allowed to wash over the 
DNA. The cuvette was incubated on ice for 5min then cells pulsed at 1.5V for 6s 
(resistance selection: low range 200Ω, high range 1500Ω, BioRad Genepulser © II, 
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BioRad). Immediately after, 1mL of ice cold YPDS media was added to the cuvette and 
the contents transferred into a sterile pre-chilled 15mL Falcon 
TM
 conical tube.  
   The cells were incubated without shaking for 3hr at 30
o
C, before being plated in 
volumes of 150µL and 250µL on YPDS agar at varied Zeocin
TM
 concentrations (100, 
200, 300, and 500µg/mL). Plates were incubated for 5 days at 30
o
C until colonies 
formed. Colonies found on those plates with higher Zeocin
TM
 concentration contain 
multiple plasmid inserts and are therefore likely to yield higher levels of protein due to 
higher expression levels.                 
2.3 Recombinant Protein Expression Using E. coli Expression Systems 
   Expression on all scales (unless otherwise stated) was carried out at 37
o
C in a shaking 
incubator (250rpm, New Brunswick Scientific Model G25, Innova 4430 incubator 
shaker, New Brunswick Scientific, St Albans, UK). For overexpression of recombinant 
proteins, plasmid DNA was transformed into either DH10β or BL21 (DE3) E. coli cells, 
as described in 2.1.2, using heat shock at 42
o
C for 45 and 30 s respectively. Otherwise, 
cells provided as glycerol stocks in Rosetta
TM
2(DE3) cells were plated on LB agar 
containing the appropriate concentrations of antibiotic in order to isolate single 
colonies. All cells were harvested by centrifugation with the Sorvall© legend RT 
centrifuge, using the Sorvall© SH-3000 swinging bucket rotor and SS-34 fixed angle 
rotor (Thermo Scientific, UK). 
 
2.3.1 Expression of RLC/MiniHMM Constructs 
 
   Original plasmids for expression of the MiniHMM fragment, human cardiac RLC and 
cardiac myosin binding protein C, domain C0, were provided by Dr Mark Pfuhl Kings 
College, London.  
   The antibiotics used for selection throughout were Amp and Kan at the concentrations 
outlined in Table 2.3. Following successful transformation of the plasmids containing 
the MiniHMM construct and the myosin RLC, a single colony was used to inoculate 
10mL of LB broth, and the culture grown over the course of one day, before 600µL was 
used to inoculate 10mL of fresh LB media. From the new culture, 500µL was added to 
each litre of LB broth (for large scale expression), and cultures grown overnight at 30
o
C 
with shaking at 200rpm. 
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    Following overnight incubation, the temperature was increased to 37
o
C, and cells 
grown until an OD600 of ~1.00 was achieved. At this point, cells were moved to 4
o
C for 
30min, before expression was induced overnight at 18
o
C, with shaking at 200rpm, with 
the addition of 100mg of IPTG (dissolved in 1mL of ddH2O) per 1L of cell culture. 
Cells were harvested by centrifugation at 6,000 rpm for 15min at 4
o
C. Supernatants 
were discarded and cells lysed. 
 
2.3.1.1 Cell Lysis of RLC/MiniHMM Constructs 
 
   Following pelleting of cells, 100mL of lysis buffer was added, and cells re-suspended. 
Cells were kept on ice for 30min, and 10mg of lysozyme added to the mixture, with 
frequent stirring. To this, 1mL of Triton X-100 (25% stock) was added, giving a final 
detergent concentration of 0.25%,  and cells kept on ice for 15min, again with frequent 
stirring.   
   Cells were frozen in liquid nitrogen for 5min before being removed and left at r.t for 
10min. Cells were broken up, and 100mL of lysis buffer added with stirring at r.t for 
15min, until all cells were thawed, and the mixture homogeneous. Cells were then 
transferred back to ice, and 500µL of DNase (2mg/mL stock) added, and cells stirred 
frequently on ice, until no longer viscous. Cells were diluted with a half volume of lysis 
buffer before being spun at 9,000rpm for 2hr at 4
o
C. 
 
2.3.2 Expression of Myoglobin Mutants and cMyBP-C Domain C0 
 
   Original plasmids for the expression of sperm whale myoglobin, as well as the 
plasmid containing the pyrrolysyl tRNA synthetase / tRNACUA(Pyl) pair for Unnatural 
amino acid incorporation were provided by Prof Jason Chin, MRC, Cambridge. 
   The antibiotics used for selection were Kan and Tet at the concentration outlined in 
Table 2.3 for cMyBP-C and Myoglobin respectively. Following successful 
transformation of plasmid DNA (2.1.2) into DH10β E. coli cells, a single colony was 
used to inoculate 100mL of LB, supplemented with the appropriate antibiotic, and the 
culture grown overnight at 37
o
C with shaking (200 rpm). Following overnight 
incubation, 10mL of the starter culture was used to sub-culture each litre of LB. Cells 
were grown until an OD600 of between 0.6 -0.8 was achieved, before protein expression 
induced for 5hr at 37
o
C with the addition of L-arabinose (0.2% final concentration) for 
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myoglobin, and 1mM (final concentration) IPTG for the cMyBP-C domain C0. Cells 
were pelleted by centrifugation, supernatants discarded, and cells kept at -20
o
C until cell 
lysis by sonication. 
 
2.3.2.1 Cell Lysis of Myoglobin Mutants and cMyBP-C Domain C0 by Sonication 
 
   All cells were allowed to thaw on ice, before being re-suspended in lysis buffer. 
Sonication was carried out on ice, using a 30s on/off cycle for 15min at 15 amplitude 
microns. The suspension was clarified by centrifugation (16,000rpm, 4
o
C) for 30min, to 
precipitate cellular debris and insoluble materials, and obtain a cell free extract. 
2.3.3 Expression of 6xHis TEV Protease 
   A glycerol stock containing Rosetta
TM
 2(DE3) cells successfully transformed with the 
recombinant 6xHIS TEV protease was kindly donated by Dr Huanting Liu and Prof. 
James H. Naismith, University of St Andrews, Scotland, UK.  
   The antibiotics used for selection throughout were Cm and Amp at the concentrations 
outlined in Table 2.3. To 10mL of LB broth, a single colony was added, and cells grown 
overnight at 37
o
C with shaking at 200rpm, before being used to inoculate 1L of LB 
broth. Cells were grown until an OD600 of 0.6 was achieved, before protein expression 
was induced by the addition of IPTG at a final concentration of 0.4mM, and cells 
incubated with shaking overnight at 37
o
C. Following overnight induction, cells were 
harvested by centrifugation at 6,000rpm for 10min at 4
o
C, and the pelleted cells kept at -
70
o
C until ready to be lysed. 
 
2.3.3.1 Cell Lysis of 6xHis TEV Protease by Sonication 
 
   Pelleted cells were thawed on ice, and re-suspended in 10mL of Lysis Buffer . Once 
homogenous, cells were sonicated on ice for 3x45s intervals, with a 1min break in 
between, at 15 amplitude microns, before being centrifuged at 10,000 rpm for 20min at 
4
o
C. The supernatant was collected and further clarified by further centrifugation at 
18,000 rpm for 30min at 4
o
C. 
 
2.3.4 Expression of Myoglobin with the UAA pK Incorporated 
 
   The antibiotics used for selection throughout were Tet and Kan at the concentrations 
outlined in Table 2.3. Following successful co-transformation of the plasmids 
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containing the myoglobin construct and the plasmid containing the relevant tRNA and 
tRNA synthetase for incorporation of the UAA pK, a single colony was used to 
inoculate 100mL of LB broth and this incubated with shaking (200rpm) overnight at 
37
o
C. Following overnight incubation, the starter culture was used to seed more LB 
broth. Cells were grown until an OD600 of 0.6-0.8 was achieved.  
   At this point, the UAA pK was added at a final concentration of 2mM and 3mM for 
single and double mutants respectively. The UAA was dissolved in DMSO. Cells were 
left shaking for 30min at r.t, before L-arabinose was added at a final concentration of 
0.2% to initiate induction. Cells were induced for 5hr at 37
o
C, before being harvested by 
centrifugation at 4,500 rpm for 15min at 4
o
C. Pelleted cells were kept at -20
o
C until 
ready to be lysed. 
 
2.3.4.1 Cell Lysis of Myoglobin containing the UAA, pK,  
 
   Pelleted cells were allowed to thaw on ice, before 10mL of r.t BugBuster
TM 
(MerkMillipore,  Massachusetts , USA) was added, and cells re-suspended. Cells were 
shaken at r.t for 60min before lysed cells were pelleted by centrifugation at 10,000rpm 
for 20min at 4
o
C. 
 
2.3.5 Expression of 14-3-3ϛ and Vps75 mutants 
 
   Agar plates from the successful transformation of the recombinant 14-3-3 ϛ and 
Vps75 proteins into Rosetta
TM
 2(DE3) were kindly provided by Dr David Norman, 
University of Dundee, Scotland, UK. From these glycerol stocks were made for 
subsequent expression. 
   The antibiotics used for selection throughout were Amp and Cm for 14-3-3ϛ and 
Vps75, respectively, at the concentrations outlined in Table 2.3. To 10mL of LB broth, 
a single colony was added, and cells grown overnight at 37
o
C with shaking at 200rpm, 
before being used to inoculate 1L of LB broth.  
   Cells were grown until an OD600 of between 0.6 and 0.8 was achieved, before protein 
expression was induced by the addition of IPTG at a final concentration of 1mM, and 
cells incubated with shaking for 4hr at 37
o
C. Following induction, cells were harvested 
by centrifugation at 6,000rpm for 10min at 4
o
C, and the pelleted cells kept at -20
o
C until 
ready to be lysed. 
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2.3.5.1 Cell Lysis of 14-3-3ϛ and Vps75 Mutants by Sonication 
 
   All cells were allowed to thaw on ice, before being re-suspended in lysis buffer. 
Sonication was carried out on ice, using a 30s on/off cycle for 15min at 10 amplitude 
microns. The suspension was clarified by centrifugation (16,000rpm, 4
o
C) for 30min, to 
precipitate cellular debris and insoluble materials, and obtain a cell free extract. 
2.4 Recombinant Protein Expression Using the P. pastoris Expression 
System 
   Expression on all scales (unless otherwise stated) was carried out at 30
o
C in a shaking 
incubator (250rpm, New Brunswick Scientific Model G25, Innova 4430 incubator 
shaker, New Brunswick Scientific, St Albans, UK). In order to optimise protein 
expression in P. pastoris there must be sufficient aeration, in particular during the 
methanol (MeOH) induction phase and therefore culture volumes did not exceed 30% of 
the total volume of the baffled flasks. All cells were harvested by centrifugation with 
the Sorvall© legend RT centrifuge, using the Sorvall© SH-3000 swinging bucket rotor, 
Thermo Scientific, UK). All media used for the expression of recombinant proteins in 
P. pastoris are included in Appendix A1 and A12. 
 
2.4.1 The P. pastoris Expression System 
   P. pastoris is a eukaryotic, single celled microorganism, ideally suited for protein 
over-expression due to the ease with which it can be manipulated and cultured. P. 
pastoris can be cultured to high cell densities for high level production of recombinant 
proteins, with the added capability in the form of post translational modifications, such 
as disulphide bond formation, protein folding, and glycosylation (Zhang et al, 2009). 
The ability to fold proteins correctly, as well as the efficient secretion of proteins extra-
cellularly puts P. pastoris at a major advantage over more traditional expression 
systems such as E. coli, especially when working with proteins with internal disulphide 
bonds and additional free cysteine residues.  
   P. pastoris is one of several expression systems capable of utilizing MeOH as both a 
carbon and energy source. This organism has a metabolic pathway for the consumption 
of MeOH based upon its oxidation to formaldehyde, catalysed by the enzyme alcohol 
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oxidase (AOX). There are numerous host strains of P. pastoris, each varying in their 
ability to utilise MeOH, due to deletions in one or both of the AOX genes. The KM71H 
strain used throughout has the Mut
S
 phenotype, meaning that it is particularly slow in 
MeOH utilisation, due to a disrupted AOX I gene. In Mut
S
 strains, transcription of the 
AOX genes is repressed when grown in the presence of sufficiently high concentrations 
of either glucose or glycerol, meaning that addition of MeOH serves primarily as an 
inducer of the disrupted AOX I promoter, whilst the alternative carbon source acts as 
the growth medium. 
   The pPICZα vector (Invitrogen) illustrated in Figure 2.1 contains the promoter for the 
AOX I region, one of the strongest known promoters in nature (Schmidt et al, 2011). 
The vector used throughout is the 3.6kb pPICZαB.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: The pPICZαB vector: The vector map summarises the features of the pPICZαB vector, and 
its use for protein expression in P. pastoris. From Invitrogen.com 
  Upon induction with MeOH, the organism expresses the protein of interest, the gene of 
which is inserted directly behind the promoter. Insertion of the foreign gene is done so 
in the multi-cloning site which houses several unique restriction sites for the insertion of 
the desired gene.  
   The transcriptional termination sequence of the AOX I gene follows. Pichia secretes 
only a small number of proteins, and so insertion of the gene encoding the yeast mating 
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α factor peptide downstream from the AOX I targets the secretory pathway, and allows 
most proteins to be secreted directly into the media. P. pastoris has favourable 
properties for the secretion of high molecular weight proteins which are otherwise 
inefficiently secreted in most other yeast species, due to the retention of the recombinant 
protein in the periplasmic space (Schmidt et al, 2011). Lastly a Zeocin
TM
 resistance 
cassette is incorporated to allow for selection in both E. coli for plasmid 
manipulation/cloning purposes and in P.  pastoris for recombinant protein expression. 
2.4.2 Small-scale protein production 
   Due to the slow growing nature of this particular strain of P. pastoris, it is necessary 
to identify those clones which show higher levels of recombinant protein expression. 
Following transformation, small – scale expression tests were carried out for this 
purpose, allowing the best clones to be selected for larger scale flask expression or for 
fermentation purposes. A single colony was used to inoculate 5mL of BMGY media 
(for test expressions from glycerol stocks, the stock was first streaked onto the 
appropriate concentration of Zeocin
TM
 on YPDS agar, to achieve single colonies) and 
grown overnight with shaking at 30
o
C. This 5mL starter culture was then used to 
inoculate a further 95mL of fresh BMGY media and shaken at 30
o
C for 72hr, allowing 
the cell density to increase with the addition of a carbon source, whilst inhibiting 
induction. Each 100mL culture was spun down at 3,000 x g for 15min to pellet cells, 
which were then re-suspended in 25mL of BMMY media. 
    Cells were incubated at 18
o
C for 96hr with shaking, supplementing cultures with 
0.5% (v/v) MeOH once every 24hr, and twice (AM and PM) in the final 24hr period. 
Cell cultures were harvested by centrifugation at 3000 x g for 15min, and supernatants 
filter sterilized (using Millex® Syringe Filter Units, 33mm, 0.22µM PES, Merck 
Millipore, Nottingham, UK). Supernatants were either concentrated by centrifugation at 
3,000rpm using Vivaspin® 20 10,000 Dalton MWCO spin concentrators (Merck 
Millipore, Nottingham, UK) to a final volume of 1mL, or samples were taken from un-
concentrated supernatants. The supernatants were analysed for protein expression by 
sodium dodecylsulfate (SDS) polyacrylamide gel electrophoresis (Section 2.7.1). Those 
clones which were found to express best were used to make glycerol stocks, from which 
all future expression and purification were performed. 
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2.4.3 Large-scale protein production 
   Once small-scale expression tests had established which clones were better expressers 
of the protein of interest, large scale flask expression could then be carried out to 
increase yield. In a similar fashion, a single colony was used to inoculate 5mL of 
BMGY media. Following overnight incubation at 30
o
C, the 5mL starter culture was 
used to inoculate 95mL of fresh BMGY media. Cells were left shaking overnight at 
30
o
C before the 100mL was used to inoculate 400mL of fresh BMGY media, giving a 
final culture volume of 500mL per 2L baffle flask. Cells were left shaking at 30
o
C for 
48hr before being spun down at 3000 x g for 15min at 4
o
C and cells re-suspended in 
125mL BMMY media. Cells were grown for a further 96hr at 18
o
C with shaking, 
supplementing the cells with 0.5% MeOH (v/v) every 24 hr for the first 48 hr, and 
subsequently 1% MeOH every 24hr for the last 48hr (AM and PM).  
   Cell cultures were then harvested by centrifugation at 3000 x g for 15min, and 
supernatants filter sterilized. Supernatants were either concentrated by centrifugation at 
3,000rpm to a final volume of 1mL, or samples were taken from un-concentrated 
supernatants. The supernatants were analysed for protein expression by sodium 
dodecylsulfate (SDS) polyacrylamide gel and kept at 4
o
C until required for purification.  
 
2.4.4 Fermentation 
   All large-scale (ten-litre) fermentations were performed by Dr. John White at the 
University of Edinburgh. Fermentation, conducted on a Bioflow 3000 (New Brunswick 
Scientific, New Jersey, USA), allowed the temperature, pH, agitation, and air flow to be 
monitored and adjusted as required to optimise protein expression. Following successful 
transformation of fH fragments into P. pastoris, the clone which was found to express 
best was used to inoculate 2x 5mL of BMGY. The starter cultures were grown 
overnight at 30
o
C, 200rpm before being used to inoculate 2x95mL of fresh BMGY 
media. This was then grown overnight at 30
o
C, 200rpm, before the two cultures were 
used to inoculate 2x400mL of fresh BMGY media, giving a final culture volume of 1L 
(2x500mL).   
   The final 2x500mL cultures were grown overnight for 48hr at 30°C, 200 rpm and 
were used to inoculate the fermenter. The fermenter was previously supplemented with 
autoclaved fermentation media. To induce gene transcription, 0.5 % (v/v) MeOH and 
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1.5% PTM1 salts were added. After the initial MeOH had been consumed, further feeds 
of MeOH – to 1.5% (v/v) - and 1% tryptone (w/v) were given for three days; the timing 
of which was based on the agitation rate and the amount of dissolved oxygen present in 
the vessel, so as to avoid overfeeding or poisoning of the cells. Following the 
fermentation procedure, cells were spun at 4,000 rpm for 60min.  
   The supernatant was then transferred to sterile centrifuge bottles and spun again for 
60min at 7,000rpm to ensure all cell mass was removed. The spinning was all carried 
out at 4
o
C. Supernatants were then carefully decanted and a final concentration of 5mM 
EDTA and 0.5mM PMSF were added to reduce protease activity. The supernatant was 
then stored at 4
o
C for immediate purification, or at -80
o
C for long term storage before 
purification. 
2.5 Purification of Recombinant Proteins 
   All columns and resins, with the exception of the Ni-NTA Superflow cartridges 
(5mL) (QIAgen), were purchased from GE healthcare Bio-Sciences (Amersham, UK).    
Dialysis was carried out using SnakeSkin™ Dialysis Tubing, with a molecular weight 
cut off (MWCO) suitable for the protein of interest, at 4
o
C with stirring. In between 
each purification step, samples were concentrated using Vivaspin® Centrifugal 
concentrators, with MWCO suitable for the protein of interest.  
   With the exception of purification steps being performed using a peristaltic pump (P-
1, GE Healthcare, Amersham, UK), all chromatography was performed using the  fast 
protein liquid protein chromatography (FPLC) systems, AKTA FPLC (GE Healthcare 
Bio-Sciences, Amersham, UK) and AKTAxpress (Amersham Bio-Sciences, Amersham, 
UK).  
   For Immobilised Metal Affinity Chromatography (IMAC), the column was stripped 
with 5CV of 100mM EDTA, washed with 5CV of ddH2O, recharged with 5CV of 
100mM NiS04 and finally washed with 5CV of ddH2O to remove residual NiSO4, before 
purification. Before being loaded onto the Ni-NTA columns, all supernatants were filter 
sterilised using Millex® Syringe Filter Units, 33mm, 0.22µM PES, Merck Millipore, 
Nottingham, UK). 
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2.5.1 Purification of 6xHIS TEV Protease Using IMAC 
   All buffers used for the purification of the TEV protease are included in Appendix 
A8. Following centrifugation to obtain a cell-free extract, the supernatants were applied 
to a 5mL Ni-NTA Superflow Cartridge, pre-equilibrated in 5CV of equilibration buffer, 
using a peristaltic pump at a flow rate of 0.5mL/min. The column was washed with 5 
CV, and the TEV protease eluted over 5CV of elution buffer in 3 mL fractions. 
Following SDS-PAGE analysis those fractions containing TEV protease were pooled, 
and the pool dialysed for 2hr at 4
o
C (Buffer 1). This was repeated, before a final 2hr 
dialysis at 4
o
C (Buffer 2). The protein was then centrifuged at 14,000rpm for 10min at 
4
o
C to remove any precipitate, and the TEV protease stored at -80
o
C at a final 
concentration of ~ 6mg/mL. 
2.5.2 Purification of RLC/MiniHMM Constructs Using IMAC 
   All buffers used for the purification of the RLC/MiniHMM are included in Appendix 
A7. Following centrifugation to obtain a cell-free extract, the supernatants were applied 
to a pre-equilibrated (5CV) 5mL Ni-NTA Superflow Cartridge, using a peristaltic pump 
at a flow rate of 5mL/min. The column was washed with 10CV of equilibration buffer, 
before a second wash of 5CV was performed. The protein was eluted in 5CV of elution 
buffer in 3mL fractions, and protein containing fractions analysed by SDS-PAGE. 
2.5.2.1 Cleavage of the Histidine Tag 
   Fractions found to contain the myosin RLC/MiniHMM complex were pooled, and to 
this, recombinant TEV protease was added in the ratio of 1 unit of TEV protease to 100 
units of target protein (weight : weight). The cleavage reaction was allowed to persist 
for 3hr at r.t, before the mixture was dialysed overnight at 4
o
C into non-imidazole 
buffer. Following overnight dialysis, the pooled protein fractions were flowed back over 
the recharged pre-equilibrated (5CV) Ni-NTA cartridge at a flow rate of 2mL/min. The 
flow through containing the cleaved RLC/MiniHMM complex was collected from the 
column, and the column washed with 5CV of wash buffer, followed by 5CV of elution 
buffer, which acts to remove un-cleaved protein, the cleaved tag and residual TEV 
protease from the column. The elution fractions were confirmed by SDS-PAGE 
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analysis, and the cysteine mutants treated with a final concentration of 10mM DTT to 
ensure the cysteine residue incorporated for SDSL purposes is free for labelling.   
2.5.3 Purification of Wild Type, Cysteine and pK Containing Myoglobin Mutants, 
and cMyBP-C Domain C0 Using IMAC 
   All buffers used for the purification of domain C0 and the myoglobin mutants are 
included in Appendix A7 and A9, respectively. Following centrifugation to obtain a 
cell-free extract, the supernatants were applied to a pre-equilibrated 5mL Ni-NTA 
Superflow Cartridge, using a peristaltic pump at a flow rate of 2mL/min, or manual 
injection using a syringe for the UAA pK containing mutants. The column was then 
washed with 20CV, and the protein eluted in 6CV, in 1.5mL fractions, and purity 
determined by SDS-PAGE analysis. Concentrated protein was stored in 50% glycerol at 
-20
o
C before the labelling reaction was carried out.  
   Purification of low spin myoglobin for data collection on HiPER differs slightly to 
that detailed in 2.5.3, and as such is described separately in detail in 5.13. 
2.5.3.1 Size Exclusion Chromatography 
   For cysteine mutants which would be subsequently spin-labelled (2.9.1.), the sample 
was treated with a final concentration of 10mM DTT at r.t for 1 hr. A pre-equilibrated 
HiLoad
TM
 16/600 Superdex
TM
 S-75 size exclusion column was loaded with the 7.5mL 
concentrated sample, which was eluted over 1CV of elution buffer, collecting 2mL 
fractions.  
 
2.5.4 Purification of 14-3-3 ϛ Using IMAC 
   All buffers used for the purification of 14-3-3ϛ are included in Appendix A10. 
Following centrifugation to obtain a cell-free extract, the supernatants were applied to a 
pre-equilibrated (5CV) 5mL Ni-NTA Superflow Cartridge, using a peristaltic pump at a 
flow rate of 5mL/min.  
   The column was washed with 10CV of equilibration buffer, before a second wash of 
5CV was performed. The protein was eluted in 5CV of elution buffer in 3mL fractions, 
and protein containing fractions analysed by SDS-PAGE. Samples were concentrated 
using Vivaspin® centrifugal concentrators. 
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2.5.4.1 Size Exclusion Chromatography 
   A HiLoad
TM
 16/600 Superdex
TM
 S-75 size exclusion column was pre-equilibrated 
with 2CV, and the concentrated 14-3-3ϛ sample loaded onto the column, and eluted 
over 1CV with elution buffer (AKTAxpress, Amersham Biosciences, UK), collecting 
2mL fractions. 
2.5.5 Purification of Vps75 Using IMAC 
   All buffers used for the purification of Vps75 are included in Appendix A11. 
Following centrifugation to obtain a cell-free extract, the supernatants were applied to a 
pre-equilibrated (5CV) 5mL Ni-NTA Superflow Cartridge, using a peristaltic pump at a 
flow rate of 5mL/min. The column was washed with 10CV of equilibration buffer, 
before a second wash of 5CV was performed. The protein was eluted in 5CV of elution 
buffer in 3mL fractions, and protein containing fractions analysed by SDS-PAGE. 
Samples were concentrated using Vivaspin® centrifugal concentrators. 
 
2.5.5.1 Size Exclusion Chromatography 
   A HiLoad
TM
 16/600 Superdex
TM
 S-75 size exclusion column was pre-equilibrated 
with 2CV, and the concentrated Vps75 sample loaded onto the column, and eluted over 
1CV with elution buffer (AKTAxpress, Amersham Biosciences, UK), collecting 2mL 
fractions. 
2.5.6 Purification of fH 1-4 K247C Fragment Using IMAC 
   All buffers used for the purification of fH1-4 K247C are included in Appendix A3. 
The inclusion of a hexa-histidine tag at the C’ terminus of the fH1-4 facilitates the use 
of IMAC as the first catchment step in the purification of fH1-4 K247C. Due to the 
addition of EDTA (5mM) following harvesting of fermentation, the supernatant was 
diluted with wash buffer to give a final concentration of <1mM EDTA, so as not to strip 
the charged Ni-NTA cartridge. The diluted supernatant was loaded onto the pre-
equilibrated column (5CV), using a peristaltic pump at a flow rate of 2mL/min. The 
column was washed with 10CV, before the bound protein was eluted using an imidazole 
gradient of 50-500mM, over 10CV, collecting 5mL fractions. Fractions were analysed 
by SDS-PAGE. 
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2.5.6.1 Anion Exchange Chromatography  
   The concentrated samples were exchanged into wash buffer to eliminate NaCl and 
facilitate binding of the fH1-4 K247C mutant to the TricornMonoQ 4.6/100 (1.7 mL 
CV) Mono Q anion exchange column. Elution of the desired protein was achieved by 
applying a linear NaCl-gradient from 100% wash buffer to 100% elution buffer, over 
20CV, at a flow rate of 2mL/min, collecting 2mL fractions. Fractions were then 
analysed using SDS-PAGE and relevant fractions pooled and concentrated before being 
treated with a final concentration of 250µM TCEP-Hydrochloride, which acts to keep 
the incorporated cysteine free for SDSL purposes, whilst maintaining the integrity of the 
internal disulphide bonds of the fH1-4 fragment (Burns et al, 1991). 
 
2.5.6.2 Size Exclusion Chromatography 
   A HiLoad
TM
 16/600 Superdex
TM
 S-75 size exclusion column was pre-equilibrated 
with 2CV, and the concentrated fH1-4 sample loaded onto the column, and eluted over 
1CV with elution buffer (AKTAxpress, Amersham Biosciences, UK), collecting 2mL 
fractions.  
2.5.7   Purification of fH19-20 G1107C Fragment Using SP Sepharose FastFlow 
Cation Exchange Chromatography Resin 
   All buffers used for the purification of fH19-20 G1107C are included in Appendix 
A4. SP Sepharose FastFlow resin was used as the first catchment step in the purification 
of the fH19-20 G1107C fragment. To an empty XK 26/20 column (GE Healthcare), 
30mL of the resin was added, and the column packed using a peristaltic pump. 
Following expression, the supernatants were diluted by a factor of 10 using ddH2O, in 
order to reduce the conductivity, which rises as a result of the addition to PTM1 salts, 
and aids binding of the fH19-20 fragment to the ion exchange resin.  
   The diluted supernatant ranges from a final volume of between 10 and 80 litres, and 
so the supernatant was applied to the packed XK 26/20 column using a peristaltic pump, 
overnight at 4
o
C at the maximum flowrate. Elution of the desired protein was achieved 
by applying a linear NaCl-gradient from 100% wash buffer to 100% elution buffer, over 
20CV, at a flow rate of 2mL/min, collecting 2mL fractions. 
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2.5.7.1 Cation Exchange Chromatography 
   The concentrated samples were exchanged into wash buffer to eliminate NaCl and 
facilitate binding of the fH19-20 G1107C mutant to the Resource
TM
 15S cation 
exchange column. Elution of the desired protein was achieved by applying a linear 
NaCl-gradient from 100% wash buffer to 100% elution buffer, over 20CV, at a flow 
rate of 2mL/min, collecting 2mL fractions. Fractions were then analysed using SDS-
PAGE and relevant fractions pooled and concentrated before being treated with a final 
concentration of 250µM TCEP-Hydrochloride, which acts to keep the incorporated 
cysteine free for SDSL purposes, whilst maintaining the integrity if the internal 
disulphide bonds of the fH19-20 fragment. 
 
2.5.7.2 Size Exclusion Chromatography 
   A HiLoad
TM
 16/600 Superdex
TM
 S-75 size exclusion column was pre-equilibrated 
with 2CV, and the concentrated fH19-20 sample loaded onto the column, and eluted 
over 1CV with elution buffer (AKTAxpress, Amersham Biosciences, UK), collecting 
2mL fractions.  
2.6 Isolation and Purification of Complement Proteins From Human 
Blood/Plasma 
   Experiments looking at the interactions of Complement Factor H and C3b began at 
the University of Edinburgh in collaboration with Prof Paul N. Barlow (2011-2013). 
Following relocation of our research group to the University of St Andrews, work 
carried out was done so in compliance with the Ethical Application Submitted to The 
University of St Andrews, School of Physics and Astronomy (Ethics Reference No: 
PA10837, 20
th
 February 2014). Copies of the application form, participant information 
forms, statement of approval, and consent forms are included as Appendices. 
2.6.1 Small-scale isolation of complement C3 
All buffers used for the purification of C3 are included in Appendix A5. 
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2.6.1.1 Obtaining the Plasma Fraction from Whole Blood 
   Complement C3 is one of the most abundant plasma proteins, present in the plasma at 
a concentration of ~ 1.2 mg/mL (Sahu & Lambris, 2001), and so was purified from 
fresh human plasma using methods adapted from Dodds, 1993. Plasma was prepared by 
collecting freshly drawn blood (typically 20mL) from healthy volunteers into 50mL 
falcon tubes containing sodium EDTA at a final concentration of 10mM. Tubes were 
inverted to ensure thorough mixing and samples left on ice for 15min before 
centrifugation at 2,000g, for 10min at 4
o
C to obtain the plasma fraction. 
2.6.1.2 Precipitation of Major Blood Proteins 
   The plasma was made 5% (w/v) by the addition of polyethylene glycol3350 (PEG3350). 
To the plasma, 5mL of a 15% PEG3350 solution (in wash buffer) was added to 
precipitate major blood proteins, such as antibodies (e.g. IgG and IgM), and rolled for 
30min at 4
o
C, before being spun at 10,000rpm for 20min to pellet the resulting 
precipitate.  
2.6.1.3 Anion Exchange Chromatography – Q-Sepharose Fast Flow Resin 
   The supernatant was then loaded at a flow rate of 2mL/min at 4
o
C onto a 20cm x 
1.6cm diameter column (GE Healthcare) packed with Q-Sepharose® FastFlow resin, 
pre-equilibrated in 95% wash buffer and 5% elution buffer. C3 was eluted with a linear 
NaCl gradient (10CV, 5-50% elution buffer at a flow rate of 1mL/min) to a final 
concentration of 500mM NaCl, collecting elution fractions (2mL) on ice. The C3 pool 
then underwent three rounds of dialysis in a final volume of 5L of wash buffer to 
eliminate NaCl and ultimately lower the ionic strength and allow binding to the higher 
resolution Mono Q column for subsequent purification steps. (Zhang et al, 2003) 
2.6.1.4 Anion Exchange Chromatography – Mono Q 
   The 5/50 Mono Q column was pre-equilibrated with 90% wash buffer, 10% elution 
buffer. The pooled C3 fractions were eluted over several rounds of anion exchange 
chromatography using a 1M NaCl gradient (20mL, 10-30% elution buffer, at a flow rate 
of 1mL/min).  Following purification on the Mono Q column, C3 fractions were pooled 
and again dialysed three times against 5L of wash buffer to again eliminate NaCl and 
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lower ionic strength. The concentration of the purified C3 was determined to be 
0.3mg/ml using a UV spectrophotometer (Eppendorf) using C3 molar Extinction 
Coefficient at 280nm of 180,000M
-1
cm
-1
. 
2.6.1.5 Size Exclusion Chromatography 
   A HiLoad
TM
 16/600 Superdex
TM
 S-75 size exclusion column was pre-equilibrated 
with 2CV, and the concentrated C3 sample loaded onto the column, and eluted over 1 
CV, collecting 2mL fractions.  
2.6.2 Large Scale Isolation of Complement C3 
   All buffers used for the purification of C3 are included in Appendix A5. The process 
was scaled up, from a starting material of 20mL of blood (giving 10 mL plasma) to 
150mL of blood (75mL plasma). The purification process was carried out as detailed 
above, however, a Resource
TM
 15 Q column (20ml) was used between the QSFF and 
Mono Q purification steps. The concentrated samples were exchanged into wash buffer 
to eliminate NaCl and facilitate binding of the protein to the Resource
TM
 15Q anion 
exchange column. Elution of the desired protein was achieved by applying a linear 
NaCl-gradient from 100% wash buffer to 100% elution buffer, over 20 CV, at a flow 
rate of 2mL/min, collecting 2mL fractions. The remainder of the purification proceeded 
as detailed above. 
2.6.3 Conversion of C3 to C3b using Trypsin 
   All buffers used for the purification of C3b are included in Appendix A6. 
   Purified C3 was then converted to C3b using methods adapted from (Wu et al,  2009). 
To successfully convert C3 to the activated C3b and release the cysteine residue in the 
thioester for spin labelling purposes, C3 must undergo a limited trypsin proteolysis at 
37
o
C to release the C3a fragment, leaving activated C3b. Purified C3 at a concentration 
of 1mg/ml was treated with a 1% trypsin solution (w/w, enzyme/protein) for 2min at 
37
o
C in PBS, to simulate physiological pH. Immediately after incubation, 5% (w/w 
inhibitor/enzyme) soybean trypsin inhibitor was added to stop the reaction.  
   For the proposed DEER experiments, C3b is required in both a labelled and non-
labelled form. For the unlabelled reaction, following trypsin proteolysis and trypsin 
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inhibition, the sample was immediately transferred to ice, followed by treatment with a 
final concentration of 20mM iodoacetamide for 30min. Iodoacetamide binds covalently 
with the newly released cysteine residue on the activated thioester on C3b, therefore 
blocking this binding site.  
   The C3b was then diluted at a ratio of 1:1 with wash buffer, and eluted over 30 CV 
with a linear salt gradient of 100-300mM NaCl from the pre-equilibrated Mono Q 
column. The fractions containing C3b in its pure form were pooled and dialysed against 
PBS, before being stored at -80
o
C. The purity of C3b was verified using SDS-PAGE. 
2.6.4 Conversion of C3 to ‘C3 (N)’ – An Alternative to C3b 
   All buffers used for the purification of C3(N) are included in Appendix A6. 
Conversion of C3 to C3(N) was done so using protocols adapted from Holm et al, 
2012). Purified C3 was treated with a final concentration of 200mM methylamine in 
wash buffer, at 37
o
C for 3hr. The pH of the buffer was adjusted following the addition 
of methylamine (pH7.5). The reaction mixture was incubated in the presence of either 
iodoacetamide (20mM final concentration) or with a 10x molar excess of MTSSL spin 
label, depending on whether the protein was required in its labelled or unlabelled form. 
   Following the 3hr incubation period, the C3 pool was then purified in the same way 
detailed above, as for C3b. Following the final SEC step, purity of the methyl amine 
treated C3, or C3 (N), was determined by SDS-PAGE analysis, and proteins 
concentrated to ~1mg/mL before being stored at -80
o
C. 
2.7 Protein Quantification 
2.7.1 Sodium-Dodecyl Sulphate Polyacrylamide Gel Electrophoresis(SDS-PAGE) 
   All gels used for protein identification were 4-12% NuPage® Bis-Tris gels (Life 
Technologies) and were run in 1X in NuPage® MES or MOPS Buffers. For improved 
resolution of high molecular weight proteins, e.g. C3, C3b and C3(N), MOPS was the 
preferred buffer. Samples were prepared, and 4x NuPage® LDS sample buffer was 
added to a final concentration of 1x. If samples were being run in their reduced form, 
then 10x NuPage® sample-reducing agent (Life Technologies) was added to a final 
concentration of 1x.  
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   Samples were heated at 95 – 100 °C for 5min. The samples were run alongside a 
protein ladder (10 – 250 kDa range) to provide a size standard, at 250V until good 
separation of the ladder was achieved (~ 25min). Prior to staining, the gel was washed 
in water followed by heating, using a microwave oven, for 30s; this was repeated 3 
times to remove the SDS from the gel.  
   Staining was performed using traditional Coomassie Blue staining for 15min with 
shaking. The gel was then destained by the addition of Coomassie Destain and heated 
for 1min before shaking, until the Coomassie was removed from the gel, and protein 
bands could be visualised. 
2.7.2 Western Blotting 
   Western Blotting was carried out for more specific detection of particular constructs 
if, following Coomassie staining, the SDS-PAGE gels was inconclusive. All antibodies 
(Table 2.10) were diluted as per the manufacturer’s instructions. 
          Table 2.10: Antibodies used for Blotting, company purchased from, and working dilution 
Anti-Factor H polyclonal antibody (raised in 
goat)  
Calbiochem 1:200 
Anti-Goat IgG (whole molecule)–Peroxidase 
antibody (raised in rabbit)  
 
Sigma Aldrich 1:50,000 
Histidine Tag (6xHis) Monoclonal Antibody 
(raised in mouse) HRP Conjugate 
 
Life Technologies 1:5,000 
 
    In this instance, a gel was run as detailed in 2.7.1, however, the Coomassie staining 
procedure was omitted. Western blotting was carried out using standard protocol and 
PVDF membrane. Blotting pads and filter paper were soaked in Towbin Transfer 
Buffer, before being layered in the blotting module with the SDS-PAGE gel, and PVDF 
membrane, pre-soaked in 100% MeOH. The transfer was carried out using XCell II.Blot 
Module (Life Technologies) at a constant voltage of 30V for 1hr in Towbin Transfer 
buffer. The transfer was monitored by staining the gel afterwards and using pre-stained 
molecular-weight markers.  
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   After the transfer, the membrane was blocked overnight on an orbital rocking platform 
at 4
o
C using PBS containing 5 % non-fat dried milk (w/v) (blocking solution, 
supermarket brand). The membrane was then placed in a 5% (w/v) non-fat milk solution 
(in PBS) with the recommended dilution (Table 2.10) of the primary antibody, and 
incubated at 4
o
C for 3hr.  
   The membrane was rinsed with PBS and washed three times with PBS containing 
0.05 % TWEEN®20 for 30min, and washed with PBS for another 10min. The 
membrane was then probed with the secondary antibody at the desired dilution in a 5% 
(w/v) solution of non-fat milk in PBS. The secondary antibody is conjugated to horse 
radish peroxidase. This was incubated for 2hr at 4
o
C. The blot was then washed as 
described above with PBS and PBS-TWEEN® before being developed.  
   The blot was developed in the developing buffer, containing 1 diamino benzidine 
(DAB) tablet and 1 urea hydrogen peroxide tablet in 15mL of ddH2O. The HRP 
conjugated to the secondary antibody oxidizes the DAB in the presence of hydrogen 
peroxide, giving the characteristic brown staining on the membrane, indicative of the 
secondary antibody bound to the primary. The membrane was shaken for 15min to 
develop and washed with water to remove excess stain, and dried overnight.  
2.7.3 Determination of Protein Concentration Using Absorbance A280 
   Protein concentrations can be determined using the Beer-Lambert Law, shown in 
equation 2.2, where (A) = the absorbance at a given wavelength, (ε) = the molar 
extinction coefficient, (c) = Protein concentration, and (l) is the path length.   
A= εcl (EQUATION 2.2) 
   The molar extinction coefficients can be determined by entering the amino acid 
sequence of the protein of interest into the ExPASy ProtParam Tool. Proteins absorb 
light at 280nm due to the presence of chromophores such as tryptophan, tyrosine and 
phenylalanine residues. 
2.7.4 Determination of Protein Concentration Using the Micro-Bradford Assay 
   The concentration of purified proteins could be determined using a modified ‘micro’ 
version of the Bradford assay (Bradford, 1976)With the micro-Bradford assay one can 
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determine protein concentrations in the range of 1 - 10 μg/mL. The assay is a 
colourimetric technique, based on a shift in absorbance from 465 to 595nm, upon 
binding of Coomassie brilliant blue to proteins. For the purposes of this assay, the 
Bradford reagent (BioRad) was diluted by a factor of 5, and a standard series of BSA at 
concentrations 0,1,3,5,7, and 10µg/mL used for calibration. The standard and samples 
were incubated with the Bradford reagent for 10min at r.t and the absorbance was read 
at 595 nm.  
 
2.8 Protein Characterisation 
 
2.8.1 Mass Spectrometry (MS) Analysis 
 
   Samples were submitted to the Scottish Instrumentation and Resource Centre for 
Advanced Mass Spectrometry (SIRCAMS) at the University of Edinburgh for high 
resolution liquid chromatography (LC) – MS, with the aim of acquiring an approximate 
mass. The samples were supplied in 2–5μM concentrations in 20μl of either 20mM 
potassium phosphate, pH 6, or PBS. Data was collected by passage through an LC-MS 
U300HPLC 500μM PSDVB monolyth column (Dionex) followed by Fourier-transform 
ion-cyclotron resonance (FT–ICR) mass spectrometry (Bruker Daltonics 12T SolariX 
Fourier Transform Ion Cyclotron Resonance Mass Spectrometer).  
   MS was carried out at the University of Edinburgh SIRCAMS facility by Dr David 
Clarke and Dr Logan Mackay.  
   At the University of St Andrews MS facility, analysis was carried out by Dr Catherine 
Botting, and Dr Sally Shirran. Proteins submitted for intact mass determination by 
Electro-Spray Ionisation-Time of Flight MS were run at a concentration of 
10pmoles/µL.  
 
2.8.2 Ellman’s Assay - For the Quantification of Free Cysteine 
 
   This assay for the quantification of free thiols was developed in 1959 by Ellman et al, 
and further modified in 1968 by Sedlak & Lindsay. When in its reduced form, one can 
use the assay to determine the concentration of free cysteine (thiol) in a given sample, 
which proves useful for this work, when quantifying free cysteine levels before SDSL is 
carried out. The Ellman’s reagent 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB), as shown 
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in Figure 2.2A, reacts quantitatively with free thiol groups, forming a mixed disulphide. 
(SH group of free cysteine, and 2-nitro-5-thiobenzoate (NTB). The NTB component is 
shown in Figure 2.2B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Ellman’s Assay Reaction. DTNB (A) reacts with a free thiol to form NTB (B), the reactive 
reagent of the Ellman’s assay.   
 
 
   During the reaction of the Ellman’s Reagent with proteins containing free thiols, the 
2-nitrobenzoate-thio-anion, NTB, is stoichiometrically released, and can be detected by 
UV at 412nm. By measuring this, one can calculate the concentration of the NTB anion 
and thus the concentration of sulfhydryl groups. To ensure all proteins were in their 
reduced form prior to performing the assay, they were treated with a final concentration 
of 1mM DTT or 250µM TCEP, for 1h at r.t. The reducing agent was then removed by 
either dialysis or buffer exchange, and the Ellman’s assay was performed. 
   The DTNB working stock was made by dissolving 40mg in 10mL of DMSO, before 
diluting this 100 fold with 0.1M Tris-HCl, pH7.5, giving a 0.1mM DTNB working 
solution. Samples were prepared by adding 50µL of standard or protein to 950µL of 
DTNB working solution, incubating at r.t for 15min before measuring the absorbance of 
samples at 412nm. The assay was calibrated using a solution of L-Cysteine at various 
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known concentrations, and utilising the known extinction coefficient of the reaction 
product, NTB (13,800 M
-1
cm
-1
). The L-cysteine calibration curve is shown in Figure 
2.3. 
 
 
 
 
 
 
 
 
Figure 2.3: L-cysteine calibration curves for determining free cysteine concentration. (A) L-cysteine 
standards measured at 412nm upon reaction with DTNB. (B) Determination of thiol concentration from 
each standard, using the extinction coefficient of the NTB component at 412nm. 
 
2.9   Protein Chemistry 
 
2.9.1 SDSL of Incorporated Cysteine Residues 
 
   As stated previously, each protein was treated with a reducing agent prior to labelling, 
to ensure that the incorporated cysteine residue was free for spin labelling purposes. 
Following quantification of free thiol levels (2.8.3), each protein could then be spin-
labelled. Typically, the MTSSL spin label (Toronto Research Chemicals, Ontario, 
Canada) was added in a 10x molar excess.  
   The spin label was first dissolved in 100µL of DMSO, before the dissolved label was 
added to ~1mL of r.t 50mM Tris-HCl (pH7.5). The label was then added directly to 
pooled protein fractions, and left overnight at 4
o
C, before excess spin label was 
removed by successive rounds of dialysis or by buffer exchange using Vivaspin® 
concentrators. 
 
 
 
 
 
       A                                                                          B 
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2.10 Functional Characterisation 
 
2.10.1 Assessing Cofactor Activity of C3b, C3 (N) and fH1-4 K247C 
 
   FH regulates the activation of the complement system by acting as a cofactor in the 
cleavage of complement C3b to its inactive form, iC3b, by fI. A fluid-phase cofactor 
assay can be used to definitively say whether plasma purified C3, converted to 
C3b/C3(N), functions as such.  
   In this particular assay, the 110kDa alpha chain of C3b is cleaved into two smaller 
components (67 and 40 kD). Figure 2.4 shows a schematic representation of cleavage of 
the alpha chain, in the presence of fH and fI. 
 
 
 
 
 
 
 
 
 
Figure 2.4: Schematic Representation of the Fluid-Phase Cofactor Assay. C3b is composed of two 
disulphide linked chains, α and β. Following incubation with both fH and fI, cleavage of the 110kDa 
alpha chain results in two smaller 67 and 40kDa components. C3b is converted to iC3b, which is 
visualised using SDS-PAGE. 
 
   Upon cleavage, C3b is converted to iC3b, and no longer functions in complement 
activation, ultimately limiting the production of the convertase C3bBb, therefore 
stopping the positive feedback loop of complement activation, and limiting activation. 
FH, fI, and C3b were purchased from Complement Technology (CompTech, Texas, 
USA). For the control reactions, all three components of the assay were from 
CompTech stocks, with the negative control being carried out in the absence of fH.  
   When assessing the function of the C3b, C3 (N) and fH1-4 K247C expressed and 
purified in this work, these proteins were used in place of the CompTech standards. For 
each reaction 45ng of fI, 120ng of fH and 3µg of C3b/C3 (N) were combined in a final 
assay volume of 20µL in PBS, pH7.4. The reaction mix was vortexed and incubated at 
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37
o
C for 2 hr in a circulating water bath. An aliquot of SDS loading dye was added to 
stop the reaction, and samples were analysed by SDS-PAGE. 
 
 2.11   EPR Spectroscopy 
   R.t. CW EPR Spectra were recorded at the University of Edinburgh on a Bruker 
ESP300 X-band EPR spectrometer. At the University of St Andrews CW EPR spectra 
were recorded on a Bruker EMX X-band EPR spectrometer, using either a rectangular 
low sensitivity cavity or high sensitivity SHQE resonator, and using the AffirmoEx 
benchtop spectrometer, by ActiveSpectrum. 
DEER experiments were performed on a Bruker Elexsys 580 X-band spectrometer, 
until 2014 when high powered Q-band was introduced.  
   For DEER measurements performed at X-band the 12ns pump pulse was set to the 
maximum of the echo detected spectrum. The 32ns observer pulse was set to 65MHz 
above.  
   For DEER measurements performed at Q-band the 14ns pump pulse was set to the 
maximum of the echo detected spectrum. The 24ns observer pulse was set to 80MHz 
below. 
   Typically, CW measurements were taken in non-deuterated buffer. Where samples 
had to be frozen for DEER, a cryo-protectant was added, either glycerol or deuterated 
glycerol to a final concentration of 50%. The glycerol helps in glass formation during 
freezing, which helps with relaxation. Deuterated buffers also help prolong spin 
coherence. 
   All experiments conducted at W-band using HiPER (Cruickshank et al, 2009) were 
performed by Miss Claire Motion, University of St Andrews, Scotland, UK. 
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Chapter 3:   The Complement Factor H (fH) – C3b 
Complex: An EPR Study 
AIMS: This body of work uses EPR spectroscopy to probe the interactions of 
complement proteins C3b and Factor H (fH). Complement is a complex cascade of 
enzymatic cleavages, cumulating in cleavage of C3 to C3b, marking cells for 
destruction by the immune system. This is tightly regulated by Factor H (fH). FH 
domains 1-4 and 19-20 are known binding sites for C3b. DEER will be used to gain 
further insight into the structure of fH in the context of C3b. FH fragments are 
expressed recombinantly in Pichia pastoris yeast, and cysteine residues incorporated 
using mutagenesis for SDSL. C3b cannot be made recombinantly, and in this work is 
generated from cleavage of the purified plasma protein C3. A hidden thioester is then 
utilised as a spin-labelling site. 
3.1 The Role of the Complement System in Innate Immunity 
   First identified in human serum in the late 19
th
 century as a complement to antibodies 
in mediating bacterial lysis, the complement system emerged more than one billion 
years ago, probably as the first humoral immune system (Liszewski & Atkinson, 2015). 
The complement system is a major primary defence and clearance mechanism which 
straddles both the innate and adaptive immune systems, providing a non-specific and 
potent first-line in defence against infection (Walport, 2001). Complement activity is 
established by the orchestration of between 35 and 40 soluble plasma and cell surface 
proteins circulating as inactive precursors, which function to mark pathogenic surfaces 
and host apoptotic cells for cell lysis and clearance, whilst stimulating the adaptive 
immune response (M. C. Carroll, 2004) (Carroll & Sim, 2011). 
    Initial protection against infection occurs as a result of generation of large numbers of 
active complement proteins that bind and target cells for phagocytosis. Cleavage of 
specific complement proteins follows, which results in the release of inflammatory 
anaphylatoxins, recruitment of immune cells to the vicinity, and the initiation of an 
amplifying cascade of further cleavages, cumulating in assembly of the membrane 
attack complex (MAC), and ultimately cellular destruction (Ricklin et al, 2010). 
Regulation of these amplification cascades is of critical importance for maintaining 
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homeostasis, as well as preventing rapid depletion of complement proteins, whilst 
limiting damage to the host (Markiewski & Lambris, 2007). 
 
3.1.1 Mechanisms of Complement Activation 
 
   Dependent upon the trigger, complement can be activated via three very distinct 
cascades, namely the classical, lectin and alternative pathways of complement 
activation. Initiation of each of these biochemical cascades occurs via the proteolytic 
cleavage of inactive complement pre-cursors upstream, producing the active enzymatic 
form, enabling activation of complement proteins further downstream.  
   Although each of the three pathways is distinct in its activation, they all converge at 
the production of C3 and its cleavage to C3a and C3b, resulting in the generation of 
anaphylatoxin C5a, activation of the common terminal pathway, and assembly of the 
MAC (as reviewed by (Merle, Church et al,  2015) and (Merle, Noe et al, 2015)). 
    Activation of complement via the alternative pathway (AP) differs somewhat from 
other means of complement activation, and it is the interactions, and protein complexes 
associated with the AP of complement activation on which this work will focus.  
 
3.1.2 The Alternative Pathway of Complement Activation 
 
   Complement activation via the AP contrasts significantly with other means of 
complement activation, in that it is continuously stimulated due to an inherent ‘tick-
over’ mechanism (Janssen & Gros, 2007), whereby a buried thioester (TE) moiety in the 
thioester domain (TED) on component C3, is spontaneously hydrolysed at a slow but 
constant rate, by nucleophilic attack by water, leading to the generation of C3(H2O).  
The tick-over mechanism of the AP of complement activation is illustrated in Figure 
3.1.  
   Binding of Factor B (fB) to the C3(H2O) complex, makes it susceptible to cleavage by 
Factor D (fD), a serine protease, generating a C3 convertase, C3(H2O)Bb, which 
initiates the proteolytic cleavage of C3, releasing anaphylatoxin C3a, and main fragment 
C3b. C3b is structurally similar to C3(H2O), and so in a similar fashion, it binds fB, 
forming C3bB – the ‘pro-convertase’ complex. This encourages cleavage by fD, 
forming the fluid phase AP convertase, C3b.Bb. 
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Figure 3.1: ‘Tick-Over’ Mechanism of the AP of Complement Activation. Spontaneous hydrolysis of 
C3 at low level, leads to the formation of C3(H2O). C3(H2O)  binds fB, enabling cleavage of this complex 
by fD, resulting in formation of a soluble C3 convertase, C3.H2O.Bb. Low levels of the C3 convertase 
C3.H2O.Bb are constantly generated resulting in cleavage of C3 to C3b, which in turn, forms the AP 
convertase C3b.Bb. 
 
   Formation of this AP convertase amplifies the response, generating a positive 
feedback loop of C3 conversion to C3b, allowing rapid deposition of large numbers of 
C3b molecules (in excess of 10
8
) onto individual cellular surfaces in a process known as 
opsonisation. This amplification loop is believed to account for up to 80% of total 
complement activation (Pouw et al, 2015).  
   Some C3b re-associate with C3b.Bb complexes, resulting in the formation of 
C3b.Bb.C3b, the C5 convertase, switching the substrate to C5, and initiating the 
terminal pathway of complement activation – formation of the MAC – and targeted 
cellular destruction (Gros, 2011).   
 
3.1.3 Complement Activation – Driven by Conformational Change 
 
   Complement component C3 is a member of a family of α2-macroglobulins (α2-M), 
also containing homologous proteins C4 and C5 (Sottrup-Jensen et al, 1985), which are 
characterised by homologous sequence features including a unique and eponymous TE 
motif (Gros, Milder, & Janssen, 2008).  
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   Human C3 is synthesised in the body as a large, 185kDa, single chain polypeptide  
(Janssen & Gros, 2007), which is processed by the selective removal of four 
consecutive arginine residues (Arg 646-Arg 649), resulting in a 110kDa alpha chain 
(residues 650-1641) and a 75kDa beta chain (residues 1-645), linked by a single 
disulphide bond. Figure 3.2 shows the XRC structures of both C3 and C3b, as well as 
the TE in both its open and closed formation. 
 
 
 
 
 
Figure 3.2: Conversion of Complement C3 to its activated form C3b. Upon activation, a previously 
hidden TE, responsible for binding of C3b to target cells in the opsonisation process, is exposed. (A) 
Cartoon representation of C3 with alpha chain shown in Cyan and beta chain in Slate. The TE domain is 
shown as purple spheres. The ANA domain (C3a) is shown in magenta. PDB_ID: 2A73 (Janssen et al, 
2006). Upon cleavage to C3b (B), the ANA domain is lost, and the remainder of the protein (now C3b) 
undergoes conformational change, exposing the previously hidden TE. PDB_ID: from 2WII (Wu et al, 
2009). (C) Stick representation of the TE formed between Cys 988 and Gln 991, which is in the closed 
state in C3. Upon conversion to C3b from C3, the TE bond is broken (D), and C3b uses the newly 
exposed and activated TE for cell binding. 
   Activation of component C3 to C3b is a crucial step in each of the distinct pathways 
of the complement cascade, in which a previously unexposed TE domain becomes 
exposed, as well as multiple cryptic binding sites on C3b for interacting complement 
proteins (Janssen et al, 2005).  
   C3 is composed of 13 domains, with the eponymous TE domain housing the iso-
glutamyl cysteine TE bond (formed between the sulphur of Cys 988 and the carbonyl 
group of Gln 991). Ultimately, localization of immune response is determined by the 
reactive TE moiety of C3 (Lambris, 1988), which is buried in a hydrophobic pocket 
(residues Met 1378, Tyr 1425, Tyr1460, Phe 1047, which are conserved across the α2-M 
family), but becomes exposed in C3b after the C3a anaphylatoxin (protective ANA 
domain) is lost from C3 (following cleavage at Ser726, Arg 727).  This results in a 
truncated alpha chain (residues 727 – 1641), whilst the beta chain remains unaffected.  
Cys 988 
Cys 988 
Gln 991 
Gln 991 
Gly 989 Gly 989 
Glu 990 
Glu 990 
      A                                  B                                     C                                           D 
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   Subsequent reshuffling of the domains via conformational change, rotates the TED by 
85
o
, rendering the TE solvent-accessible (Gros et al, 2008). Rearrangement of the TED 
cleaves the newly exposed TE into a highly reactive thiolate anion on Cys 988 and an 
acyl-imidazole intermediate by Gln 991, which will react with any nucleophile, 
particularly carbohydrates and hydroxyl groups on target cellular surfaces.  
   It is via this TE moiety that nascent C3b molecules bind covalently to cellular surfaces 
in a process known as opsonisation. Amplification of complement activity is achieved 
by association of surface bound C3b and pro-enzyme fB, yielding the short-lived C3 
convertase C3bBb of the AP (Half Life (T1/2) = 90s). Conversion of subsequent C3 
molecules to C3a and C3b stimulates the relevant immune response whilst amplifying 
the positive feedback loop of complement activation (Law & Dodds, 1997a), enabling 
elimination of both self and non-self target cells. It is the covalent coupling of C3b via 
this TE to target particles which is critical in the generation of local complement 
activation and amplification (Gros et al, 2008). 
3.1.4 Derivatization of Complement C3 – Labelling with Bio-Reporters 
   The highly labile and conserved TE motif of the α2-M class of proteins is an 
extremely rare and distinctive post –translational modification, making these proteins 
theoretically amenable to selective, site specific, labelling (Cole et al, 2009). 
  Upon activation from C3 to C3b, although the TE becomes more exposed, and 
extremely reactive to many nucleophiles, this reactivity is very short lived, and the 
coupling efficiency of C3b to targets is greatly reduced, due to the shortened life span of 
the TE (Holm et al, 2012). The fast hydrolysis of the TE in C3b provides  means to 
contain the potentially damaging reaction to the immediate proximity of the site of 
activation, however, this greatly reduces the potential of labelling the free cysteine of 
the newly cleaved TE with specific probes e.g. with nitroxide spin labels for EPR 
studies.  
   The previously discussed inherent ‘tick over’ mechanism of the AP of complement 
activation, whereby intact C3 is slowly hydrolysed at low level to C3(H2O), 
demonstrates that the TE bond of C3, although buried in the inactive form, is solvent 
exposed. The intact TE protein behaves as a typical protein TE, with an estimated half- 
life of hydrolysis of ~160 hours (Holm et al, 2012), and so it seems that this particular 
part of the pathway would be an ideal point for the incorporation of such probes.  
Chapter 3: The C3b:fH Complex – An EPR Study 
94 
 
This hydrolysis of C3 to C3(H2O) demonstrates that protection of the TE before 
activation from C3 to C3b is not absolute, with small nucleophiles capable of making 
similar conformational rearrangements in the native C3 (Cole et al, 2009).  
   C3 can be treated with small nucleophiles, such as methylamine, which are covalently 
incorporated into the protein, in this case forming C3(N). The TE is amino-lysed, and 
the metastable cysteine side chain of the TE bond becomes transiently available for 
chemical derivatization. This is demonstrated in Figure 3.3. 
 
 
 
 
 
 
Figure 3.3: Generalised Reaction Mechanism for the Reaction of a Nucleophile with the TE of C3. 
This gives route for the modification of the intact C3 protein without need for activation. 
   This was demonstrated by (Cole et al, 2009) and their incorporation of nucleophiles 
with different functionalities (biotin, various small peptides, tags (V5 and FLAG) and 
fluorescein) into C3 via the TE. Breaking of the TE bond using small nucleophiles 
generates C3(N), which adopts a ‘C3b-like’ structure (Law & Dodds, 1997), with ‘C3b-
like’ function (Isenman, et al, 1981), whilst the ANA domain remains bound, with 
interaction sites for fH and fI remaining exposed.  
   The TE of C3b has a t1/2 of ~60µs, making derivitization with EPR spin labels 
particularly challenging.  However, using C3(N) as an alternative, it is still possible to 
incorporate spin labels via the cysteine residue that becomes accessible following 
treatment with a nucleophile. Although the cysteine has to be derivatized relatively 
quickly, to prevent oxidation or disulphide bond formation, the potential labelling time 
is greatly increased, and should facilitate more efficient labelling of C3(N).  
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3.1.5 Regulators of Complement – fH 
   The efficacy of complement mediated immunity is dependent on maintaining a 
delicate balance between activation and regulation (Wu, et al 2010).  Labelling of cells 
with complement component C3b is indiscriminate between pathogenic invaders and 
host cells (as reviewed by Pangburn, 2000) and so the system is tightly regulated by a 
number of proteins, which ensure C3 activation in the fluid phase is kept to a minimum, 
whilst deposition of C3b on cellular surfaces, and therefore further amplification of 
complement activation, is limited to pathogenic surfaces (as reviewd by De Córdoba & 
De Jorge, 2008) 
   FH is the chief regulator of complement C3, and circulates abundantly as a 155kDa 
single chain glycoprotein in the serum, at a concentration of ~300-800µg/mL (Sim & 
DiScipio, 1982), however recent estimates have been lowered to ~150-300µg/mL 
(Hakobyan et al, 2008). Upon binding to cellular membranes via the recognition of 
specific poly-anions (Pangburn, 2000), and to C3b, fH can modulate surface-associated 
and fluid-phase amplification of complement (Pangburn, et al 2000) (Sharma & 
Pangburn, 1996).  
   FH is composed of twenty homologous repeating domains, or complement control 
protein domains (CCPs), arranged in a ‘beads on a string’ like motif, each containing 
approximately 60 amino acid residues, and separated by short linkers of between 3 and 
8 amino acids (as reviewed by Makou et al, 2013) (Pouw, et al 2015). Figure 3.4 shows 
a schematic representation of fH, showing the number of residues per CCP, and the 
number of linking residues. 
 
 
 
 
Figure 3.4: Linker lengths and residues in Complement fH. Each CCP domain is labelled 1-20 on 
complement fH, with the number of residues found in each CCP stated underneath, as well as the number 
of linking residues between neighbouring CCP domains. Figure generated from data obtained from: 
http://www.bionmr.chem.ed.ac.uk/bionmr/public_html/Residue_lengths.pdf 
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   It is these short linker sequences which introduce a degree of flexibility in the protein, 
and it is proposed that these linkers allow the protein to adopt a ‘bent-back’ 
arrangement, bringing the N’ and C’ termini in close proximity.  
   With the exception of CCPs 9, 14, and 17, which have not yet been solved, it has been 
found that all CCPs share a similar globular structure (Makou et al, 2012, Morgan et al, 
2012), stabilized by two disulphide bonds per CCP module, formed between four 
conserved cysteine residues present in each CCP (between Cys I and Cys III, and 
between Cys II and Cys IV) (Barlow et al, 1991). Figure 3.5 shows the solution NMR 
structure of one CCP module (CCP 16), with the internal disulphides shown as sticks.   
 
 
 
 
 
 
 
 
Figure 3.5: NMR derived three- dimensional cartoon representation of CCP 16 of fH in solution. 
The amino acid sequence of CCP 16 is shown, with the four invariant cysteine residues highlighted. In the 
structure the four invariant cysteine residues are represented as sticks, in the same colours as highlighted 
in the protein sequence. The structure was visualized using PyMOL (PDB_ID: 1HCC). 
 
   Presently, fH has not been crystallised in its entirety, this being accredited to its 
relatively large size, its ability to readily self-associate, forming dimers and higher order 
oligomers, the extent of glycosylation throughout the intact protein, and the potential 
flexibility introduced via the inter-domain linkers between neighbouring CCPs 
(Rodriguez et al, 2014).  
   Efforts have been made to obtain some degree of information on the entire fH 
structure, including solution scattering, analytical centrifugation and transmission 
electron microscopy (DiScipio, 1992) (Perkins et al, 1991) (Okemefuna et al, 2009) 
which point to an overall flexible structure that is, nonetheless, more compact, and 
predicted to be approximately half as long than would be the case if the protein existed 
in a fully extended conformation (Aslam & Perkins, 2001) (Makou et al, 2010). The 
Cys I Cys III 
Cys II Cys IV 
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bent-back structure of fH is shown schematically in Figure 3.6, and the binding sites for 
C3b highlighted. 
 
 
 
 
 
 
 
 
Figure 3.6: Schematic representation of a ‘bent back’ fH, showing distinct interaction sites for C3b. 
(N’ terminal CCPS 1-4, responsible for cofactor and decay acceleration activities shown in pink. C’ 
terminal CCPs 19-20, responsible for cell surface regulation shown in green). In this conformation the N 
and C’ termini of fH are in close proximity. 
 
   Full length fH possesses interaction sites for C3b allowing for control of C3b 
deposition, with distinct function attributed to N’ terminal CCPs 1-4 and C’ terminal 
CCPs 19-20. 
 Structural and functional analyses have shown that domains 1-4 assert their function 
via down-regulation of the feedback loop of activation, by accelerating the decay of the 
C3 convertase (Gigli et al, 1979) (Mullick et al, 2005) as well as acting as a cofactor for 
the fI mediated cleavage of C3b to its inactivated form, iC3b (Gordon et al, 1995). 
Furthermore fH1-4 accelerates the decay of the fluid phase convertase C3bBb, limiting 
the conversion of C3b from C3 (Bhattacharjee et al, 2010).  
    Sugar molecules, such as glycosaminoglycans (GAGs)and sialic acids, provide a 
diverse and complex mechanism by which the complement system can not only identify 
bacteria and other pathogens, but also identify host cell surfaces that require protection 
(Langford-Smith et al, 2015). The function of host discrimination, assigned to the C' 
terminal CCPs 19 and 20 is made possible due to the specific binding of this region to 
the C3d portion of C3b, and to poly-anionic surfaces, such as GAGs (Clark et al, 2013) 
and sialic acids (Kajander et al, 2011) (Blaum et al, 2014).  
   FH engages most effectively with C3b or C3bBb convertases, when bound to surfaces 
carrying such poly-anion markers (Ferreira et al, 2013). A High level of poly-anionic 
markers on self surfaces results in a high level of bound fH in the vicinity, and low 
levels on pathogenic surfaces, which lack these distinct markers. It is this characteristic 
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which allows discrimination by the innate immune system and activation of a relevant 
immune response (Morgan et al, 2011).   
   The importance of fH in maintaining a well-balanced immune response is reflected in 
the increasing number of diseases found to have strong association with mutations and 
polymorphisms in the gene encoding fH (Wu et al, 2009).  
   Irregular complement activation has association with a number of inflammatory 
conditions and autoimmune diseases (De Córdoba & De Jorge, 2008). Tight regulation 
of the complement response at a cellular level and in the fluid phase is of critical 
importance in providing selectivity against foreign bodies, and preventing complement 
mediated tissue damage. This is  reflected in the number of medical conditions, such as 
age related macular degeneration (AMD) and atypical haemolytic uremic syndrome 
(aHUS), which occur as a result of abnormal or incomplete complement activation or 
consumption (Pechtl et al, 2011). Therapeutic targeting of fH is considered of vital 
importance for the treatment of such conditions, associated with loss of complement 
control (Wu et al, 2009).  
 
3.1.6 The fH-C3b Interaction 
 
   The fH1-4 interaction with C3b has been well characterised, and the crystal structure, 
shown in Figure 3.7A solved (Wu et al, 2009), however, the interaction of C3b with 
fH19-20 is not as well defined, despite a small cluster of disease associated mutations 
being present in these modules, together with a polyanion-binding site that is necessary 
for self-surface recognition by fH (Morgan et al, 2011).  
   Work by Morgan et al, has shown that a complex formed between the C3d segment of 
C3b (TED) and fH19-20 emulates the interaction between fH19-20 and C3b in its 
entirety. Crystallisation of the fH19-20:TED complex resulted in three distinct 
structures within the crystal. In Figure 3.7 (BI, BII & BIII) the three potential 
conformations are shown. 
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Figure 3.7: Crystal Structures of fH bound to C3b, shown as cartoons, with accompanying 
schematics. (Crystal structures visualised using PyMOL). (A) Complement C3b (blue) bound to fH1-4 
(purple). (Wu et al, 2009) (PDB_ID: 2WII). (BI, BII, BIII) Three conformations of the TED of 
complement C3b (cyan), bound to fH19-20 (green). (Morgan et al, 2011) (PDB_ID: 3OXU). (CI, CII, 
CIII) Schematic representations of structure (A) superimposed onto each of the three fH19-20:TED 
complexes (BI, BII, BIII). 
 
   Superposition of each of the three potential fH19-20:TED structures onto the crystal 
structure of the fH1-4-C3b complex, suggests that orientation BIII corresponds to the 
physiologically crucial interface between the C’ terminal CCPs 19-20 of fH and C3b. 
This is shown in Figure 3.8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Superposition of the X-Ray Crystal structure of fH1-4 bound to C3b, with fH19-20 
bound to the TED of C3b. Visualised using PyMOL and adapted from Morgan et al, 2011. 
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   In such a position, fH does not experience any steric clashes when this interface is 
extrapolated onto the corresponding TED of C3b, nor does it impede or sterically hinder 
the functionally crucial TED interface, via which C3b is deposited on cellular surfaces. 
The alternative complexes are not possible, as these complexes would involve 
substantial steric clashes between the fH 1-4 and fH19-20 binding sites on C3b.  
   Superposition of the ternary complex places fH19-20 immediately adjacent to CCP 4 
of fH1-4, with both fragments occupying distinct regions on C3b, consistent with 
simultaneous binding, leaving CCP 20 exposed and well positioned to interact with 
poly-anionic surface markers in its role in cellular discrimination. In the modelled 
ternary complex of fH1-4:fH19-20:C3b, the C’ terminus of CCP 4 and the N’ terminus 
of CCP 19 lay in close proximity, on the same side of C3b – but most importantly they 
do not clash. This conformation is consistent with a 1:1 complex of C3b:fH, in which 
intervening CCPs form a compact bent-back structure, or with a 1:2 fH:C3b complex, 
whereby fH extends and bridges between two C3b molecules.  
   The mid-region of fH, on average, contains longer amino acid linkers between CCPs 
(Schmidt et al, 2010) and so it is proposed that it is this region, in particular between 
CCPs 12 and 13 (Schmidt et al , 2010) that acts as a flexible connection between the 
two ends of the protein, introducing a bend in the middle of the single chain 
polypeptide, and allowing it to bend back on itself. Although this hypothesis is 
desirable, it offers incomplete experimental evidence on the architecture of fH, 
particularly in the context of C3b. The above superposition of both N’ and C’ termini of 
fH with C3b can be coupled with other structural data obtained on more CCPs of fH 
using SAXS modelling, NMR spectroscopy and X-Ray Crystallography (PDB_ID: 
2WII (Wu et al, 2009), 3OXU (Morgan et al, 2011), 3SW0 (Morgan et al, 2012), 1HFH 
(Barlow et al, 1993), 2UWN (Prosser et al, 2007), 4B2R, 4B2S (Makou et al, 2012), 
2KMS (Schmidt et al, 2010). Figure 3.9 illustrates a potential model for the fH:C3b 
structure, using the structures of already defined fH fragments. 
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Figure 3.9: Model for the interaction of full length fH with C3b. The model is based on structures of 
individual CCPs, multiple CCPs, and multiple CCPs bound to C3b, as determined by X-Ray 
Crystallography and NMR Spectroscopy. In the model complex, the structures of fH CCP5, fH CCPs 6-8, 
fH CCPs 10-13 and fH CCPs 15-16 were solved by NMR Spectroscopy. The structure of fH CCPs 18-20 
was solved by X-Ray Crystallography, as is the ternary fH1-4:fH19-20:C3b. 
 
   Combining this structural data, it is proposed that fH binds C3b in a 1:1 ratio, bending 
back on itself, so that the N’ terminus is perfectly placed to carry out its cofactor and 
decay acceleration activities, whilst the C’ terminus is primed for recognition of the 
TED of C3b, and poly-anionic carbohydrates. It is these functions which stop the 
unwarranted amplification of complement activity, whilst ensuring self surfaces can be 
distinguished from bacterial. Determining whether or not the isolated domains of fH can 
simultaneously bind C3b will help shed some light onto this complex problem, and 
perhaps provide further insight into the mechanisms of fH, and consequently C3b. 
3.1.7 Aims of this work 
   To prove the hypothesis that at a given moment in time, fH can adopt a ‘bent-back’ 
structure with both N’ and C’ termini engaged simultaneously with a single molecule of 
C3b, this must be investigated at a structural level. Adopting higher resolution structural 
techniques, such as X-ray crystallography or NMR spectroscopy, would be the preferred 
strategy for probing such interactions, however, the nature of this complex is outwith 
the limits of these particular techniques.  
fH1-4:C3b:fH19-20 
ternary complex  
(proposed following 
superposition of individual 
X-Ray structures 
PDB_ID: 2WII, 3OXU 
fH10-13  
NMR Structures 
PDB_ID: 4B2R, 4B2S, 
 & 2KMS 
fH15-16 NMR        
Structure 
 PDB_ID: 1HFH 
fH18-20                                 
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   Therefore EPR spectroscopy can be employed to measure nm distances to investigate 
this large bio-macromolecular complex, as the flexibility, as well as size of the 
interacting proteins, is not limited by this technique. 
   This work is done in collaboration with Professor Paul N. Barlow, University of 
Edinburgh. Using FRET, Barlow’s group  (Pechtl et al, 2010) positioned fH1-4 bound 
to C3b with CCP module 1 furthest from, and CCP4 closest to the TE domain, placing 
subsequent fH modules nearest any other surface to which C3b is bound. This data 
validates that of the proposed fH1-4/C3b crystal structure (Wu et al, 2009).     
   Consequently, it is the aim of this study to use EPR in a similar manner, using both 
regions of fH, (1-4 and 19-20) which bind C3b to address the problem which other 
structural methods cannot answer. Those fH fragments which bind C3b, namely fH1-4 
and fH19-20 will be expressed recombinantly using the P. pastoris expression system, 
following cysteine substitution mutagenesis to incorporate cysteine residues at sites of 
interest for EPR studies. Two different fH19-20 mutants, G1107C and R1210C, will be 
used for this study, alongside the fH1-4 K247C mutant. The R1210C mutant was 
provided as purified protein by Dr Andy Herbert, University of Edinburgh, which was 
then spin-labelled, whilst the fH19-20 G1107C fragment was cloned and expressed 
specifically for this work. 
   C3b cannot be made recombinantly, and so will be purified directly from human 
plasma, before the eponymous TED is utilized as a spin labelling site.  
 
 
 
 
 
 
 
 
 
Figure 3.10: Schematic representation of fH bound to Complement C3 – as shown in Figure 3.9. 
Potential spin labelling sites are represented as orange circles. Of the 20 fH CCPs, the fragments 
highlighted in red and green represent the fH1-4 and fH19-20 fragments, respectively. C3b is shown in 
blue, with the TED domain coloured light blue. In this conformation, one molecule of fH is bound to one 
molecule of C3b at any given point in time, and using SDSL, EPR will be implemented to prove this 
hypothesis. 
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   Figure 3.10 shows a schematic representation of the fH:C3b interaction, with spin 
labelling sites indicated. These aims will prove particularly challenging due to the large 
nature of the complex, and the presence of cysteine residues throughout the fH 
fragments. 
 
3.2   Simulation of the DEER Experiment for the fH:C3b Complex 
Using MMM 
 
   Using MMM, the DEER time traces and distance distributions were obtained between 
each of sites for SDSL on fH, and the TE of C3b (Figure 3.11). All give distances that 
should be measurable by DEER, although distances to the fH19-20 R1210C may be on 
the long side for precise measurements, but therefore act as a good gauge of the 
correctness of the model. 
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Figure 3.11: MMM Simulations of the DEER Time Traces (I) and Distance Distributions (II) for 
fH/C3b complexes. (A) fH1-4 K247C to the Cys988 of C3b, (B) fH1-4 K247C to fH19-20 G1107C (C) 
fH1-4 K247C to fH19-20 R1210C, (D) fH19-20 G1107C to the Cys988 of C3b (E) fH19-20 R1210C to 
the Cys988 of C3b. 
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3.3 Generation of Spin-Labelled fH1-4 K247C Fragment for EPR 
Studies, Using the P. pastoris Expression System 
   The first step in forming the complex was the generation of a fragment of fH 
containing just CCPs 1-4, however following cloning and expression tests this 
construct, which shall be known as fH1-4 K247C(A) showed no expression. 
3.3.1 Mutagenesis 
 
   Following SDM (2.1.1) to incorporate a C’ terminal cysteine into the fH1-4 K247C 
construct for SDSL purposes, the mutated fH DNA fragment was ligated into the 
pPICZαB vector, before the plasmid was transformed into P. pastoris for protein 
expression. Figure 3.12 shows the sequence chromatogram of the cysteine mutation, 
which can be compared to the wt sequence shown in Appendix A2.  
 
 
 
 
 
 
 
 
 
Figure 3.12: Sequencing Chromatogram confirming the presence of a cysteine residue in the fH1-4 
construct – K247C. 
 
3.3.2 Small Scale Test Expression of fH K247C 
 
   Following successful transformation of the K247C fragment into P. pastoris, multiple 
colonies were screened in small-scale expression volumes (initial volume 100mL) in 
order to identify the most highly expressing clone. At the transformation stage, cells 
were plated onto increasing concentrations of Zeocin
TM
, as those which successfully 
grow on higher concentrations during selection contain a higher copy number of 
plasmid, and are therefore most likely to give better yield. Two clones A and B, from a 
500µg/mL Zeocin
TM
 plate underwent expression tests using two different induction 
media, namely BMM and BMMY, in order to ascertain which gives better protein 
expression. After harvesting, the cell pellet was discarded and the supernatant, which 
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contained the secreted protein, filtered (0.22μm) and the pH adjusted to 7.5. 
Concentrated supernatants were analysed by SDS-PAGE, as shown in Figure 3.13. 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: SDS-PAGE Analysis of small scale test expression of the fH1-4 K247C mutant. Sample 
lanes 1-4 and 5-8 show expression of clones A & B respectively, induced in both BMM and BMMY 
media. 
 
   The fH1-4 K247C should run at approximately 30kDa following SDS-PAGE analysis, 
and in sample lanes 3 and 4, and 7 and 8 there is indication of a band (circled) 
corresponding to this expected molecular weight. As stated prior, the samples were run 
in both their reduced and non-reduced forms, and, as so, there should be a notable 
difference between the observed molecular weights of these samples. When reduced, 
the fH1-4 K247C runs at a slightly higher molecular weight, due to a reduction of the 
internal disulphide bonds in fH, forcing it to migrate more slowly through the gel. It can 
therefore be assumed that any bands corresponding to the expected molecular weight 
are most likely yeast proteins found in the concentrated, un-purified supernatants, as the 
expected banding pattern is not observed.  
 
3.3.3 The need for an Affinity Tag 
 
   fH1-4 is susceptible to proteolysis and degradation over time. Problems with its 
stability mean its expression and purification in high yield proves problematic 
(Hocking, 2008). Codon optimisation of the fH gene allows for optimal expression 
using the P. pastoris expression system, however, further methods must be employed to 
optimise expression and yield.  
   Previous work carried out by Dr. David Kavanagh, University of Edinburgh, found 
that inclusion of a C’ terminal hexa-histidine affinity tag as well as an N’ terminal c-
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Myc-epitope (EQKLISEEDL) onto a non-codon-optimised fH1-4 fragment helped 
stabilise the construct, with evidence of reduced proteolytic degradation, as well as the 
additional advantage of ease of purification using IMAC, thus minimising sample 
handling (Pechtl et al, 2011).  
 
3.3.4 Mutagenesis – Incorporation of a C’ Hexa-Histidine Tag onto fH1-4 K247C 
 
   A C’ terminal histidine tag was incorporated onto the fH1-4 K247C construct using 
SDM (Figure 3.14) in hopes of increasing yields and facilitating easier purification.  
   From this point onwards, fH1-4 K247C refers to the K247C mutant with the C’ 
terminal hexa-histidine tag. Following successful transformation into P. pastoris, as 
before, small scale expression tests were carried out in order to identity the clones, if 
any, which gave best expression. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Confirmation of the presence of a hexa-Histidine tag onto fH1-4 K247C. (A) shows 
sequencing chromatogram for the wt fH1-4 protein, whilst (B) shows the sequencing chromatogram for 
the modified fH1-4 K247C mutant, with the inclusion of the affinity tag. 
 
3.3.5 Small Scale Test Expression of fH1-4 K247C 
 
   Small scale test expressions were used to establish which clones expressed best, using 
three colonies from each of the three selection plates (200, 300 and 500µg/mL 
Zeocin
TM
). From the test expressions of fH K247C, before the addition of the hexa-
histidine tag, although there was no expression of fH, SDS-PAGE analysis shows that 
endogenous P. pastoris proteins showed better expression levels.  
A 
 
 
 
 
 
B 
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   Consequently, the enriched media BMGY was used, with BMMY used for induction, 
in order to optimise protein expression and improve yield. After harvesting, the cell 
pellet was discarded and the supernatant, which contained the secreted protein, was 
filtered (0.22 μm) and the pH adjusted to 7.5. SDS-PAGE analysis (Figure 3.15) was 
carried out on the un-concentrated supernatants. 
   From SDS-PAGE analysis, it is clear that the incorporation of a hexa-histidine tag 
onto the C’ terminus of the fH1-4 K247C construct is sufficient to induce expression of 
the fragment.  
 
 
Figure 3.15: SDS-PAGE Analysis of fH1-4 K247C Expression Tests. (A) supernatants from the 
expression of three different fH1-4 K247C clones, selected on 200µg/mL Zeocin
TM
, run both non-reduced 
and reduced (B) supernatants from the expression of three different fH1-4 K247C clones, selected on 300 
and 500µg/mL Zeocin
TM
. 
 
3.3.6 Large Scale Expression of fH1-4 K247C 
 
   As described in 2.4.3, the fH1-4 K247C fragment was expressed on a larger scale of 8 
x 500mL (initial culture volume). Following culturing, cells were harvested, and a pool 
was made of all filtered supernatants and SDS-PAGE analysis carried out, as shown in 
Figure 3.16A.  To confirm that the expression bands visualised by SDS-PAGE analysis 
were indeed fH1-4 K247C, western blotting was carried out as described in 2.7.2 using 
a primary polyclonal antibody, specific for the detection of purified human fH. Results 
are shown in Figure 3.16B. 
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Figure 3.16: SDS-PAGE and Western Blotting Analysis of Expression from a single fH1-4 K247C 
clone. (A) SDS-PAGE analysis of the pooled supernatants. (B) Western blotting analysis of the pooled 
supernatants, probed with a polyclonal antibody specific for the detection of purified human fH. 
 
From both SDS-PAGE analysis and western blotting, it was confirmed that that 
believed to be fH1-4 K247C is so. 
 
3.3.7 Purification of fH1-4 K247C 
 
3.3.7.1 IMAC 
   IMAC was used as a first catchment step in the purification of fH1-4 K247C due to 
the incorporation of the hexa-histidine tag. The application of the protein to, and elution 
from the Ni-NTA Superflow Cartridge was performed using peristaltic pump. 
Purification was monitored by SDS-PAGE analysis of the flow-through (FT) from the 
column, the wash fraction, and elution fractions (E1-8), as shown in Figure 3.17.  
 
 
 
 
 
 
 
 
 
 
Figure 3.17: SDS-PAGE Analysis of the Elution of fH1-4 K247C from the Ni-NTA Superflow 
IMAC Cartridge. A sample was taken of the material that flowed through the column. A washing step 
was carried out before the protein was eluted in eight 1mL fractions (E1-E8).  
25 
20 
37 
50 
R 
  
 
25 
20 
37 
50 
R 
NR                                                NR 
        MW                                                             MW  
        kDa                                                             kDa 
NR: Non-Reduced 
R: Reduced 
A                                                          B 
25 
20 
37 
50 
75 
100 
150 
 R                                 R                                
    NR    NR    NR            NR    NR   NR                 
MW  
kDa FT  WASH  E1     E2     E3    E4   E5    E6      E7    E8 
NR: Non-Reduced 
R: Reduced 
Chapter 3: The C3b:fH Complex – An EPR Study 
110 
 
3.3.7.2 Anion Exchange Chromatography (AEC)   Tricorn
TM
 Mono Q 4.6/100 PE 
 
   A common step in the purification of proteins which have been expressed under acidic 
conditions, such as those expressed in P. pastoris, is cation exchange chromatography 
(CEC). Usually, CEC is performed at least one pH unit below the isoelectric point (pI) 
of the protein of interest. The pI of fH1-4 K247C is ~ 5.2, meaning CEC would need to 
be performed at ~ pH4, which nears the limit of the resin (Sepharose is stable in the pH 
range 4-9, Turkova et al, 1978). AEC was carried out instead, at a pH of 9. Figure 3.18 
shows the FPLC elution profile for the elution of fH1-4 K247C from the Mono Q 
column and the corresponding SDS-PAGE analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: Anion Exchange chromatography of fH1-4 K247C. (A) Elution profile of fH1-4 K247C 
from the MonoQ column and (B) resulting SDS-PAGE analysis of fractions run within the circled peak. 
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3.3.7.3 Size Exclusion Chromatography  
   From the SDS-PAGE analysis of the elution from the Mono Q, there appears to be 
some dimer in several of the non-reduced fractions, therefore the pooled fractions were 
treated with a final concentration of 250µM TCEP, before SEC was performed as a final 
step. Shown in Figure 3.19 is one SEC run from the pooled fractions, with resulting 
SDS-PAGE analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19: Size Exclusion Chromatography of the fH1-4 K247C Fragment. (A) Elution profile of 
the fH1-4 K247C construct and (B) resulting SDS-PAGE analysis of relevant fractions. 
 
3.4   Generation of a Spin-Labelled fH19-20 Fragment for EPR Studies 
Using the P. pastoris Expression System 
 
3.4.1 Mutagenesis 
 
   Following SDM to incorporate an N’ terminal cysteine into the fH19-20 construct for 
SDSL purposes, the mutated fH DNA fragment was ligated into the pPICZαB vector, 
before the plasmid was transformed into P. pastoris for protein expression. Figure 3.20 
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shows the sequence chromatogram of the cysteine mutation, alongside that of the wt 
construct.  
 
 
 
 
 
 
 
 
Figure 3.20: Confirmation of the presence of a cysteine residue in the fH19-20 construct, G1107C. 
 
 
3.4.2 Small Scale Test Expression of fH19-20 G1107C 
 
   Nine different clones were selected which grew successfully on a range of different 
antibiotic concentrations, and screened in small-scale expression volumes in order to 
identify the most highly expressing clone. After harvesting, the cell pellet was discarded 
and the supernatant, which contained the secreted protein, was filtered (0.22μm) and the 
pH adjusted to 7.5. Concentrated supernatants were analysed by SDS-PAGE, as shown 
in Figure 3.21. 
 
 
Figure 3.21: SDS-PAGE Analysis of fH19-20 G1107C Expression Tests. (A) supernatants from the 
expression of three different fH19-20 G1107C clones, selected on 200µg/mL Zeocin
TM
 (B) supernatants 
from the expression of three different fH19-20 G1107C clones, selected on 300µg/mL Zeocin
TM
 (C) 
supernatants from the expression of three different fH19-20 G1107C clones, selected on 500µg/mL 
Zeocin
TM
.  
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   Unlike the fH1-4 construct, there is no need for the addition of tags to fH19-20 for 
stability. However, in Figure 3.21B, it is clear that of the three clones which were 
selected with 300µg/mL Zeocin
TM
, only two actually showed any level of protein 
expression. This result reinforces the necessity of screening multiple clones for 
expression, before large scale expressions/fermentations were performed. Of those 
clones which expressed, the levels of expression seemed consistent across all selection 
conditions. Protein expression appears consistent across all antibiotic concentrations.    
Those clones which express following selection with higher antibiotic concentrations 
generally produce more protein (Invitrogen EasySelect Manual), therefore clones 7, 8 
and 9 would appear to be the best candidates for large scale expressions. Due to the high 
molecular weight protein that appears following expression from clone 7, this clone was 
rejected. This protein is likely endogenous yeast proteins. Clones 8 and 9 were used to 
make glycerol stocks, which were subsequently used for large scale expressions. 
 
3.4.3 Fermentation of fH19-20 G1107C 
 
   As the fH19-20 G1107C construct shows good levels of expression on a small scale, it 
was decided to perform a 10L fermentation, to yield enough protein for all experiments 
required for this body of work.  
 
 
 
 
 
 
 
 
 
Figure 3.22: Example Fermentation Log from the Bioflo4500 Vessel. Throughout the fermentation 
process the agitation (red), pH (green), temperature (black)  and percentage dissolved oxygen are 
displayed on the vessel, indicating when glycerol and MeOH feeds should be carried out. 
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   During the course of the fermentation procedure, the agitation rates, levels of 
dissolved oxygen, temperature, and pH were monitored. Shown in Figure 3.22, is an 
example of the Fermentation Log obtained from the BioFlo4500 fermentation vessel. 
   Upon addition of the cells (A) to the fermentation vessel, a spike in agitation occurred. 
The yeast have begun consumption of the initial glycerol available to them, and the 
spike in agitation occurs as a result of maintaining oxygen levels in the vessel at 40%. 
Once all of the available glycerol was consumed, additional glycerol feeds were 
performed (B) in order to bulk cell mass.  
   At this point the temperature in the vessel was reduced from 30
o
C to 15
o
C before 
MeOH induction, which acts to decrease proteolysis. MeOH was then added (C) and a 
spike in agitation confirms consumption of the MeOH by the P. pastoris. Additional 
MeOH feeds followed (D) over a 72 hr period, before cells were harvested (E) by 
centrifugation.  
 
3.4.4 Purification of fH19-20 G1107C Following Fermentation 
 
3.4.4.1 SP-Sepharose FastFlow
TM
 CEC Resin 
 
    Following harvesting of cells, the crude supernatant was diluted by a factor of 10, in 
order to reduce the conductivity of the supernatant. The addition of PTM1 salts during 
the fermentation process increases the conductivity, and so diluting the supernatant 
accordingly, promotes binding of the target protein to ion exchange chromatography 
(IEC) resins, which are used throughout the purification process.  EDTA and PMSF 
were added to the diluted supernatant to a final concentration of 1mM and 0.5mM 
respectively, in order to reduce protease activity, and the pH of the supernatant was 
adjusted to ~ pH5.5.  
   The supernatant (~80 L) was flowed over a XK 26/20 column, packed with 50mL of 
SP-Sepharose Fastflow
TM
 resin, pre-equilibrated in non-salt buffer, using a peristaltic 
pump and maximum flowrate. Following application of the diluted supernatant to the 
column, the protein is eluted using a linear 1M NaCl gradient. Figure 3.23 shows the 
resulting elution profile and corresponding SDS-PAGE analysis of relevant fractions. 
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Figure 3.23: Cation Exchange Chromatography of fH19-20 G1107C from 10 Litre Fermentation. 
(A) Elution profile and (B) resulting SDS-PAGE analysis. Alternating fractions were run under the large 
peak, indicated by the red arrow in (A), with fractions run in both their reduced and non-reduced form. 
 
   Following SDS-PAGE analysis, those fractions which were found to contain fH19-20 
G1107C were pooled. It was estimated that ~3g of the recombinant protein had been 
expressed.  
 
3.4.5 Selection of an Appropriate Reducing Agent 
 
   In order to spin label the cysteine residue incorporated into fH19-20 G1107C, the 
protein must be in its monomeric form, and the cysteine residue free and accessible. 
Typically, following the final purification step, recombinant proteins are treated with a 
reducing agent, usually Dithiothreitol (DTT) in order to reduce any cystine which may 
form as a result of cysteine oxidation in the fermentation vessel, as well as reduce any 
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intra and intermolecular disulphide bonds formed between cysteine residues of proteins. 
Figure 3.24 shows the reversible oxidation of cysteine to cystine. 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24: Reversible Oxidation of Cysteine to Cystine, visualised using Chemdraw ®. 
 
   The SP-Sepharose resin is a low resolution cation exchanger, and simply acts as a first 
catchment step in the purification of the fH19-20 G1107C from the crude supernatant. 
Immediately following the initial catchment step, the fH19-20 G1107C was treated with 
a final concentration of 5mM DTT, however DTT at this concentration was not 
sufficient to efficiently reduce the dimeric protein to an entirely monomeric species. A 
second sample was treated with 10mM DTT, which successfully reduced the dimeric 
fH19-20 to an entirely monomeric species, and following further purification using 
higher resolution CEC, the fH19-20 G1107C appeared clean under SDS-PAGE analysis 
(not shown). 
   Following unsuccessful attempts to spin label the purified proteins, it was proposed 
that at such high concentrations of DTT, the intermolecular disulphide bonds of the fH 
fragment had been compromised, resulting in a potential mis-folding of the protein. 
   Consequently, the stability fH19-20 G1107C in the presence of various concentrations 
of DTT, and in the presence of alternative reducing agents was tested. DTT is the most 
Cysteine 
 
 
 
Cystine 
 [reduction]            [oxidation] 
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commonly used thiol reductant (Netto & Stadtman, 1996),  forming two products from 
one reactant, with the DTT being converted to a stable and cyclic disulphide through an 
intramolecular reaction (Getz et al, 1999), as shown in Figure 3.25. 
 
 
 
 
 
 
 
 
 
 
Figure 3.25:  Mechanism for the reduction of a disulphide with DTT, visualised using Chemdraw®. 
 
   However, trialkylphosphines are also powerful reductants, selective in the reduction 
of disulphides (Cline et al, 2004). Tris (2-carboxyethyl) phosphine (TCEP) is one such 
reductant, which is able to reduce disulphides, driven by the formation of a strong 
phosphorus-oxygen bond, as shown in Figure 3.26. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26: Mechanism for the reduction of a disulphide bond with TCEP, visualised using 
Chemdraw ®. 
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   To assess which reducing agent was optimal for keeping the fH19-20 G1107C 
monomeric without disruption to the internal disulphide bonds, the purified protein was 
treated with varying concentrations of TCEP and DTT. The proteins were then analysed 
by SDS-PAGE to ensure complete reduction, before the amount of free thiol in each 
sample was quantified by the Ellman’s reagent, DTNB. Results are presented in Figure 
3.27 and Table 3.1. 
 
 
 
 
 
 
 
 
 
 
Figure 3.27:  SDS-PAGE Analysis of the reduction of fH19-20 G1107C with varying concentrations 
of DTT and TCEP. 
 
Table 3.1:  Concentration of free cysteine in the fH19-20 G1107C samples following reduction, as 
determined by the Ellman's assay (DTNB). 
 
 
 
 
* Initial protein concentration - 45µM 
 
   The initial concentration of the fH19-20 G1107C sample was calculated to be 
approximately 45µM (as tested by the Bradford Assay, as described in 2.7.4) and 
confirmed by checking the absorbance at 280nm. In the fH19-20 construct, there should 
be only one free cysteine residue, as the remainder should be engaged in the 
intermolecular disulphide bonds found in the CCP residues.  
   Following reduction, the amount of free thiol (cysteine) in each sample can be 
quantified when the sample is reacted with DTNB. Previously it was found that a final 
Reducing Agent (final conc.) Conc. Free Cysteine* 
DTT (5mM) Significantly exceeds 45µM 
TCEP (500µM) 54µM 
TCEP (375µM) 48µM 
TCEP (250µM) 43µM 
TCEP (125µM) 27µM 
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concentration of 1mM DTT was not sufficient to efficiently reduce the fH and keep it in 
its monomeric form. With this is mind, the ability of higher concentrations of DTT as 
well as varying concentrations of an alternative reducing agent were assessed in their 
ability to efficiently reduce fH. Upon reduction of the fH19-20 with a final 
concentration of 5mM DTT and a final concentration of over 250µM TCEP, the amount 
of free thiol in each sample significantly exceeded the protein concentration (45µM).     
This suggests that at these concentrations the reducing agent is present in high enough 
concentrations to disrupt and initiate the reduction of the internal disulphide bonds of 
the fH19-20, and potentially explains the problems with spin-labelling experienced. 
   There are a number of advantages in using TCEP as an alternative to DTT. Besides 
being odourless compared to DTT, TCEP has been shown to be more stable than DTT 
over a wider pH range (pH1.5-8.5), with increased stability at higher pH (7.5), and more 
efficient reduction at pH values below pH8 (Getz et al, 1999). A final TCEP 
concentration of 250µM was used for the reduction of any fH constructs due to 
disruption of the internal disulphide bonds as well as reduced stability at higher 
reducing concentrations. 
   Following quantification of free cysteine levels, it was concluded that purifying the fH 
fragments in the presence of such high levels of DTT is detrimental to the protein fold. 
Consequently, the fH fragment was prepared again, only large scale flask expression 
was performed instead of fermentation. The fH19-20 fragment expresses well, and 
therefore flask expression should provide enough material, whilst reducing the levels 
observed in the fermentation process. This should facilitate a quicker purification 
process, with less sample handling, and consequently less sample degradation. 
 
3.4.6 Purification of fH19-20 G1107C Following Large Scale Flask Expression 
 
   In order to overcome the problems encountered during the fermentation process, large 
scale flask expression was carried out (8 x 500mL initial culture volume) for the fH19-
20 G1107C construct. 
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3.4.6.1 SP-Sepharose FastFlow
TM
 CEC Resin 
 
   The first purification step was carried out as for the fermentation. The elution 
chromatogram and resulting SDS-PAGE analysis of relevant fractions (as indicated by 
the red arrow) are shown in Figure 3.28. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28: Cation Exchange Chromatography of fH19-20 G1107C from Large Scale Flask 
Expression (SP Sepharose). (A) Elution profile and (B) resulting SDS-PAGE analysis. Alternating 
fractions were run under the large peak, indicated by the red arrow in (A), with fractions run in both their 
reduced and non-reduced form. 
 
3.4.6.2 Resource 15S
TM 
CEC
 
 
   Following the initial catchment step, the fH19-20 was subsequently purified by 
multiple rounds of higher resolution cation exchange chromatography, using the 
Resource 15 S column. The protein was eluted using a linear NaCl gradient up to 1M 
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NaCl. From previous purification steps, it was found that fH19-20 elutes at ~230mM 
NaCl, and so the fractions in the first major peak were analysed by SDS-PAGE. The 
elution chromatogram from one of the runs is shown alongside the resulting SDS page 
analysis in Figure 3.29. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.29: Cation Exchange Chromatography of fH19-20 G1107C from Large Scale Flask 
Expression (Source 15 S). (A) Elution profile and (B) resulting SDS-PAGE analysis of alternating 
fractions run under the second major peak (C) SDS-PAGE analysis of the central fraction from the first 
major peak. 
 
   Alternating fractions were analysed by SDS-PAGE under both major peaks. Under 
reducing conditions, two main bands are detected from those fractions under peak one, 
with the lower band likely corresponding to fH19-20 that had been proteolytically 
clipped (but remained intact until the disulphide bonds had been reduced. Those 
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fractions from the second major did not appear to have any clipped protein present, and 
so these were the fractions which were pooled for subsequent purification steps. 
 
3.4.6.3 Size Exclusion Chromatography  
   From the SDS-PAGE analysis of the elution from the Resource 15S, there appears to 
be a little dimer in the non-reduced fractions, therefore the pooled fractions were treated 
with a final concentration of 250µM TCEP, before SEC was performed as a final 
purification step. Shown in Figure 3.30 is one run from the pooled fractions, with 
resulting SDS-PAGE analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.30: Size Exclusion Chromatography of the fH19-20 G1107C Fragment. (A) Elution profile 
of the fH19-20 G1107C construct and (B) resulting SDS-PAGE analysis of relevant fractions. 
 
3.5 Spin labelling of fH Fragments 1-4 K247C and 19-20 G1107C 
   Following reduction of the purified fH proteins with a final concentration of 250µM 
TCEP, and quantification of free cysteine levels by the Ellman’s Reagent DTNB, the fH 
fragments, K247C and G1107C were labelled with a 10x molar excess of the spin label 
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MTSSL, as described in 2.9.1. The excess spin label was removed, and r.t CW EPR 
spectra of the labelled fH samples collected. The CW EPR spectra are shown in Figure 
3.31. 
    
 
 
 
 
 
 
 
 
 
 
 
Figure 3.31: X-band CW EPR of fH1-4 K247C and fH19-20 G1107C constructs. Spectra taken at r.t 
(non-saturating conditions), using a Bruker EMX X-band EPR spectrometer, using a rectangular low 
sensitivity cavity. 
 
   The solution EPR results are important for two reasons: the degree of spin labelling 
can be determined and the rigidity of the label bound to the protein can be assessed. 
Solutions (40μL) of 4-hydroxy-TEMPO were used as calibration standards, and the spin 
labelling efficiency was deemed to be between 90 and 95% for the fH1-4 and fH19-20 
samples respectively. Labelling efficiency can be approximated by quantifying the 
absolute number of spins in the sample through double integration of the CW-EPR 
spectrum, and comparing this value to the concentration  
   The spin-labelled fH fragments were frozen in 50% glycerol in PBS, and kept at -
20
o
C, however, upon thawing of fH fragments the CW EPR spectra for both fragments 
had changed considerably. Figure 3.32 shows the CW EPR spectra taken for the fH1-4 
fragment following freeze-thaw.   
   It is evident that the spectrum obtained is not the characteristic three –line spectrum of 
a typical nitroxide radical. The same was observed for the fH19-20 G1107C mutant. It 
is proposed that upon freezing, due to the extensive disulphide bonds present in the 
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fragments, there has been a potential reshuffling of the disulphide bonds, forcing the 
incorporated spin labels from the residues used for incorporation.   
 
 
 
 
 
 
 
Figure 3.32: X-Band CW EPR Spectrum of the fH1-4 K247C construct following freezing. Spectrum 
taken at r.t under non-saturating conditions, using the AffirmoEx benchtop spectrometer, by 
ActiveSpectrum. 
   Typically, a five-line spectrum like the one shown above is indicative of biradical.  In 
this instance that equates to the label which has been removed ‘talking’ to any label 
which remains bound to the protein of interest. At this stage, both fragments were 
extensively washed, in order to remove any now unbound label, however the bi-radical 
effect, although improved, was impossible to completely remove. 
   Going ahead with fH fragments in which labelling efficiencies could now not be 
determined, and the state of the label unsure was not possible, and so unfortunately, at 
this stage attempts were abandoned to salvage the labelled fragments, and they were 
both expressed again. 
   Halfway through this project, the lab was relocated, and so expression from the 
original glycerol stocks was tested to ensure expression was as it had been. 
Unfortunately these had not survived in transit, and so for each fragment, the entire 
transformation/test expression and large scale expression steps had to be repeated, and 
the proteins purified, assayed and finally spin labelled. These steps were repeated 
exactly as before, using large-scale flask expressions (8x500mL starting volume). 
Figure 3.33 shows the SDS-PAGE analysis and CW EPR of the new spin-labelled fH 
fragments.  
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   The fH19-20 R1210C (purified by Dr Andy Herbert, University of Edinburgh, 
Scotland, UK) mutant was treated with a final concentration of 250µM TCEP, and spin 
labelled. The CW EPR spectrum and SDS-PAGE analysis of this mutant is shown 
alongside the SDS-PAGE analysis of the new fH1-4 K247C and fH19-20 G1107C 
fragments, as well as their CW EPR spectra in Figure 3.33. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.33: CW EPR spectra and SDS-PAGE analysis of fH1-4K247C (A&D), fH19-20 G1107C 
(B&E) and fH19-20 R1210C (C&F). CW EPR spectra were taken at r.t under non saturating conditions 
using the AffirmoEx benchtop spectrometer, by ActiveSpectrum, whilst SDS-PAGE analysis shows 
samples run in both their educed and non-reduced forms. 
 
Final yields from the final fH preps used for EPR experiments are shown in Table 3.2. 
Table 3.2: FH fragments yields following expression in P. pastoris, and purification 
 
 
 
 
 
 
fH Fragment Expression Volume Final Yield 
   
fH1-4 K247C 8 x 500mL (starting volume) ~1.7mg 
fH19-20 G1107C 8 x 500mL (starting volume) ~6mg 
fH19-20 R1210C 8 x 500mL (starting volume) ~3.4mg 
-15
-10
-5
0
5
10
15
20
25
3440 3460 3480 3500 3520 3540 3560
in
te
n
s
it
y
 
Magnetic Field (G) 
-150
-100
-50
0
50
100
150
200
3440 3460 3480 3500 3520 3540 3560
in
te
n
s
it
y
 
Magnetic Field (G) 
-200
-100
0
100
200
300
3440 3460 3480 3500 3520 3540 3560
in
te
n
s
it
y
 
Magnetic Field 
 
C                                                    D                                   E                                 F 
10 
15 
25 
35 
55 
MW 
kDa 
MW 
kDa 
10 
  15 
25 
37 
20 
A                                                          B 
fH1-4 
K247C 
fH19-20 
G1107C 
fH19-20 
R1210C 
50 
35 
25 
15 
10 
M
W 
Chapter 3: The C3b:fH Complex – An EPR Study 
126 
 
3.6 Generation of Spin-Labelled C3b, Following Isolation and 
Purification of C3  
   Unlike the fH fragments which can be made recombinantly, C3b cannot be made 
using recombinant methods and so there is need for a different strategy for purification. 
C3b for the EPR study was derived from complement component C3, which was first 
isolated and purified from human plasma. In native C3, the highly reactive TE is 
shielded from reacting nucleophiles, however, upon activation to C3b, the TE domain 
becomes exposed, and can be exploited for SDSL of complement C3b. 
3.6.1 Small Scale Isolation of C3/C3b 
3.6.1.1 Q-Sepharose FastFlow
TM
 AEC Resin 
   Complement component C3 is one of the most abundant plasma proteins, and, as so, 
was purified from human plasma, following methods adapted from (Dodds, 1993). 
Following precipitation of the plasma fraction with PEG3350, the supernatant containing 
C3 and C4 was loaded onto a XK 26/20 column packed with 10mL of pre-equilibrated 
QSFF resin following centrifugation. The protein was eluted at a flow rate of 2mL/min 
using a linear 1M NaCl gradient.  
   C3 was eluted from the column approximately halfway through the NaCl gradient at 
~300mM NaCl, as indicated on the chromatogram. Its elution is directly preceded by 
the elution of the copper containing plasma protein ceruloplasmin, which appears blue 
in colour.  Under reducing conditions, the two chains of C3 (a 70 and 110 kDa chain) 
run separately under SDS-PAGE analysis, and so can be distinguished from the three-
chain C4 structure on the reducing gel, which elutes immediately after C3. 
    Care was taken to pool those fractions containing just C3, whilst avoiding 
contaminants such as C4 and ceruloplasmin. Avoiding these proteins resulted in a 
substantial loss of the original quantities, however, ceruloplasmin and C4 are abundant 
plasma proteins which prove difficult to eliminate in subsequent purification steps. The 
resulting elution chromatogram is shown alongside SDS-PAGE analysis of relevant 
elution fractions in Figure 3.34. 
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Figure 3.34: Anion Exchange Chromatography of Plasma C3 following PEG3350 Precipitation. (A) 
Elution Chromatogram and (B) resulting SDS-PAGE analysis of the separation of complement 
components from human plasma. Every fourth fraction eluted between 210mM and 500mM NaCl was 
run in their reduced form.  
3.6.1.2 Anion Exchange Chromatography (AEC) - Tricorn
TM
 Mono Q 4.6/100 PE          
   The pooled C3 fractions were diluted with a half volume of ddH2O to lower the ionic 
strength and facilitate binding to the MonoQ column for subsequent purification steps. 
The mono Q column was equilibrated in 90% equilibration buffer and 10% elution 
buffer, and the pooled C3 fractions loaded in several batches, and eluted within a 20mL 
linear NaCl gradient to a final concentration of 500mM NaCl, at a flow rate of 1ml/min. 
Figure 3.35 shows the elution profile obtained for one of these runs, and SDS-PAGE 
analysis of the relevant fractions. 
   Similarly to the initial catchment step, the C3 protein elutes at ~300mM NaCl. The 
fractions indicated by the red arrow in Figure 3.35 were analysed by SDS-PAGE, with 
both the alpha and beta chains of C3 visible. All C3 containing fractions from the 
multiple Mono Q purifications were pooled and dialysed into non-NaCl buffer. The 
concentration of C3 was approximated using UV absorbance at 280nm and a molar 
extinction coefficient of 180,000M
-1
cm
-1
 of C3. 
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Figure 3.35: Anion Exchange Chromatography (Mono Q) of pooled C3 Fractions Following the 
QSFF Catchment Step. (A) Elution profile from multiple pooled fractions of C3 and (B) resulting SDS-
PAGE analysis. C3 eluted form the Mono Q column at ~300mM NaCl. The fractions indicated in the 
major peak were all run in their reduced form. 
3.6.2 Conversion of C3 to C3b Using Limited Trypsin Digestion 
    In nature, conversion of C3 to C3b arises via cleavage of C3 by the C3bBb 
convertase, yielding anaphylatoxin C3a and main fragment C3b. Production of C3bBb 
in the body requires the presence of C3b first, due to the cyclic nature of the 
complement cascade, and so use of the actual convertase is not possible.  
    CVFBb, a structural mimic of the C3bBb convertase (Fritzinger et al, 2009) can be 
used as an alternative for the conversion of C3 to C3b, however, due to species 
protection, CVF cannot be imported into the U.K. Therefore, to successfully convert C3 
to the activated C3b and release the cysteine residue in the TE for spin labelling 
purposes, C3 must undergo a limited trypsin proteolysis at 37
o
C to release the C3a 
fragment, leaving activated C3b.  
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   Purified C3 at a concentration of 1mg/mL was treated with a 1% trypsin solution 
(w/w, enzyme/protein) for 2min at 37
o
C in PBS, to simulate physiological pH.     
Immediately after incubation, 5% (w/w inhibitor/enzyme) soybean trypsin inhibitor was 
added to halt the reaction.  
   Following trypsin proteolysis and trypsin inhibition, the sample was immediately 
transferred to ice, followed by treatment with a 10 x molar excess of MTSSL or a final 
concentration of iodoacetamide. The labelled C3b is then diluted at a ratio of 1:1 with 
the non-salt buffer, and eluted over 30 column volumes with a linear salt gradient of 
100-300mM NaCl from the same pre-equilibrated Mono Q column. The Mono Q AEC 
purification step acts to purify the C3b from unconverted C3, as well as removing any 
excess MTSSL/iodoacetamide. The fractions containing C3b in its pure form were 
pooled and dialysed against PBS, before being stored at -80
o
C. The purity of C3b was 
verified using SDS-PAGE, as shown in Figure 3.36. 
 
 
 
 
 
 
 
 
 
 
Figure 3.36: Anion Exchange Chromatography (Mono Q) of Digested Plasma Purified C3, 
converted to C3b. (A) Elution profile of C3b and (B) resulting SDS-PAGE analysis of fractions which 
fall under the major peak to the left, and the circled central peak. 
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3.6.3 Small Scale Isolation of C3/C3b – Troubleshooting 
   Due to the unspecific nature of trypsin proteolysis, final yields of C3b were drastically 
reduced. The theoretical yield from 10mL of human plasma is between 8 and 12 mg of 
C3, however, upon conversion to the activated C3b, the yield of C3b is approximately 
1% of the starting material. The process was scaled up, from a starting material of 20mL 
of blood (giving 10 mL plasma) to 100mL of blood (50mL of plasma). The purification 
process was carried out in the same way as detailed above, however, a Resource 15 Q 
(20mL) anion exchange column was used as an intermediate purification step between 
the QSFF and Mono Q purification steps. 
   Resource 15 Q resin is another strong anion exchanger, with higher resolution than the 
initial QSFF step. It was hoped that further cleaning before the final highest resolution 
Mono Q purification step would increase purification efficiency and reduce sample 
handling; however it was impossible to isolate C3b in its pure form following digest of 
the purified C3. The scaled up procedure was repeated, with slight modification to 
protocol, with slight modification to flow rates and pH, as well as the inclusion of a 
CEC step in between in hopes of eliminating contaminants before conversion to C3b. 
The resulting SDS-PAGE analyses are shown in Figure 3.37. 
 
Figure 3.37: SDS-PAGE analysis of C3 Purification Troubleshooting. (A) Inclusion of a Resource Q 
purification step following the initial QSFF catchment step (B) Inclusion of a CEC (Resource S) 
purification step following MonoQ purification of the C3 pool (C) A reduction in flow rate from 
1mL/min to 0.25mL/min during elution from the Mono Q (D) change in pH from 6.6 to 6. 
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   Following purification of C3, it is evident that although care has been taken to avoid 
those fractions containing the protein ceruloplasmin, C3 co-purifies alongside it, as 
confirmed by in-gel digest of the relevant band and mass spectrometry of the impurity 
using MALDI MS and MSMS at the University of St Andrews, as shown in Figure 
3.38. Following conversion from C3 to C3b, this is not eliminated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.38: Peptide Fingerprinting of the C3 α and β chains, as well as ceruloplasmin, following in-
gel digest.  
MS matches to Ceruloplasmin 
MS matches to Complement C3 Chain B  
MS matches to Complement C3 Chain A A 
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   Following slight modification of the purification procedures, as shown in the SDS-
PAGE analysis in Figure 3.37, the ceruloplasmin impurity could not be separated from 
C3b. A small degree of impurity may not prove problematic when using the C3b 
samples for DEER, however, the ceruloplasmin is present in large quantities. 
Ceruloplasmin is a cysteine rich protein, which means specific labelling of just the 
cysteine in the exposed TE of C3b would prove impossible. Furthermore, ceruloplasmin 
has an EPR signal from some of its copper centres (Cannistraro et al, 1990) which could 
interfere with proposed DEER experiments. Figure 3.39 shows the XRC structure of 
ceruloplasmin. 
 
 
 
 
 
Figure 3.39: Structure of Plasma Protein Ceruloplasmin showing the copper centres (orange 
spheres). (PDB_ID: 4ENZ,(Samygina et al, 2013)). 
   The protein ceruloplasmin has a theoretical pI of 5.44, and C3b 5.66, which highlights 
the difficulty in separating them using I.E.C., as based on their theoretical pIs, they 
should elute simultaneously from an anion exchange column at similar places along the 
NaCl concentration gradient. Following extensive troubleshooting it was decided new 
methods must be adopted to address these recurring issues.
 
 
3.7 Generation of Spin-Labelled C3(N), an Alternative to C3b, 
Following Isolation and Purification of C3  
   Although conversion of C3 to C3b drastically reduces the overall yield of C3b when 
using limited trypsin digest, isolation and purification of component C3 from human 
plasma gives a yield of between 85-92%. Methods were established which eliminate the 
need for proteolytic digest of C3 to C3b, and instead exploit the high yields of C3. The 
TE of C3, although buried, is accessible to small nucleophiles. With this in mind, C3 
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isolated and purified from 50mL of human plasma was treated with a small nucleophile, 
namely methylamine, activating the TE in C3, without eliminating the C3a portion.  
   C3(N) has C3b like properties, and the problem with unspecific digest of C3 
eliminated. The C3 was isolated from human plasma exactly as described above, by the 
QSFF anion exchange catchment step, followed by a higher resolution Mono Q anion 
exchange chromatography step of the pooled C3 fractions from QSFF. Figure 3.40 
shows the elution profile for one batch of pooled C3 fractions from QSFF after they had 
undergone the Mono Q purification step, as well as resulting SDS-PAGE analysis.  
 
 
 
 
 
 
 
 
 
 
Figure 3.40: Anion Exchange Chromatography of C3 pool, following QSFF, and before treatment 
with the nucleophile methylamine. (A) Elution profile from the Mono Q Anion exchanger, and (B) 
resulting SDS-PAGE analysis of alternating fractions, eluted between 40 and 80mL, all run in their 
reduced form. 
   Purified C3 was treated with a final concentration of 200mM methylamine (pH7.5), at 
37
o
C for 3hr. The reaction mixture was incubated in the presence of either 
iodoacetamide (20mM final concentration) or with a 10x molar excess of MTSSL spin 
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label, depending on whether the protein was required in its labelled or unlabelled form. 
Treatment with the methylamine allows cleavage of the internal thiol ester of C3, 
releasing a free thiol group for spin labelling purposes or alternatively allows for 
blocking of the cysteine residue with iodoacetamide.  
   Following the 3 hr incubation period, the C3 pool was then purified in a similar 
fashion as described for C3b activated using trypsin proteolysis. Following purification 
on Mono Q, purity of the C3(N), was determined by SDS-PAGE analysis, as shown in 
Figure 3.41, and proteins concentrated to ~1mg/mL before being stored at -80
o
C. 
 
 
Figure 3.41: Anion Exchange Chromatography of Methylamine treated purified C3 and its 
conversion to C3(N). (A) Elution profile from the Mono Q Anion exchanger of the MTSSL labelled 
C3(N) and (B) Elution profile from the Mono Q Anion exchanger of the iodoacetamide treated C3(N) (C) 
Resulting SDS-PAGE analysis of both the labelled and unlabelled C3(N). 
 
   From the SDS-PAGE analysis of the labelled and unlabelled C3(N), it is evident that 
the ceruloplasmin impurity has been eliminated, as just C3(N) in both its reduced and 
non-reduced forms is detectable. Table 3.3 summarises approximate yields of C3, and 
the absolute yields of C3b and C3(N) following the standard purifications detailed 
above, as well as those carried out with slight modification to protocol. 
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Table 3.3:  Summary of C3/C3b/C3(N) Yields following Isolation and purification From Plasma 
    
 
 
 
 
 
 
 
 
* 
Theoretical Yield of C3 = ~1mg/mL of fresh human plasma 
 
   From each individual C3 prep, the approximate yield of C3 following its purification 
from human plasma has been, on average, over 80%, based on theoretical yields. 
However, upon cleavage of C3 to C3b using limited trypsin digest the final yield of C3b 
is dramatically reduced, on average, to less than 0.1mg of C3b/10mL plasma.       
   Consequently, using C3(N) as an alternative, which is functional as C3b with the 
addition of the un-cleaved C3a segment, increases yield from 0.1mg/10mL of plasma to 
~5mg/10mL of plasma, a 50 fold increase. This, coupled with the ability to remove 
impurities in the purification process highlight the benefits of using C3(N) as an 
alternative to C3b, in both its labelled and unlabelled forms. 
 
3.8 Spin labelling of C3b and C3(N) 
 
   For the C3b sample, following activation from C3 by limited trypsin digest, and for 
C3(N), the samples were labelled, and excess spin label removed. The r.t CW EPR 
spectra of the labelled C3b and C3(N) samples were collected, as shown in Figure 3.42. 
 
 
 
 
Volume 
of 
Plasma 
(mL) 
Purification 
Procedure 
C3 
Yield 
(mg) 
C3 
Yield 
(%)
*
 
C3b Yield 
following 
digest  
C3(N) yield 
following 
methylamine 
treatment of  
C3 (mg) 
10 Standard 9 90 0.1 n/a 
50 Standard 38 76 0.7 n/a 
50 + Resource Q 42 84 1.1 n/a 
50 + Resource S 33 66 0.4 n/a 
50 Reduced Flow 41 82 0.9 n/a 
50 Reduced pH 43 83 0.5 n/a 
50 Standard 46 92 n/a 25 
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Figure 3.42:  X-band CW EPR of spin-labelled (A) C3b and (B) C3(N). Spectra taken at r.t (non-
saturating conditions), using a Bruker EMX X-band EPR spectrometer, using the high sensitive SHQE 
resonator. 
 
   From the CW EPR spectra, the labelling efficiencies of the C3b and C3(N) were 
determined to be between 85 and 90% respectively. There is a great deal of noise in the 
C3b CW spectrum due to the low concentration of the sample. Sample concentration 
could not be increased, as for the C3b prep, very little C3b was produced, due to 
unspecific cleavage of the purified C3 by trypsin. The C3(N) has a much better signal to 
noise, showing a nice broad spectrum, indicative of slow tumbling of the large C3(N) 
protein. There is indication of some free spin label in this sample.  
 
3.9 Functional Characterisation – fH mediated cleavage of C3b and 
C3(N) by fI 
   As described in 2.10.1, a fluid phase cofactor assay can be carried out to visualise the 
fI mediated cleavage of complement component C3b to inactivated C3b (iC3b), for 
which fH is a cofactor. For the C3b and C3(N) proteins isolated and purified from 
plasma, their cleavage by fI can be monitored, to assess whether both the labelled and 
non-labelled forms give the banding pattern expected upon conversion to iC3b.  
   In the positive control reactions, C3b generated from plasma purified C3 was 
incubated with full length plasma purified fI and fH (all Complement Technology Inc, 
Texas, USA). The negative control contained no fH.  
   The C3b and C3(N) made in this body of work were assayed in both their spin-
labelled and unlabelled forms. The ability of the fH1-4 K247C fragment, in both its 
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spin-labelled and unlabelled forms, to act as a cofactor in the cleavage of C3b to iC3b 
was also assessed. The two disulphide linked chains of C3b can be visualised using 
SDS-PAGE. Upon cleavage to iC3b by fI, the 110kDa alpha chain of C3b is cleaved 
into two smaller chains (67 & 40kDa). Reduction of the alpha chain can be visualised as 
well as the formation of the two smaller alpha chain fragments. All assays are shown in 
Figure 3.43. 
 
 
 
 
 
 
 
Figure 3.43:  Fluid-Phase Cofactor Assay. This assay monitors the cleavage of C3b and C3(N) to iC3b 
by fI in the presence of fH. The assay also assesses the ability of fH1-4 to act as a cofactor in the cleavage 
of C3b to its inactive form. In all controls, full length native plasma purified proteins (Comptech) are 
used. FH is omitted from the negative control, whilst the positive control includes fH,fI, and C3b. (A) 
Shows both positive and negative CompTech controls, with the cleavage of C3(N) (labelled and 
unlabelled) and C3b (labelled) by fI being monitored, in the presence of fH (fI and fH both CompTech). 
(B) and (C) Show both positive and negative CompTech controls, whilst monitoring the ability of fH1-4 
(unlabelled and labelled, respectively) to act as a cofactor for the cleavage of C3b to iC3b. (C3b, and fI 
both Comptech). 
 
   From SDS-PAGE analysis of the cofactor assays, it is clear that C3b and C3(N) 
display the same banding pattern as shown in the positive control, showing that in the 
presence of fI and fH, C3b and C3(N) are cleaved to the inactive iC3b. This suggests 
that the C3b and C3(N) made for these experiments bind fH and fI in the same manner 
as native plasma C3b. Similarly, the fH1-4 K247C, in both its labelled and unlabelled 
form is sufficient to act as a cofactor for the cleavage of plasma C3 to iC3b, however it 
is clear that the fH fragment is not as functionally active as the full length fH purified 
from plasma.  
 
3.10  The fH1-4. C3(N). fH19-20 Complex – An EPR Study 
   Following confirmation of spin-labelling of the fH fragments, the complex was ready 
to be formed for DEER measurements. In order to prepare samples, the binding 
dissociation constants (Kds) were carefully considered. The Kd of the fH1-4-C3b 
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interaction is ~ 10µM (Schmidt et al, 2008) (Wu et al, 2009) whilst the Kd of the fH19-
20-C3b interaction is 1.4µM (Kajander et al, 2011). At the end of the preparations there 
was 55µl of 87µM fH1-4 K247C, 120µl of 777µM fH19-20 G1107C (which was 
observed to be slightly pink), 90µl of 548µM fH19-20 R1210C, 30µl of 50µM C3(N) 
iodo and 81µl of 55µM of C3(N)-SL.  
   Both C3(N) samples had been concentrated from frozen stocks and all proteins were 
washed into deuterated PBS. DEER samples were made with 40µl protein solutions or 
buffer and 20µl deuterated glycerol. Sample compositions are summarised in Table 3.4. 
 
Table 3.4: Compositions of Samples analysed by DEER 
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Figure 3.44: Raw data from the EPR experiments taken for the spin labelled fH fragments in 
complex with either labelled or unlabelled C3(N). Sample compositions shown in Table 3.4. 
   Following assessment of the cofactor ability of the fH1-4 fragment in both its labelled 
and unlabelled forms, with C3b and C3N, it is clear that the fH1-4 fragment is binding, 
as evidenced by the banding patterns following SDS-PAGE analysis. 
   In the EPR experiments, there is some indication of interactions of the individual fH 
fragments when mixed with C3(N), however this interaction is also observed with the 
labelled fH fragments without C3(N) being present (Figures 3.44 C & E). On their own, 
there should be no dipolar signal, and so this could perhaps be an indication of protein 
aggregation, or a multiple labelling effect. 
   When considering complex formation, the final concentration of each protein in the 
sample was determined based on Kds obtained from surface plasmon resonance (SPR) 
of the intact fH:C3b complex.  
   Work carried out by Barlow (Pechtl et al, 2011) used FRET as an orthogonal 
technique to validate the already proposed crystal structure of the fH1-4 complex. As 
discussed prior, EPR and FRET are similar techniques used to extract long range 
distances between probes introduced specifically in samples of interest. Final 
concentrations of fH1-4 and C3b for the FRET study were 33µM and 400nm or 400nm 
and 33µM, respectively. FRET is more sensitive to concentration than EPR, however in 
this study the concentrations of fH used exceeds that used in our work. Taking this into 
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consideration, as well as the excess of C3(N) used, this could somewhat explain the lack 
of complex formation, as well as the aggregation observed. 
 
3.11 Outlook and Future Work 
   The application of EPR, where cysteine residues must be incorporated and specifically 
modified, to a system which is protein rich proved far more complex than was first 
anticipated. Although the cysteine residues in the fH fragments are orchestrated in 
disulphide bonds, protein aggregation, as well as problems with reducing agents, and 
spin labelling would suggest that other avenues for the SDSL of fH be explored. 
Chapter 5 of this thesis looks at the development of new spin labels and spin labelling 
techniques.  
  The complement system is tightly orchestrated so as to effectively eliminate 
pathogens, whilst limiting damage to the host. This thesis has explored the interactions 
of C3b (or C3(N)) with complement fH, a key regulator of the AP of complement 
activation. However, C3b also associates with other complement proteins, e.g. the 
Decay Accelerating Factor (DAF). DAF recognises C3b, allowing association of DAF 
with cell associated C3b, thus preventing the formation of the C3 convertase C3bBb. 
Preventing convertase formation has an important regulatory role in preventing MAC 
assembly. Our group has experience with the expression and purification of DAF for 
spin labelling studies (Lovett et al, 2013), and so the interaction of DAF with C3b 
(C3(N)) could be further explored, to give further insight into its interactions and 
regulatory role. 
    The highly reactive TE motif of complement C3b is a rare post-translational 
modification. As stated previously the relatively short lifespan of the TE bond as it 
becomes exposed upon conversion from C3 makes this thiol specific labelling site 
difficult to exploit. However, protection of the TE in C3 is not absolute, and so we have 
shown that treatment with small nucleophiles facilitates the manipulation of the TE for 
spin labelling purposes.  
   Access of the TE via chemical modification by nucleophiles is limited to the size of 
the attacking nucleophile. The MTSSL spin label is relatively small, and able to 
efficiently label the TE upon freeing of the cysteine residue with methylamine. This 
highlights the potential for studying TE proteins in vivo following chemical 
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modification with thiol specific probes. TE proteins have major roles in immunity and 
in host defence, and consequently, advancing our understanding of their interactions in 
vivo could pave the way for the development of and application of novel 
immunotherapies and in vaccine design (Cole et al., 2009). 
   Furthermore, TE domains have found to be particularly prevalent in Gram positive 
bacteria, proving essential for binding to host cells, highlighting their role in 
pathogenesis. 
   This opens the avenue of chemical modification of Gram positive bacteria to study 
their interactions on the cell surface (Walden et al, 2015) as well as highlighting the 
attraction of targeting TEs with small molecules with the potential to inhibit infection. 
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Chapter 4:   Probing the Interaction of the Cardiac 
Myosin Regulatory Light Chain with Myosin Binding 
Protein C (cMyBP-C) Using EPR Spectroscopy 
 
AIMS: This body of work uses EPR spectroscopy to probe the interactions of the 
Regulatory Light Chain (RLC) of human cardiac myosin, with the cardiac specific 
domain, C0, of the regulatory protein cMyBP-C. There are two potential models for the 
C0-RLC interaction, which potentially influence the relative orientation of the S1 
myosin heads. The cardiac specific cMyBP-C domain C0 will be expressed in E. coli. 
The RLC construct will be expressed alongside the MiniHMM (myosin fragment) 
construct. Mutations in the RLC will then be introduced at sites of interest for EPR 
studies. If the proposed mechanism stands true, and C0 alters the positions of the S1 
myosin heads, there should be a notable difference in distance measurements with and 
without C0, as confirmed, or otherwise by EPR spectroscopy.  
 
4.1 Muscle Contraction - The ‘Dance’ of Actin and Myosin, and 
regulation in the sarcomere 
  
  The heart is a muscular organ in humans and other vertebrates, which undergoes 
calcium dependent contraction in order to pump blood through the blood vessels of the 
circulatory system, providing the body with the oxygen and nutrients essential for 
survival. The vertebrate heart is principally made of connective tissue and cardiac 
muscle which belongs to the category of striated muscle, so called due to the striated 
pattern formed by a series of basic muscle units called sarcomeres (Ford, 2000)    
   The main protein components of striated muscle are myosin and actin, originally 
discovered by Kuhne (1859) and Straub (1942) respectively (Szent-Györgyi, 2004), 
which localise to different positions within the sarcomere, into thick myosin and thin 
actin filaments (Hanson & Huxley, 1953), as illustrated in Figure 4.1.  Muscle 
contraction occurs as a result of an interaction between actin and myosin, together with 
many accessory sarcomeric proteins. 
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Figure 4.1: Schematic Representation of Actin and Myosin Positioned in the Sarcomere. Repetition 
of the basic unit of muscle – the sarcomere – results in the distinctive pattern associated with striated 
muscle. The thin filament (composed of the actin monomer and other regulatory proteins) is shown in 
light blue, whilst the thick myosin filament is shown in dark blue. Figure adapted from Krans et al, 2010. 
 
   The main protein components of striated muscle are myosin and actin, originally 
discovered by Kuhne (1859) and Straub (1942) respectively (Szent-Györgyi, 2004), 
which localise to different positions within the sarcomere, into thick myosin and thin 
actin filaments (Hanson & Huxley, 1953). Muscle contraction occurs as a result of an 
interaction between actin and myosin, together with many accessory sarcomeric 
proteins.  
   The contraction and relaxation of this striated muscle is the function of a complex 
macromolecular machine, in which force is generated by filamentous actin and thicker 
myosin filaments sliding past one another towards the centre of the A-band (Luther & 
Squire, 2014) (Figure 4.1) in an Adenosine Tri-Phosphate (ATP) dependent manner 
(Gruen & Gautel, 1999), thus shortening the length of the sarcomere.  
   Actin and myosin interact in a cyclic series, linked to the hydrolysis of ATP (Hanson 
& Huxley, 1954). Hydrolysis of ATP generates ADP and a free phosphate (Pi) (Geeves 
& Holmes, 2000). This de-phosphorylation reaction releases energy, which is then 
harnessed to drive further chemical reactions, which in this case would be the 
interaction of actin and myosin, and ultimately actomyosin contraction (Root, 2002). 
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4.1.1 Cardiac Myosin Structure 
   Myosin exists in the sarcomere as a hexameric structure, composed of two heavy 
chains and two pairs of light chains, the Essential Light Chain (ELC) and Regulatory 
Light Chain (RLC). Myosin can be further divided into light ‐ mero ‐ myosin (LMM) 
and heavy mero – myosin (HMM) (Figure 4.2A), the latter of which can be further 
divided into the globular N’ terminal S1 head group containing the myosin motor 
domain and light chains, whilst the C’ terminal tails (S2) take on a coiled coil structure, 
holding the head groups in place (Figure 4.2B) (Al-khayat, 2013). The light chains bind 
the heavy chains in the ‘neck’ region, the interface between the S1 heads and the S2 tail 
(Ratti et al, 2011). 
 
 
 
 
 
 
 
 
 
  
Figure 4.2: Schematic Representation of the Thick Myosin Filament Structure. (A) Shows how 
myosin can be further divided into both heavy and light mero-myosin (HMM & LMM). (B) The heavy 
chains, composed of the S1 heads and S2 coiled coil, are shown alongside the Essential and Regulatory 
Light Chains. Figures adapted from (Sadayappan et al, 2009). 
   
   The globular S1 head of the myosin molecule, also known as the myosin cross ‐ 
bridge, is the molecular motor that hydrolyzes the ATP necessary for muscle 
contraction. The formation of these cross ‐ bridges in striated muscle (Huxley, 1957) is 
regulated by Ca
2+
 (Figure 4.3). 
Thick myosin filament 
S2 coiled coil 
RLC 
ELC 
A                                                                                           B 
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Figure 4.3: Schematic Representation of the Actin-Myosin Interaction in Striated Muscle. (A) ATP 
binding to the myosin head results in a conformation that cannot bind actin. (B) Hydrolysis of ATP to 
ADP and Pi by the globular S1 heads release energy which is then harnessed to initiate the cross bridge, 
linking the thin and thick filaments. (C)(D) The cross bridge pulls the actin filament (the ‘power stroke’), 
releasing Pi and ADP from myosin. The myosin heads then bind the actin filament and the power stoke is 
released.  
 
   Binding of ATP in a cleft at the back of the myosin head region causes a conformation 
of myosin that is unable to bind actin. As the ATP is hydrolysed, the head swings back, 
approximately 5nm, to a ‘cocked’ position, and ADP and Pi remain bound. The next 
stages of the cycle are the force generating steps when the Pi is released from myosin. 
The head group is free to bind myosin and the ‘power stroke’ is released. At this stage, 
the myosin heads are bound to actin in the rigor state (tightly bound). The mechanism of 
actin-myosin binding allows the ‘cross-bridge’ formation between the globular myosin 
head groups and the adjacent actin filaments (Baker & Voth, 2013). This event, which is 
part of a cycle driven by the hydrolysis of 1 ATP molecule, is known as the ‘Power 
Stroke’ (Holmes & Geeves, 2000). The release of ADP releases myosin from the actin 
filaments. Further hydrolysis of another ATP molecule results in further actin-myosin 
binding, thus repeating the cycle.  
   The combined effect of this myriad of power strokes causes muscle contraction, and 
the motion can be described as myosin ‘walking along’ the actin filaments (Root, 2002). 
Although actin and myosin alone can generate force via contraction, they cannot 
reproduce all of the properties of the contractile system of striated muscle, and so 
regulatory proteins, such as the RLC control the calcium dependent transitions between 
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resting and force generation, by blocking actin-myosin interactions in the absence of 
calcium (Morita et al, 1985). 
 
4.1.2   The Light Chain Domains – ELC & RLC 
    The molecular mechanism, whereby actin and myosin are regulated in cardiac muscle 
contraction is still not fully understood. The light chain domain of myosin, often 
referred to as the ‘lever arm’ or ‘neck’ region, consists of both ELC and RLC, wrapped 
round the heavy chain through a series of hydrophobic and polar interactions (Ho & 
Chisholm, 1997) providing stability to the lever arm.  
   The function of the ELC has not as yet been defined, however, a cluster of mutations 
within the RLC found to have strong association with heart conditions such as Familial 
Hypertrophic Cardiomyopathy, linked to high risks of cardiac failure and sudden 
cardiac death (Longhi et al., 2011), suggest that the RLC perhaps has more purpose than 
a regulatory role. Selective removal of the RLC causes a change in the structure of the 
cardiac myosin, leading to myosin disorder and weakens binding to other regulatory 
proteins (Pant et al, 2009) (Garrigos et al, 1992). Such links with disease, as well as the 
impact of complete removal, suggest RLC actively engages in muscle contraction at 
both a structural and functional level. 
4.1.3 Myosin Binding Protein-C (cMyBP-C) 
   In addition to the principal components of the sarcomere; the thick and thin filaments, 
the sarcomere also contains several accessory proteins that are essential for assembly, 
maintenance of structural integrity, and regulation of contractile activity. One such 
regulatory protein identified in recent years is the multi-domain myosin binding protein-
C (cMyBP-C), which is involved in both sarcomere formation and in contraction 
regulation.  
  cMyBP-C was first detected as an impurity in skeletal muscle myosin preparations, co-
purifying with myosin, suggesting a role in myosin-binding (Craig et al, 2014). There 
are three different isoforms of cMyBP-C associated with adult muscle, namely the fast 
skeletal, slow skeletal and cardiac isoforms, with unique genes encoding each isoform. 
Cardiac MyBP-C (cMyBP-C) is a137kDa multi-domain protein of the immunoglobulin 
superfamily of proteins, associated with the thick filament, and contributing 1-2% of the 
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myofibriallar mass (Winegrad, 1999). The protein is localised to the cross-bridge 
containing C-zones of striated muscle sarcomeres (Oakley et al, 2004) (Figure 4.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Schematic representation of cMyBP-C positioning in the C zone of the sarcomere, in 
relation to the thick and thin filaments. As before, the thin filament (composed of the actin monomer 
and other regulatory proteins) is shown in light blue, the thick myosin filament is shown in dark blue, and 
cMyBP-C in green. Figure adapted from (Oakley et al, 2004). 
 
   The role of cMyBP-C in the sarcomere is complex and not as yet fully understood, 
however, it has been proposed that as well as playing a structural role, cMyBP-C may 
have a possible role in force regulation (Witt et al, 2001). Of the three isoforms 
occurring in nature, the cardiac isoform presents some unique features.  
   The cardiac isoform is exclusively expressed in the heart of mammals and is 
composed of eleven domains, eight of which are immunoglobulin I – like (IgI), and the 
remaining three fibronectin type III-like domains. Consisting of 11 modules labelled C0 
to C10, from the N’ to the C’ terminus, the cardiac isoform differs from the skeletal 
isoforms with three additional characteristics: an additional IgI domain, namely C0, 
three additional phosphorylation sites between domain C1 and C2 at the N’ terminus, 
and an additional 30 amino acids within the C5 domain (Howarth et al, 2012) (Idowu et 
al, 2003) (Figure 4.5). 
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Figure 4.5: Schematic representation of cMyBP-C showing features unique to the cardiac isoform, 
including the 3D NMR Structure of domain C0. (A) Immunoglobulin I type and Fibronectin Type III 
domains are shown as circles and squares respectively. The additional phosphorylation sites in the C1-C2 
linker are represented as stars and the additional thirty amino acids in domain C5 are highlighted. (B) 3D 
NMR structure of domain C0 of  cMyBP-C. (PDB_ID: 2K1M, (Ratti et al., 2011)). This structure 
conforms to the IgI fold typical of the majority of cMyBP-C IgI domains. 
 
   cMyBP-C contributes to thick filament structure via interactions at the C’ terminus 
(domains C7-C10) with the LMM section of the myosin rod, and also has a role in 
contraction regulation due to interactions at its N’ terminus with the S2 region of 
myosin, close to the myosin motor (Ababou et al, 2007). cMyBP-C was initially 
suggested to simply act as a tether, holding the myosin heads close to the neck region of 
the myosin molecule via its N’ terminus (Harris et al, 2004), and subsequently 
preventing cross-bridge formation and actomyosin contraction (Ababou et al, 2008) 
(Figure 4.6).  
   It is suggested that binding of the N’ terminal portion of cMyBP-C to myosin in the 
region of the S1 heads holds the myosin heads back, reducing their ability for actin 
interaction and force generation. This returns to normal upon phosphorylation of 
cMyBP-C, which results in the release of the head groups (Figure 4.6A). 
Phosphorylation occurs at three sites in cMyBP-C (between domains C1 and C2) 
(Figure 4.5). This 100-residue region, the cMyBP-C motif, is highly conserved between 
all isoforms of cMyBP-C and between species (Kunst et al, 2000).  
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Figure 4.6: Cartoon depicting the current understanding of cMyBP-C Function. (A) Effect of 
phosphorylation of the N’ terminal myosin binding site. cMyBP-C is dislodged, releasing the S2 coiled 
coil and promoting cross-bridge formation and ultimately muscle contraction, via interaction of the S1 
cross-bridge with the thin filament. (B) A possible interpretation of the observation that cMyBP-C 
constructs too short to act as a tether can influence muscle contraction. In this interpretation, the N’-
terminus directly affects the orientation of the myosin head group, indicated by the arrows. (C) 
Alternative interpretation whereby the cross-bridge formation occurs as a direct result of the N’ terminal 
domains on cMyBP-C interacting with the thin actin filaments. Figure adapted from Ratti et al, 2011. 
   It is suggested that binding of the N’ terminal portion of cMyBP-C to myosin in the 
region of the S1 heads holds the myosin heads back, reducing their ability for actin 
interaction and force generation. This returns to normal upon phosphorylation of 
cMyBP-C, which results in the release of the head groups (Figure 4.6A). 
Phosphorylation occurs at three sites in cMyBP-C (between domains C1 and C2) 
(Figure 4.5). This 100-residue region, the cMyBP-C motif, is highly conserved between 
all isoforms of cMyBP-C and between species (Kunst et al, 2000).  
   It is suggested that the function of cMyBP-C extends beyond that of a mere tether, as 
cMyBP-C fragments which are too short to exhibit this tethering role can still influence 
muscle contraction (Figure 4.6B). Knockout mouse studies with altered cMyBP-C show 
that domains C0-C2 are sufficient for cross-bridge formation, showing cMyBP-C 
fragments too short to perform the tether role could still bridge the gap between the S1 
heads and the thin filaments (Harris et al, 2002). 
    Furthermore, using knock-in mouse models (Witt et al, 2001) carrying a gene for 
shortened cMyBP-C without the cardiac specific C0 domain, all animals with the 
deletion were still viable with no significant ultrastructural changes to the heart, or 
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impaired lifespan. The mutant cMyBP-C was still phosphorylated, however, there 
appeared to be a decrease in the levels of force generated, suggesting the additional 
domain in the cardiac isoform could be an evolutionary change, introduced by nature to 
aid in force regulation at the cross-bridge level (Witt et al, 2001).  
   The presence of the extra C0 domain as well as the phosphorylatable linker between 
domains C1 and C2 suggest this may be vital for effective regulation of cardiac muscle 
contraction at the cross bridge level, and how extensions of these finding could suggest 
a mechanism whereby N’ terminal mutations in the cMyBP-C could cause Familial 
Hypertrophic Cardiomyopathy. 
 
4.1.4 The RLC-C0 interaction 
 
   It is clear from the above that the C0 domain is crucial for cMyBP-C participation in 
muscle contraction regulation, and that this is perhaps by more direct means than simply 
acting as a mere tether (Granzier & Campbell, 2006). An interaction between the 
cardiac isoform of cMyBP-C and the RLC has been proposed as early as 1985 
(Margossian, 1985) and most likely occurs via the cardiac specific C0 domain.  
   NMR, ITC, and in vivo immuno-fluorescent localisation of C0 (Ratti et al, 2011) 
places the N’ terminus of cMyBP-C right on top of the S1-S2 hinge interface, and 
therefore in the immediate vicinity of the light chains. In this position, cMyBP-C is 
ideally situated to directly interact with the hinge region, potentially influencing the 
position of the S1 heads, an interaction which is attributed to the cardiac specific 
domain C0. The ability to manipulate the S1-S2 junction would give cMyBP-C the 
potential to directly adjust the position of the S1 heads and therefore subtly influence 
muscle contraction.  
   Confirmation of an interaction between C0 and RLC drives this study, which aims to 
use EPR spectroscopy to further characterise this interaction, and its contribution to 
muscle contraction. 
 
4.1.5 Aims of this work 
   There are two potential models for C0-RLC interaction, suggesting that C0 could bind 
both RLCs on one myosin molecule simultaneously (Figure 4.7A), and in this position 
could influence the relative orientation of the S1 heads. Wedging C0 between the RLCs 
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could push the S1 heads apart, or pull them together. Otherwise it is proposed that C0 
binds only one RLC leading to an asymmetry of the S1 heads (Figure 4.7B). It is most 
likely that the former is the case, reinforced by data accumulated from both structural 
and binding studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Model for the arrangement of the N’ terminus of cMyBP-C around the myosin S1-S2 
junction and the light chains. cMyBP-C domains C1 and C2 bind to the S2 chain very close to the 
S1/S2 junction, whereas C0 binds to the RLC. Illustrated here are the two proposed mechanisms whereby 
domain C0 can interact with the RLCs. In (A), C0 could be placed between the RLC, and in such a 
position could change the position of the S1 heads by pulling them closer together, or by pushing them 
further apart. Alternatively in (B), domain C0 could interact with only one RLC, leading to an asymmetry 
of the S1 heads. 
 
   It is the aim of this project to first express and purify cMyBP-C domain C0 in E. coli. 
The RLC construct will be expressed alongside the MiniHMM (myosin fragment) 
construct. Mutations in the RLC will then be introduced at sites of interest for EPR 
studies. 
   EPR measurements will then be made, with and without C0. If the proposed 
mechanism stands true, and C0 alters the positions of the S1 heads by bringing them 
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closer together, or by pushing them apart, there should be a notable difference in 
distance measurements with and without C0, as confirmed, or otherwise by EPR 
spectroscopy. No matter which model is preferred following EPR, we hope to learn 
more about the positioning of the RLC in myosin, in relation to regulatory proteins such 
as cMyBP-C, with these preliminary results opening avenues for further research. 
 
4.2 Small Scale Test Expressions of cMyBP-C C0 and RLC/MiniHMM 
   Before expression of the recombinant proteins was carried out on a large scale, 
expression was first tested on a small scale (100mL). Figure 4.8 shows the resulting 
SDS-PAGE analysis of samples taken from the crude cultures before and after induction 
for the cMyBP-C C0 domain and the RLC/MiniHMM Complex.  
 
 
 
 
 
 
 
 
 
 
Figure 4.8: SDS-PAGE Analysis Following Small-Scale Test Expression (100mL) of the C0 and 
RLC/MiniHMM Constructs. Sample lanes 1 and 2 are samples taken from the crude cultures before 
induction. Sample lanes 3 and 4 are samples taken from the crude RLC/MiniHMM cultures, run both 
reduced and non-reduced, respectively. Sample lanes 5 and 6 are samples taken from the crude C0 
culture, run both reduced and non-reduced, respectively. 
 
   Following small scale test expression, expression of the C0 domain of cMyBP-C is 
clear, however, it appears that the RLC/MiniHMM complex is not expressing in the 
soluble fraction. cMyBP-C domain C0 was then expressed and purified on a larger scale 
before problems with the RLC/MiniHMM were addressed. 
 
 
 
15 
20 
25 
 37 
 50 
75 
 100 
150 
MW  
kDa  1       2       3       4       5       6 
Chapter 4: Myosin RLC and cMyBP-C: An EPR Study  
 
154 
 
4.3 Expression and Purification of cMyBP-C Domain C0 
   NMR and binding studies have confirmed an interaction between the cardiac specific 
C0 domain of cMyBP-C and the cardiac RLC of myosin. The cardiac specific domain 
C0 was expressed and purified using an E. coli expression system, as described in 2.3.2. 
The C0 construct contains a C’ terminal hexa-histidine tag, and therefore IMAC can be 
used as the first catchment step. Figure 4.9 shows the elution chromatogram following 
IMAC and corresponding SDS-PAGE analysis, following purification of the construct. 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Elution profile and corresponding SDS-PAGE analysis for the cMyBP-C Domain C0 
Following IMAC. Every third fraction from 10-40 beneath the circled peak was analysed.  
   Following determination of purity by SDS-PAGE analysis, fractions 10 - 40 were 
pooled and concentrated before being dialysed overnight at 4
o
C into non-imidazole 
buffer. The final yield was determined as ~20mg from 1Litre of culture.  The protein 
was diluted with a half volume of glycerol before being stored at -20
o
C. A sample was 
submitted for Mass Spectrometry to the SIRCAMS facility, University of Edinburgh. 
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Figure 4.10: Mass Spectrum of cMyBP-C, domain C0, performed at SIRCAMS, using FT–ICR 
mass spectrometry. 
MS was performed in order to obtain an intact and accurate mass for the cMyBP-C 
domain C0. The mass obtained (13,519.2 Da) was as predicted using the ExPASy 
Molecular weight calculator (13,520.05 Da). 
 
4.4 Optimisation of Expression of the WT RLC/MiniHMM Complex 
   In order to characterise the interaction of the RLC with C0, the RLC was co-expressed 
with a myosin fragment – ‘MiniHMM’ containing residues 806-963 (806-835 = RLC 
binding site) of the S2 coiled coil. Co-expression of the RLC with the MiniHMM 
ensures proper folding of the RLC, and provides stability to the binding site, promoting 
formation of the complex (Ratti et al, 2011) shown in Figure 4.11. 
 
 
 
 
 
 
 
  
 
 
 
Figure 4.11: Schematic Representations of the Myosin Heavy and Light chains (A), zoomed in 
showing the MiniHMM Fragment, with bound RLC (B). 
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   Expression of the WT RLC/MiniHMM complex was optimised on a small scale, 
before cysteine mutagenesis was carried out, and mutants expressed. Previous work 
using the RLC/MiniHMM complex has shown that the protein expression is partly 
insoluble, and expression levels irregular (Mark Pfuhl, personal communication), and so 
optimisation of expression should facilitate an easier transfer of protocols to cysteine 
mutants. Following adjustments to induction time, temperature and IPTG concentrations 
the majority of the protein was expressed in the insoluble fraction. 
 
4.4.1 Modification of the MiniHMM Construct  
   The original MiniHMM construct contains two cysteine residues. Shown in Figure 
4.12 is the structure of the coiled coil, highlighting cysteine positioning. 
 
 
 
  
 
 
 
Figure 4.12: Crystal structure of human cardiac beta-myosin II S2∆ (PDB_ID: 2FXM, Blankenfeldt 
et al, 2006). 
   From Figure 4.12, it is clear that the cysteine residues are in such close proximity, that 
it is likely that they form disulphide bonds. This was confirmed using mutagenesis 
studies, however the presence of disulphide bonds in the S2∆, led to an instability, and 
precipitation of the protein at temperatures above 25
o
C (Mark Pfuhl, personal 
communication). 
   Typically, coiled coil structures are based on the hydrophobic interactions of two 
helices, rather than an interaction based on disulphide bond formation. To optimise 
packing, the two helices wrap around one another, hence the coiled coil structure, which 
are often based on a sequence motif known as the leucine zipper, as illustrated in Figure 
4.13. 
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Figure 4.13: Schematic representation of the Leucine Zipper motif. 
 
   The leucine residues form a hydrophobic core, stabilising the coiled coil structure, 
holding it in place. Therefore substituting the cysteine residues for leucine residues, as 
shown in Figure 4.14, promotes the leucine zipper formation, by eliminating the 
potential to form disulphide bonds, whilst improving stability.   
 
 
 
 
 
 
 
Figure 4.14: Sequence of the original MiniHMM construct aligned with the modified MiniHMM.  
In the new construct the Cys residues at positions 117 (905) and 160 (947) are substituted for Leu 
residues. 
 
   From this point the RLC/MiniHMM complex refers to the RLC bound to this 
modified cysteine-free MiniHMM complex. 
 
4.5 Large Scale Expression of wt RLC/MiniHMM  
   In order to avoid the RLC/MiniHMM complex being expressed in the insoluble 
fraction, both the expression and cell lysis conditions were altered from standard 
protocol (Growth at 37
o
C, induction at 37
o
C; 5hr with 1mM IPTG, lysis by sonication) 
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to the methods outlined in Chapter 2 which were developed and optimised on a visit to 
Dr Lena Rostkova from Dr Mark Pfuhl’s group at King’s College London.  
   In cooling induction temperatures and reducing the final concentration of IPTG used 
for induction, this encourages a reduced rate of expression, which promotes expression 
of more soluble protein (Graslund, 2008), whilst lysis using repeated freeze thaw 
techniques ensures all cells are fully lysed, and the protein not exposed to high 
temperatures unnecessarily during the sonciation procedure. 
 
4.5.1 IMAC of wt RLC/MiniHMM 
   The MiniHMM construct contains an N’ terminal hexa-histidine tag, and therefore 
IMAC can be used as the first catchment step. The histidine tag can then be removed 
using TEV protease, as described in 2.3.1, 2.5.2, and 2.5.2.1.  
   Figure 4.15 shows the resulting SDS-PAGE analysis from large scale expression of 
the WT RLC/MiniHMM complex following modification to protocols and expression 
using IMAC. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4:15 SDS-PAGE Analysis Following Large Scale Expression and Purification of WT 
RLC/MiniHMM Using IMAC. (A) Samples taken throughout the purification process. 1. Crude cell-
free extract before IMAC. 2. Flow-though from IMAC. 3. Wash. 4. Wash 5. Elution Fraction. 6. Elution 
Fraction. (B) 1. Flow-through from IMAC following TEV (cleaved protein) 2. 500mM imidazole wash. 
   Following purification of the wt RLC/MiniHMM complex, the protein has been 
solubilised, and final yields were ~5mg/1L of culture. It is evident that modification to 
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both the expression and lysis protocols promotes expression of a soluble 
RLC/MiniHMM complex, as the MiniHMM can be seen running at ~15kDa, and the 
RLC at ~20kDa, as indicated by the box. Although TEV protease was used for cleavage 
of the hexa-histidine tag, (Figure 4.15B), the cleavage reaction was not complete, as 
there appears to be some uncleaved material in elution fraction 2 (Figure 4.15B), as 
assessed by SDS-PAGE. 
 
4.5.2 Size Exclusion Chromatography of wt RLC/MiniHMM 
   Following the cleavage reaction, the wt RLC/MiniHMM was further purified using 
SEC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: SEC elution profile (A) and SDS-PAGE analysis (B) for wt RLC/MiniHMM 
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   Figure 4.16 shows the SDS-PAGE analysis and elution profile for the wt 
RLC/MiniHMM construct. The protein was treated with a final concentration of 10mM 
DTT before SEC was performed, to mimic the treatment for cysteine mutants, and allow 
comparison. From the SDS-PAGE analysis, the wt RLC/MiniHMM complex has eluted 
from the SEC column in the first major peak, whilst the DTT elutes in the second. The 
protein does not elute in the centre of the main peak, but instead towards the shoulder 
(fractions C7-C10).   
   Following purification of the wt RLC/MiniHMM complex, the protein has been 
solubilised, and final yields were ~5mg/1L of culture. It is evident that modification to 
both the expression and lysis protocols promotes expression of a soluble 
RLC/MiniHMM complex, as the MiniHMM can be seen running at ~15kDa, and the 
RLC at ~20kDa, as indicated by the box. Although TEV protease was used for cleavage 
of the hexa-histidine tag, the cleavage reaction was not complete.  
 
4.6 Generation of Cysteine Mutants of the myosin RLC for SDSL 
Purposes 
   Mutations have been made in the chicken isoform of the myosin RLC for the purposes 
of fluorescence studies (Hopkins et al, 1998) and exchanged into muscle fibres to check 
the effect of the mutation on force. Consequently, the mutations from the chicken 
isoform could be transferred onto the human isoform due to significant sequence 
homology, and SDM performed to generate the cysteine mutants.  
 
 
 
 
 
Figure 4.17: Sequence alignment of the Chicken RLC with the Human RLC. Mutations chosen in the 
human protein were selected based on functional cysteine mutants in the chicken isoform. Mutations are 
highlighted underneath the residue. 
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Figure 4.17 shows the sequence of the chicken RLC aligned with the human RLC. The 
residues selected in the chicken sequence have been successfully mutated to cysteine 
residues, and so the corresponding residues in the human sequence (K30, E88, E97, 
D117, and T125) were selected for SDSL purposes. Mutations were selected in both N’ 
and C’ terminal regions to optimise potential for observing changes in distance 
measurements with and without C0. 
 
4.7 MMM Simulation of the DEER Experiment for RLC/MiniHMM 
Cysteine Mutants 
 
   As stated above, cardiac myosin is composed of 4 chains, two heavy and two light. 
The two light chains, the RLC and ELC, bind the heavy S2 coiled coil chain, in the 
vicinity of the heavy S1 head group, as sown in Figure 4.18.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18: Structures illustrating the positioning of the RLC in the S2 junction, in the vicinity of 
the S1 heads. (A) Schematic representation and (B) Surface representation of the S1 heads (cyan), with 
the RLC (pink) and ELC (purple) bound to the S2 junction (Modelled using chicken proteins, from which 
our mutations are based) (C) RLC (pink) bound to part of the S2 (purple) with cysteine mutations 
represented as cyan spheres. (B and C visualised using PDB_ID:1M8Q, Chen et al, 2002). 
 
   Figure 4.18 shows the structure of the chicken proteins, from which our mutations 
have been based. Using MMM, the DEER time traces and distance distributions were 
modelled between pairs of RLC bound to the MiniHMM complex, in the off state, i.e. 
without C0 (Figure 4.19). All show distances that should be measurable by DEER. 
From Figure 4.18C, and from models generated by Dr Mark Pfuhl based on the 
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sequence of the human cardiac RLC, we hypothesise that if the C0 wedges between the 
RLC proteins and moves them apart, the K30C distance should provide the 
measurement that is both easiest to measure with DEER and will change upon C0 
binding. 
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Figure 4.19: MMM Simulations of the DEER Time Traces (I) and Distance Distributions (II) shown 
alongside PyMOL cartoons illustrating the site for cysteine mutagenesis. These calculations were 
performed on the chicken structure (PDB_ID:1M8Q, Chen et al, 2002) (A) K30C (B) E88C (C) E97C 
(D) D117C (E) T125C. 
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4.8 Generation of Cysteine Mutants of the myosin RLC for SDSL 
Purposes 
   Mutations have been made in the chicken isoform of the myosin RLC for the purposes 
of fluorescence studies (Hopkins et al, 1998) and exchanged into muscle fibres to check 
the effect of the mutation on force. Consequently, the mutations from the chicken 
isoform could be transferred onto the human isoform due to significant sequence 
homology, and SDM performed to generate the cysteine mutants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20: Sequencing chromatograms, comparing the wt sequence to the sequence following 
SDM, showing successful substitution for cysteine in all cases. (A) K30C (B) E88C (C) E97C (D) 
D117C and (E) T125C. 
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Figure 4.20 shows sequencing chromatograms for the five of the single cysteine mutants 
chosen for this study, compared to the wt. 
4.9 Large Scale Expression and Purification of cardiac Myosin RLC 
Cysteine Mutants 
   Utilising the histidine tag on the MiniHMM fragment, each of the cysteine mutants 
were expressed using the modified expression and lysis protocols, before being purified 
using IMAC, with manual elution using a peristaltic pump. Figure 4.21 shows the SDS-
PAGE analysis from the purification of each of the four cysteine mutants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21 SDS-PAGE analysis following purification of each of the Cysteine RLC/MiniHMM 
Mutants following IMAC. (A) purification of K30C (B) purification of E88C (C) purification of E97C 
(D) purification of D117C and (E) purification of T125C. 
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   As for the wt RLC/MiniHMM complex, complete cleavage of the hexa-histidine tag 
was not achieved for the cysteine mutants. Following passage of the 500mM elution 
fraction over the Ni-NTA column (post –TEV cleavage), the RLC/MiniHMM complex 
did not bind to the column, indicative of cleaved histag. The column was washed with 
buffer containing 500mM imidazole which serves to remove bound cleaved histag and 
the TEV protease. Figure 4.22 shows the SDS-PAGE analysis of elution from the Ni-
NTA column for the E88C mutant following cleavage of the Histag by TEV protease. 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.22: SDS-PAGE analysis of the E88C RLC/MiniHMM Mutant, showing purification using 
IMAC and elution from the Ni-NTA following Histag Cleavage. 
 
   Following the cleavage reaction the sample was flowed over the Ni-NTA cartridge. 
The cleaved protein now contains no histidine tag and so does not bind (sample lane 8). 
Following washing with a final concentration of 500mM imidazole there appears to be 
some RLC/MiniHMM complex in this fraction. This is indicative of an incomplete 
cleavage reaction, as some complex remains bound to the column via the histidine tag. 
At this stage, only the cleaved fraction was used for subsequent experiments for each 
mutant. 
   Expression levels varied considerably between mutants. Illustrated in Table 4.1 are 
final yields obtained for the wt protein, compared to the single cysteine mutants. 
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Table 4.1: Final Yields of RLC/MiniHMM Mutants per Litre of Cell Culture 
 
 
 
 
 
 
   It is clear looking at Table 4.1 that the final yields for all cysteine mutants vary 
considerable from the wt. For each mutant, typically 4L of E. coli culture was grown, 
and even when scaled up to 12L there was little effect on final yields. Of the five 
mutants selected, only the K30C and E88C mutants showed expression levels that 
would yield enough protein for future experiments.  
   Expression was repeated numerous times for the remaining mutants, however 
expression and purity at this stage could not be improved. K30C and E88C were taken 
on since they would give a good preliminary idea of whether the inter-RLC distance 
changes upon C0 binding. 
 
4.9.1 Further Purification of K30C RLC/MiniHMM 
   Although Table 4.1 gives the final yield of the K30C mutant, this is not a true 
representation of the final yield, as the yield was calculated based on A280, and it is clear 
from the SDS-PAGE analysis in Figure 4.21A, that there are a lot of contaminating 
proteins that will be contributing towards the A280 value given. Figure 4.23 shows the 
SDS-PAGE analysis of the K30C mutant, following cleavage of the histidine tag. 
 
 
 
 
 
 
 
 
Figure 4.23: SDS-PAGE analysis of the TEV-treated K30C mutant following passage over the 
IMAC column. 
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   Following the cleavage reaction, the mutant is still contaminated, and like the wt 
protein, the K30C underwent SEC in hopes of eliminating the contaminants. The elution 
profile and SDS-PAGE analysis for the K30C mutant following SEC is shown in Figure 
4.24. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.24: Elution profile for the K30C RLC/MiniHMM mutant following SEC and resulting 
SDS-PAGE analysis. 
 
   Looking at the elution profile for the K30C mutant, it elutes in the same place as the 
wt protein, with a slight shoulder to the left of the first peak. Following SDS-PAGE 
analysis, some of this shoulder is separated from the main peak, however not all 
contaminants are removed. The RLC/MiniHMM complex is shown in the circled 
fractions. Unlike the wt RLC/MiniHMM, SEC has not improved the purity of this 
mutant, and so at this stage, the E88C mutant was the only one selected for DEER 
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measurements, as this gave reasonable protein yield with which to work, as well as 
appearing clean following SDS-PAGE analysis (Figure 4.21). Optimisation of one 
mutant, with high purity, good spin labelling efficiencies and overall good yield would 
ensure that one could be confident that any changes observed during the DEER 
experiments were true. 
  
4.10 Spin labelling of the E88C RLC/MiniHMM Mutant 
   Following cleavage of the hexa-histidine tag, the E88C mutant was treated with a final 
concentration of 10mM DTT, and free cysteine levels quantified using the Ellman’s 
reagent DTNB. From SDS-PAGE analysis (Figure 4.21) it is clear that the sample is not 
entirely homogenous in regards to purity, and so Ellman’s testing can only give a rough 
estimate as to the quantification of free cysteine in each sample.  
   DTT was eliminated by extensive dialysis, and mutants spin-labelled with MTSSL 
(10x molar excess, relative to free cysteine concentration). Excess spin label was 
removed using Vivaspin® centrifugal concentrators, before a CW EPR spectrum was 
recorded which showed some level of free spin label contaminant, shown in Figure 
4.25. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.25: CW EPR spectrum for the E88C mutant. Taken at r.t under non-saturating conditions, 
using the AffirmoEx benchtop spectrometer, by ActiveSpectrum. 
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4.11 DEER Measurements of E88C RLC/MiniHMM, With and 
Without cMyBP-C domain C0. 
 
   Before DEER measurements were taken, the sample was dialysed into the deuterated 
form of the buffer used throughout (minus imidazole). When studying the binding 
interaction of C0 with the RLC using ITC (Ratti et al, 2011), an excess of C0 over 
MiniHMM of ~ 1.5-2 confirms an interaction (dissociation constant of 3.2 ± 1.7μm). 
Consequently, concentrated C0 (1mM) was added to the E88C mutant in a 6 times 
excess, to ensure an interaction, in a final volume of 50µL, before the addition of a 
further 50µL of deuterated glycerol.  
   The data we measured did not highlight a large change upon C0 addition but also was 
very non-specific with respect to any particularly distance. The modulation depth is low 
for nitroxide-nitroxide DEER, which is likely a result of low spin-labelling efficiencies 
of the E88C mutant. It was estimated that labelling efficiency was in the range of 25% 
by protein concentration, when compared to standard nitroxide solution (TEMPO). 
Further, long after the sample was disposed of we found a fault with the video amplifier 
which was leading to distorted data. This has cast more doubt on the results since we 
don’t know whether slight changes are true or if we masked larger changes.         
   At this stage we decided that a new sample would have to be made, and measurements 
taken again. 
  At this time Mark Pfuhl also found that the MiniHMM complex can form dimers and 
that these could potentially block the interaction site for C0. An increase in NaCl 
destabilises this dimer, although may also abrogate C0 binding. Our plan therefore was 
to repeat E88C DEER measurement in high and low salt conditions.  
 
4.12 DEER Measurements of E88C in High and Low NaCl 
Following IMAC, the wash and elution fractions were pooled and concentrated using 
Vivaspin® centrifugal concentrators. The free cysteine levels were quantified using the 
Ellman’s reagent, before the E88C mutant was spin-labelled. Figure 4.26A shows the 
final SDS-PAGE analysis of the new E88C sample following elution from IMAC. The 
sample was treated with a final concentration of 10mM DTT, and dialysis used to 
remove this. Based on absorbance at 280nm, the protein concentration was determined 
to be approximately 50 µM. The quantity of free cysteine was determined to be 
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approximately 73 µM by Ellman’s testing. It should be noted at this point that the E88C 
mutant is not entirely pure (~60%), and so quantification of free cysteine also accounts 
for any free cysteine in contaminating proteins. The E88C was spin labelled and a CW 
EPR spectrum was taken, as shown in Figure 4.26B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.26: (A) SDS-PAGE analysis and (B) CW EPR spectrum for the E88C mutant. of the 
elution of the new E88C sample following IMAC. The elution from the IMAC column was performed 
manually using a syringe, and the wash and elution fractions pooled. The CW EPR spectrum was taken at 
r.t under non-saturating conditions, using the AffirmoEx benchtop spectrometer, by ActiveSpectrum. 
 
    
   Comparing the new labelled E88C mutant with standards of known concentration, it 
was estimated that labelling efficiency was improved from ~25% to somewhere in the 
region of 40-50%. Following purification of the RLC mutants, the proteins were stored 
in the same buffer used throughout the purification process, as detailed in Appendix A7 
(minus imidazole). However, in retrospect, for future preparations, it may be 
worthwhile considering spin-labelling the RLC/MiniHMM constructs in the presence of 
high NaCl, as dimer formation of the MiniHMM could be affecting labelling 
efficiencies. 
   Samples were prepared washing E88C and E88C/C0 samples into either 50mM 
Hepes, 250mM NaCl or 100mM Hepes, 500mM NaCl with deuterated water. Finally 
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40% deuterated glycerol was added. Protein concentrations are 54µM (E88C) and 
171µM for C0.  
   Following communication with collaborators, it was suggested that the MiniHMM 
complex has the potential to form dimers, which could explain why there is no 
indication of complex formation. This dimerization of the MiniHMM construct could be 
inhibiting the binding site for C0. Measurements were therefore taken in both low and 
high salt conditions (Figure 4.27). 
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Figure 4.27: Raw DEER data obtained from the RLC E88C mutant. (A) Compares E88C mutant in 
both high and low salt (B) Compares E88C mutant with and without C0 (both measured in high salt) (C) 
Compares two different E88C mutants prepared under the same conditions. 
When looking at the raw EPR data, it seems that there is no difference observed in both 
high and low salt for the E88C mutant. When looking at the mutant with and without 
C0, again no change is observed in the data collected. 
   This suggests that in the presence of C0, there is no change in the position of the RLC, 
however, when comparing the data obtained here, to that obtained in previous 
experiments for the E88C mutant, there is a difference. Although both protein 
preparations followed the same protocol, and were of similar concentrations and levels 
of purity, the EPR is not reproducible. This brings into question the state of the proteins 
under study 
   During cell lysis, cells  were treated with Triton detergent to promote lysis and 
increase solubility, however it is possible that the use of detergents in the preparation 
are potentially affecting the fold of the protein, which could explain low spin-labelling 
efficiencies, even in the presence of a high concentration of free cysteine (as determined 
by the Ellman’s Assay).  
   Furthermore, the inclusion of detergents is possibly solubilising endogenous E coli 
proteins, which are being brought through with the protein of interest, and approve 
difficult to eliminate with subsequent purification steps. Labelling should therefore be 
done in the presence of high and low salt, rather than transferring to high/low salt before 
the EPR experiment is run. If no signal is observed in this instance than a potential 
protein misfold as a result of that discussed above, should be considered. 
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4.13 Outlook and Future Work 
   Unfortunately, from the data obtained thus far for the RLC/MiniHMM/C0 interaction, 
no solid conclusions can be drawn. From the outset, this particular project appeared 
relatively straightforward, in that the constructs had been expressed before and the 
interaction between RLC and C0 confirmed. 
   E88C, E97C, D117C and T125C were chosen based on mutations previously made 
with the chicken RLC protein, with which there is a high degree of sequence homology, 
and corresponding mutants in chicken appear fully functional in force analysis when 
reconstituted into muscle fibres. This may not be true for the same mutants in the 
human protein. The K30C mutant was made following modelling from our 
collaborators which indicated more flexibility in the N’ terminus of the human 
MiniHMM complex, with the RLC folded more towards the S2 junction, and therefore 
we hoped that the K30C mutant would help differentiate between the chicken complex 
and the human. Unfortunately it is difficult to predict how different mutants will behave 
before they are expressed, and so using models from other species is far from ideal, but 
otherwise would be done blindly.  
   Significant problems also arose from solubility issues, in that even the wt protein was 
not initially expressed in its soluble form. It was only after extensive optimisation and 
significant changes to the protocols, that expression of the wt protein could be 
visualised by SDS-PAGE. Frequently mutant expression levels are less than for wt but 
we saw a significant loss, and more problematic was our finding that the 
RLC/miniHMM complex could not be purified adequately for most mutations. In fact, 
while we repeated expression multiple times (not discussed here in detail) we only ever 
had adequate protein from the E88C mutant. 
   Our first DEER experiments with E88C did not show promising results but later we 
found that there was a fault which may have distorted our measurements and therefore 
these results needed to be abandoned. We did however find from these DEER 
experiments and the CW EPR scans that the labelling efficiency was quite low. We 
planned to repeat the experiment and additionally use both high and low salt conditions 
in case the MiniHMM dimerises at higher concentrations in low salt and this abrogates 
the C0 binding. However, different spectrometer problems have led to a delay in 
measuring these samples.  
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   The C0 expressed beautifully and in high yield, and so there is a possibility of 
introducing a cysteine residue to C0. This would lead to triangulation which, if the 
distributions are somewhat broad, can cause inaccuracies in analysing DEER data for 
distances. However, if the label on the C0 had an EPR spectrum that does not fully 
overlap with the nitroxide, then selective DEER measurements should be possible. This 
is the basis of orthogonal spin labelling using e.g. Gd
3+
 labels (Garbuio et al, 2013). 
   Thoughts on how one could explore the interaction further: Preliminary work done by 
our collaborators, has shown that upon phosphorylation of the RLC, the MiniHMM 
dissociates (Figure 4.28)  from a heterotetramer composed of 2RLCs (red) and 2 heavy 
chains which form a coiled coil (blue), to 2 heterodimers composed of 1 heavy chain 
and 1 RLC. This is a result of dissociation of the S2 coiled coil. 
 
 
 
 
 
Figure 4.28 Schematic representation of the effect phosphorylation of the RLC has on the 
RLC/MiniHMM complex. 
 
   The MiniHMM construct used in this body of work, contains only 25% (Figure 
4.29A) of the entire myosin S2 coiled coil (Figure 4.29B), and therefore dissociation of 
the entire coil in vivo is highly unlikely. It is proposed that upon phosphorylation of the 
RLC, the N’ terminal portion of the S2 coil, in the immediate proximity to the RLC 
dissociates.  
   The spin-labelled RLC mutants (spin-labelling sites represented as yellow triangles) 
could then be phosphorylated, and EPR used to monitor the effect of phosphorylation of 
the RLC, on the myosin fragment (Figure 4.29C).  
   The MiniHMM fragment would be lengthened, so it remains a tetramer upon 
phosphorylation. Spin labels could also then be placed along the coil itself, to measure 
by EPR the dissociation that occurs as a result of phosphorylation of the RLC, and 
assess how far the coiled coil opens. The same can be done in the presence of C0, and 
longer cMyBP-C constructs (Figure 4.29D). 
 
              
MiniHMM                                               
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Figure: 4.29 Schematic representations of the RLC/MiniHMM complex, showing how SDSL could 
be used to monitor dissociation of the S2 coiled coil upon phosphorylation of the RLC, both in the 
absence and presence of C0. 
   
   Further elucidation of the Myosin/cMyBP-C interaction is essential in understanding 
the regulation of cardiac muscle contraction in health and disease. Although less vital in 
triggering contraction in cardiac muscle, phosphorylation of the RLC is vital for the 
control and power development and for precise mechanical operation of cardiac muscle.     
   Despite its value and significance in muscle contraction, as far as the human cardiac 
isoform is concerned there are few functional data, and no structural information 
regarding its function. If the problems with yield can be addressed, and better data 
obtained using EPR for more N’ terminal mutants , this could provide for the first time a 
detailed insight into the Myosin/cMyBP-C interaction, and the effects of 
phosphorylation on heart muscle contraction.  
   These experiments could then be extended into mutations associated with disease, 
providing further understanding of the origin of cardiomyopathies, with the ultimate 
goal of advancement in medical treatments for conditions associated with mutations in 
these genes. 
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Chapter 5: Development of New Strategies for the Site-
Directed Spin–Labelling of Cysteine Rich Proteins 
AIMS: This body of work aims to develop a range of new methods for the site-directed 
spin-labelling of cysteine rich proteins. The ability of E. coli to read through the amber 
stop codon will be exploited for the incorporation of unnatural amino acids for spin-
labelling purposes, and novel spin labels, specific for labelling cysteine pairs will be 
tested in several model systems. Furthermore, native paramagnetic centres in 
recombinant proteins will be explored as potential labelling sites.  
 
5.1 The Limits of SDSL by Cysteine Substitution Mutagenesis  
Traditional methods of SDSL involving cysteine substitution mutagenesis are effective 
but what happens when this is not feasible? As discussed in detail in 1.4.2 the site 
specificity of EPR spectroscopy is typically introduced via the incorporation of spin 
labels into proteins of interest, via the thiol group of cysteine residues, due to its high 
reactivity at physiological pH. Cysteine residues are rarely present as free thiols in 
extracellular proteins, and are usually found in disulphide bonds, if at all. For this 
reason a great number of extracellular proteins have been engineered at specific sites of 
interest to incorporate cysteine residues for SDSL.  
   However, a huge caveat to using EPR to obtain distance measurements in biological 
systems is that the technique is at its most accurate in the simplest of cases; when 
looking at the interaction between a pair of radicals. When considering the application 
of EPR to the study of intracellular proteins, which are typically cysteine rich, the issue 
of specificity is raised. In order to specifically study the interaction between any two 
naturally occurring cysteine residues within a cysteine rich protein, any additional 
cysteine residues would need to be selectively removed, which could prove detrimental 
to both protein fold and function.  
   Structure underpins function, even at the simplest level, and so the field of structural 
biology is constantly evolving, with EPR spectroscopy expanding into in vivo studies, in 
order to elucidate how protein-protein interactions manifest in the natural environment 
of the cell. These principles and problems extend to all sorts of techniques that require 
specific labelling of isolated proteins or proteins within a living organism. The 
development of new labelling techniques for the specific labelling of cysteine rich 
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proteins, as well as the development of new spin labels which can withstand the 
reducing environment of the cell, is paramount for the study of proteins which are 
otherwise out with the realms of this technique, and for the study of protein-protein 
interactions in vivo. 
 
5.2 Site Directed Site Labelling via Reassignment of the Amber Stop 
Codon 
   Over fifty years ago, the revolutionary work of Nirenberg and Matthaei,1961 initiated 
the cracking of the genetic code, by discovering that the amino acid (AA) phenylalanine 
was specifically incorporated into proteins in response to the codon UUU. This 
pioneering work paved the way in uncovering the rules that govern the translation of an 
organism’s genetic lexicon for the ribosomal biosynthesis of proteins, with each of the 
64 codons assigned to the 20 proteinogenic AAs, and the three termination signals. 
   With few exceptions, all living organisms are confined to the use of only twenty 
canonical AAs for protein biosynthesis. It is therefore somewhat remarkable that 
polypeptide synthesis from these 20 AAs is sufficient for performing all complex 
processes of life. It is clear that many proteins require more chemical complexity to 
function, as illustrated by the frequent use of post translational modification, and the 
dependence of many enzymes on cofactors (Young & Schultz, 2010). Therefore, the 
addition of new AAs to the genetic code, with novel chemical, biological and physical 
properties, could further expand the range of functions available to proteins, and provide 
powerful means for probing protein structure, function, and dynamics, both in vitro and 
in vivo (Loscha et al, 2012). 
 
5.2.1   Translation of mRNA into a Polypeptide at the Ribosome 
   Translation is the process by which genetic information in the form of messenger 
RNA (mRNA) is converted into a sequence of corresponding AAs following ribosomal 
processing, forming a peptide chain, which is later folded into an active protein . This is 
illustrated in Figure 5.1. 
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Figure 5.1: Schematic representation of mRNA processing at the ribosome, and resulting 
polypeptide synthesis. 
The process of protein translation from mRNA occurs via four distinct steps.  
INITIATION: In the first instance the ribosome and accessory proteins assemble on 
the target mRNA strand. The initiator tRNA binds via complementary base pairing, 
following recognition of the start codon AUG (Met) on the mRNA strand. 
ELONGATION: In response to the relevant anti-codon on the tRNA, specific AAs are 
delivered to the tRNA molecule by a tRNA synthetase, specific for that AA.                                                                                                                    
TRANSLOCATION: The ribosome then moves in a 5’ to 3’ direction, to the next 
mRNA codon, continuing the process, and creating an extended AA chain.           
TERMINATION: Upon recognition of a stop codon on the polypeptide strand, the 
ribosome releases the protein. 
   Although the process of cellular translation at the ribosome functions to produce 
proteins composed entirely of the twenty canonical amino acids, it also represents the 
ultimate paradigm for the encoded synthesis of proteins containing additional amino 
acids, with novel function, with the potential to the evolve into the synthesis of 
completely unnatural polymers.  
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5.2.2   Incorporation of Unnatural Amino Acids (UAAs) into Recombinant 
Proteins 
 
   Although recent advances in synthetic and semi-synthetic methods have proven useful 
for the incorporation of UAAs into proteins (as discussed in 1.5.1), they are generally 
limited by low yields and are technically challenging in the production of proteins of 
large molecular weight. The use of cellular biosynthetic machinery to introduce novel 
AAs abrogates issues relating to scalability and protein size, whilst simplifying the 
study of modified proteins in living cells (Young & Schultz, 2010). This body of work 
looks at exploiting the ability for E. coli cells to read through the amber stop codon. 
   In order to expand the genetic repertoire beyond that of the 20 canonical AAs, a codon 
unique for the incorporation of a novel (or unnatural) AA must be assigned. The twenty 
AAs are encoded by 61 degenerate triplet codons, leaving the remaining three codons 
(TAG, amber; TAA, ochre; TGA, opal) to serve as translational termination signals. 
Using the redundancy of what is essentially a blank codon, together with the ribosomal 
machinery of the cell, many UAAs have been site-specifically incorporated into proteins 
in response to the amber stop codon in E. coli (Chin et al, 2002a), yeasts 
Saccharomyces cerevisiae (Hancock et al, 2010) and Pichia pastoris (Young et al, 
2009), mammalian cell cultures (Gautier et al, 2010), and most recently a full animal 
model (Greiss & Chin, 2011). 
 
5.3   Project Aims 
   Inspired by the pioneering work of Peter Schultz and Jason Chin, this thesis aims to 
exploit the ability of E. coli to read-through the amber stop codon, TAG, for the specific 
incorporation of UAAs with novel functional groups. Specifically; sperm whale 
myoglobin will be expressed and purified with the UAA propargyl lysine (pK) (Lysine 
modified with alkyne function group) incorporated at multiple sites.  
   Myoglobin is where the science of protein structure really began, with John Kendrew 
laying the foundation for an era of biological understanding in solving the first protein 
structure - sperm whale myoglobin – by X-Ray analysis (Kendrew et al, 1958). The 
XRC structure is shown in Figure 5.2.  
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Figure 5.2: X-Ray Crystal Structure of Sperm Whale Myoglobin.  The heme group of the myoglobin 
is represented as yellow sticks, and the blue spheres represent potential spin labelling sites, via both 
cysteine substitution mutagenesis, and pK incorporation. (Visualised using PyMOL & PDB_ID: 1MBN, 
H.C. Watson, 1969). 
Consequently, myoglobin is very well characterised, with well-defined structure and 
function, and therefore a good model system for this work.  
   The UAA pK links an alkyne functional group to a lysine residue via a carbamate 
bond forming an aliphatic alkyne, as shown in Figure 5.3. The flexibility of the 
carbamate linkage facilitates more efficient incorporation of the pK into cells (Nguyen 
et al, 2009), and, unlike aromatic azides previously reported in the literature, is photo-
stable, and consequently easier to handle. Copper-catalysed azide-alkyne cycloaddition 
(or ‘click’) reactions (Kolb et al, 2001) will then be performed to conjugate the pK 
containing protein to azide spin labels, in a manner that is comparable and orthogonal to 
cysteine labelling (Nguyen et al, 2009).            
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Figure 5.3: Chemical Structures of (A) Lysine and (B) the UAA propargyl Lysine (pK), visualised 
using ChemDraw ®. The structure of pK shows a Lysine residue modified by the addition of an alkyne 
functional group (circled). 
   EPR will be performed to assess whether this method of spin labelling is a surrogate 
for traditional methods, using cysteine substitution mutagenesis. The pK will be 
incorporated using the pyrrolysyl tRNA synthetase /tRNACUA(Pyl) pair from 
Methanosarcina barkeri, which is orthogonal in E. coli, ensuring no cross talk between 
endogenous sets. A lack of cross-reactivity should ensure that pK, is incorporated with 
high fidelity, only in response to the non-sense codon TAG (Young et al, 2010). 
    Even in the wake of recent improvements in protein synthesis techniques, it is 
challenging to predict the facility  in incorporating a specific UAA in vitro, at a given 
site, prior to performing the experiment  (Short et al, 1999). To date, phenylalanine 
derivatives bearing alkynyl (Deiters & Schultz, 2005), azido (Chin et al, 2002b) and 
keto (Fleissner et al, 2009) groups that are bio orthogonal in their chemical reactivity 
have been incorporated into recombinant proteins in response to the amber stop codon.  
   Generally, the efficiency of incorporation of an UAA can be predicted to some extent, 
based on the chemical nature and structure of that being incorporated, with hydrophobic 
AAs being incorporated with high efficiency, and dipolar AAs proving troublesome 
(Short et al, 1999). However, the incorporation of aromatic UAAs into proteins where 
aliphatic AAs are naturally found may cause the protein to become misfolded, or result 
in an entire loss of protein function (Nguyen et al, 2009). Consequently, there is great 
need for the incorporation of aliphatic AAs, that contain bio-orthogonal chemical 
A                                              B 
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handles, which can subsequently be used for the specific labelling of recombinant 
proteins.  
   UAAs are incorporated with low efficiencies in comparison to natural AAs, possibly 
due to competition between the tRNA and endogenous cellular release factors, which 
function to recognise stop codons and terminate translation  (Loscha et al, 2012). A 
significant decrease in incorporation efficiency, as well as truncated proteins being 
expressed may influence the target protein, or prove deleterious to the host. 
Furthermore, yields drop precipitously with the addition of even a second stop codon 
(Johnson et al, 2011).  
   Consequently, the site of interest, the cell line required for expression, as well as the 
effect on incorporation efficiency as multiple stop codons are introduced, must all be 
considered in order to optimise expression of the target protein. Proving the latter can be 
overcome, and DEER results show that SDSL via genetic code expansion is a viable 
alternative to cysteine substitution mutagenesis, there is potential to extend these 
methodologies into cysteine rich proteins, which otherwise are out-with the realms of 
the technique. 
 
5.4 Generation of Single (SC4 &S C118) and Double Cysteine 
(S4CS118C (or C4C118)) Myoglobin Mutants 
 
   The plasmids pBk-Pyls and pMyo4-TAG-PylT used throughout this work were kindly 
supplied by Prof. Jason Chin. The pBk-Pyls plasmid contains the pyrrolysyl tRNA 
synthetase / tRNACUA(Pyl) pair whilst the pMyo4-TAG-PylT contains the gene for 
recombinant myoglobin expression. 
5.4.1 Mutagenesis 
   Before myoglobin could be expressed with the UAA, pK, it was first expressed as the 
single cysteine mutants S4C and S118C and the double cysteine mutant S4CS118C, 
with the native serine residues at position 4 and 118 mutated to cysteine residues. Figure 
5.4 shows the sequence chromatogram of the cysteine substitution mutagenesis, which 
can be compared to the wt. To generate the double mutant, the confirmed C4 mutant 
was used as template DNA. 
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Figure 5.4: Confirmation of mutagenesis of S4C and S118C in sperm whale myoglobin.  
 
 
5.4.2 Expression and Purification of the S4CS118C Myoglobin Mutant 
 
   Following transformation of the template DNA into DH10β E. coli cells, large scale 
flask expression was carried out, and the proteins purified by IMAC and SEC as 
described in 2.3.4 & 2.5.3. For each of the myoglobin mutants (Cys and pK mutants), 
due to the presence of a C’ terminal hexa-histidine tag, IMAC can be used for the initial 
catchment step. The SDS-PAGE analysis from all stages of purification, as well as the 
elution profile following the final purification step are shown in Figure 5.5. 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Expression and purification of the Sperm Whale Myoglobin, S4CS118C mutant. (A) 
SDS-PAGE analysis of the first catchment step; manual elution following IMAC. (B) SDS-PAGE 
analysis from small scale expression (10mL), testing reducing conditions. (C) Elution from the S75 SEC 
column, and resulting SDS-PAGE analysis.    
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   Following the initial catchment step, using IMAC, from the S4CS118C elution 
fractions, it is clear (Figure 5.5A) that although the majority of the myoglobin 
S4CS118C mutant is present as a monomeric species, there is a significant amount of 
dimer present. Typically, myoglobin does not contain any free thiols, and so it can be 
assumed that the dimerization is a result of disulphide bond formation between the 
introduced cysteine residues.  
   Therefore, the C4C118 mutant was treated with 1mM and 10mM DTT in order to 
reduce the disulphide bonds, and free the newly incorporated cysteine residues for spin 
labelling purposes. From the SDS-PAGE analysis in (Figure 5.5B), treatment with 1mM 
DTT is enough to reduce the disulphide bonds, although a little dimer remains, 
therefore, following IMAC, the pooled elution fractions were treated with a final 
concentration of 10mM DTT, before undergoing SEC.  
 
5.4.3 Expression and Purification of the Single Cysteine Mutants S4C and S118C  
 
   Following transformation of the template DNA into DH10β E. coli cells, large scale 
flask expression was carried out, and the proteins purified by IMAC as described in 
2.3.4 & 2.5.3. Figures 5.6 and 5.7 show the SDS-PAGE analysis for all stages of 
purification, as well as the elution profile following the final purification step, for both 
the S4C and S118C mutants, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: Development of New Methods for SDSL  
 
186 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: SDS-PAGE analysis following purification of the S4C Mutant following IMAC (A), 
shown alongside the elution profile (B) and resulting SDS-PAGE analysis following SEC (post-DTT 
treatment) (C). 
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Figure 5.7: SDS-PAGE analysis following purification of the S118C Mutant following IMAC (A), 
shown alongside the elution profile (B) and resulting SDS-PAGE analysis following SEC (post-DTT 
treatment) (C). 
5.4.4 Spin Labelling of Cysteine Myoglobin Mutants 
   Ideally, following treatment with DTT, an Ellman’s assay would be performed as 
described in 2.8.2 in order to quantify the amount of free cysteine before spin labelling, 
however, due to the characteristic red colour of myoglobin, it is impossible to monitor 
the release of the NTB component at 412nm, and so it must be assumed that any 
cysteine/cystine is reduced by the addition of 10mM DTT. 
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   Immediately following SEC, relevant fractions were pooled and treated with a 10x 
molar excess of MTSSL. The excess MTSSL was removed using extensive dialysis of 
the samples into PBS. The CW EPR spectrum of the double mutant, S4CS118C, is 
shown in Figure 5.8. The degree of spin labelling is close to 100%. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: X-band CW EPR of myoglobin S4CS118C SL. Taken on the AffirmoEx at r.t. in aqueous 
buffer. 
 
5.5 Expression and Purification of Sperm Whale Myoglobin Mutants 
with the UAA, pK. 
 
5.5.1   Mutagenesis 
   For incorporation of the pK UAA into myoglobin, the serine residues at position 4 and 
118 were changed to the amber stop codon, TAG. Figure 5.9 shows the sequence 
chromatogram of the mutagenesis, compared to wt. 
 
 
 
 
 
 
 
Figure 5.9: Confirmation of mutagenesis of S4pK and S118pK in sperm whale myoglobin. 
 
 
 
M            V              L             S            E              G            E             E                    M            V               L         STOP         E             G            E             
  
H            V              L           H             S             R            H              P                       H             V             L             H         STOP         R             H             P   
A                                                                           B 
 
 
 
 
 
 
 
C                                                                           D 
Chapter 5: Development of New Methods for SDSL  
 
189 
 
5.5.2 Small-Scale Expression of Myoglobin pK Single Mutants 
   Following transformation of the template DNA (S4pK and S118pK) into DH10β E. 
coli cells, alongside the plasmid containing the pyrrolysyl tRNA synthetase 
/tRNACUA(Pyl) pair, the single pK mutants were expressed on a 10mL scale, with the 
media supplemented with a final concentration of 2mM pK.  
   The pK used for the small scale test expressions was provided as the TFA salt, by Dr 
Alison Hulme, University of Edinburgh, Scotland, UK. It is suggested that 
supplementing the media with the UAA from inoculation yields higher expression 
levels, and reduces leaky expression, however, supplementing the media with the UAA 
pK at different points in the growth stage, (start, OD600 0.2, OD600 0.6, OD600 1.0) shows 
that when the UAA acid is added to the growth media has no effect on final yield.  
   Supplementing the growth media with the UAA significantly reduces the growth rate 
of the E. coli cells, when compared to expression of wt myoglobin, or cysteine mutants. 
Adding pK later in the expression proves more economical, as if cells do not reach their 
exponential growth phase, the pK, which must be synthesised, is not added 
unnecessarily. Figure 5.10 shows the SDS-PAGE analysis of the small scale expression 
tests of both the S4pK and S118pK single mutants.  
 
 
 
 
 
 
 
Figure 5.10: SDS-PAGE Analysis of Small Scale Test Expressions OF the single pK mutants (A) 
S4pK and (B) S118pK. For each mutant two different clones were tested for myoglobin expression. All 
clones were tested with and without the UAA pK in the growth media, as well as a sample taken before 
induction. 
   In both Figures 5.10A and B, before induction with L-arabinose (final concentration 
0.2%) there is no indication of protein expression in cultures containing pK. In those 
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clones which were grown in the absence of pK, there is no protein expression post-
induction. When looking at the clones expressed in the presence of pK, for both single 
mutants, as highlighted by the circled bands, there is a definite over-expression of 
protein, which appears at the expected MW of myoglobin. At this stage, both mutants 
must be expressed on a larger scale, and the over-expressed protein further 
characterised, to determine whether it is myoglobin containing the UAA, pK. 
5.5.3 Large Scale Expression and Purification of Myoglobin Single pK Mutants  
   Small scale expression of both single pK myoglobin mutants suggest that pK is being 
incorporated in response to the amber stop codon and so expression must be scaled up, 
so the proteins can be purified and further characterised. Figure 5.11 shows the SDS-
PAGE analysis from large scale expression (1 litre) of each of the single pK mutants, as 
well as Western Blotting Analysis, of samples probed with an antibody that specifically 
detects a C’ terminal histidine tag. 
 
 
 
 
 
 
Figure 5.11: SDS-PAGE analysis from large scale expression of the single mutants. (A) S4pK and 
(B) S118pK, and corresponding (C) western blotting analysis, of samples probes with an antibody 
specific for the detection of a C’ terminal hexa-histidine tag. 
   From the SDS-PAGE analysis of the S4pK mutant (A), the circled area represents 
elution fractions containing protein corresponding to the MW of myoglobin. Similarly 
in the SDS-PAGE analysis of the S118pK mutant, the elution fractions thought to 
contain myoglobin are circled. Following western blotting analysis of both mutants with 
an antibody conjugated to HRP, and specific for the detection of C’ terminal histidine 
tags, the bands circled in (C) indicate that a C’ terminal histidine tag has been detected. 
The bands on the western blot suggest that the E. coli cells have read through the stop 
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codon for both mutants, as the histidine tag follows the myoglobin gene. However, 
looking at the SDS-PAGE analysis from the S118pK mutant, there is indication of a 
lower molecular weight band. It can be assumed that the circled bands appearing at 
~18kDa in (A) and (B) are pK containing myoglobin. The lower molecular weight band 
in (B) was excised from the SDS-PAGE gel, and sent for tryptic digest mass 
spectrometry (MS). MS confirmed that the circled lower molecular weight band in (B) 
had 52% identity to myoglobin, with no peptides identified beyond pK. This suggests at 
the 118 position, there is early termination of protein synthesis due to latent reading of 
the amber stop codon.  
5.5.4 Expression of the double mutant S4pKS118pK 
   Small scale expression tests were carried out for several clones of the myoglobin 
containing pK at both positions 4 and 118, however, following SDS-PAGE analysis 
there appeared to be no expression of the recombinant protein. This is not particularly 
surprising due to the reduced yields of single mutants when compared to wt, coupled 
with the drop off in expression that results from an increase in stop codons. 
    Following successful transformation of the template DNA, as well as the plasmids 
encoding the pyrrolysyl tRNA synthetase /tRNACUA(Pyl) pair, 2L of LB was 
supplemented with a final concentration of 3mM pK.  The double mutant was purified 
using IMAC, utilising the histidine tag at the C’ terminal of the myoglobin gene in the 
first catchment step, and fractions analysed by SDS-PAGE. Figure 5.12 shows the SDS-
PAGE analysis for the double pK mutant. For the cysteine mutants, at this point SEC 
would be performed to further purify the myoglobin, however, due to the small sample 
volumes, this was avoided. From the SDS-PAGE analysis, purity was estimated to be 
approximately ~60%, and final yields calculated based on absorbance of the soret band 
(409nm), rather than at 280nm.  
   For large-scale expression of the double mutant, the sodium salt of pK was used, 
rather than the TFA salt to aid solubility of the UAA in water. (Synthesised by Dr. 
Bouchra Hajjaj, University of St Andrews, Scotland, UK). From the SDS-PAGE 
analysis, the fractions in the circled region were pooled, ready for spin labelling via 
‘click’ chemistry of the azide spin label to the pK containing myoglobin. 
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Figure 5.12: SDS-PAGE analysis from large scale expression of double pK mutant S4pKS118pK. 
                 Table 5.1   Protein Yields for Myoglobin Mutants Per Litre of Cell Culture 
 
 
 
 
 
5.6 Coupling of a Peptide Containing pK to an Azide Spin Label Using 
‘Click’ Chemistry 
The reported work described in 5.1.3 and 5.1.4 was undertaken by a PDRA in our lab, 
Dr Bouchra Hajjaj. 
   Before the pK containing protein was conjugated to an azide spin label using ‘click’ 
chemistry, the reaction was tested with a small peptide containing pK, flanked either 
side by alanine residues.  
   The synthesized pK peptide, 1 (see Figure 5.13) (6.3mg, 5mM final concentration) 
and the spin label 21 (3.0mg, 5mM final concentration) were solubilized in freshly 
degassed water (3.1mL).  A r.t CW EPR spectrum and HPLC analysis were taken of this 
solution to ensure the radical was stable before the addition of the ascorbic acid, which 
can reduce the nitroxide. The reaction mechanism is shown in Figure 5.13. 
                                                          
1
 Azide spin label was synthesized by Marius Haugland  - University of Oxford 
Myoglobin Mutant Yield/Litre of Culture) 
wt 18mg 
S4C118 9mg 
C4S118 12mg 
C4C118 8mg 
S4pK 1.6mg 
S118pK 0.871mg 
pK4pK118 1.2 & 1.8mg 
Elution fractions 1-14 (1.5mL) 
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   A 10mM solution of Copper (II) sulphate, TBTA in 55% (v) DMSO (61.4µM; 0.2mM) 
was then added followed by ascorbic acid (0.1mg; final concentration 0.2mM). The 
reaction mixture was stirred at r.t under Argon, before an HPLC of the crude mixture 
performed, after 30min and 1h30min. The HPLC traces are shown in Figure 5.14.  
   HPLC analyses show that the coupling reaction is complete after 30min at r.t. A r.t 
CW EPR was recorded for the uncoupled reagents and the coupled product after 2h 
reaction time at r.t, and formation of the desired product, 3. 
 
 
 
 
 
Figure 5.13: Reaction Mechanism for the copper catalyzed azide-alkyne cycloaddition of the pK 
containing peptide to spin label.  
 
 
 
 
 
 
 
 
 
 
Figure 5.14: HPLC (Shimadzu) of the reaction mixture at t=0, 30, 90min using Phenomenex C18 
column 150*4.60mM. (A) the pK peptide and azide spin label before coupling (B) after coupling 
(30min) and (C) after coupling (1h30min). A shift in retention time was recorded from 30min for the 
uncoupled reagents to 20 min for the coupled product.  
+ 
Cu, TBTA,                                
Ascorbic acid 
  1                                             2                                       3 
t=1h30 
t=0 min 
t=30 min 
A 
 
 
 
 
B 
 
 
 
 
C 
Uncoupled reagents 
Coupled product 
Chapter 5: Development of New Methods for SDSL  
 
194 
 
5.7 Coupling of pK containing myoglobin to an azide spin label 
5.7.1 From Peptide to Protein - Optimisation of Coupling 
   Although coupling of the peptide to the azide spin label proves successful, the 
conditions must be optimised, as the coupling reaction must be performed in aqueous 
buffers, in conditions which would not result in denaturation of the protein. The initial 
coupling reaction was performed using 5mM peptide and 5mM label, as highlighted in 
Test 1 (Table 5.2).  
   Obtaining final yields in the milli-molar range for recombinant proteins expressed 
with unnatural amino acids is unheard of and so the coupling reaction must be adjusted 
accordingly. Shown in Table 5.2 are a variety of coupling conditions tested for the 
coupling of the peptide to the azide spin label, which subsequently could be transferred 
to coupling of the protein, which will likely be in the micro-molar concentration range. 
 
Table 5.2 Test Coupling Conditions of the Peptide to the Spin Label 
 
Of all of the conditions tested, it was found that only test 5, using a final concentration 
of 34µM peptide, 5mM label, 0.2mM CuTBTA and 0.2mM ascorbic acid resulted in a 
successful coupling reaction, whilst maintaining the nitroxide radical. 
These conditions were then used for the coupling of the proteins to the azide spin label. 
 
Test Peptide Label Cu TBTA Ascorbic acid Water 50mM 
Hepes, 
125NaCl, 
pH7.0 
time 
1 5mM 5mM 0.2mM 0.2mM - Yes 1h 
2 34µM 34µM 1.4µM 1.4µM Yes Yes 1h & 
overnight 
3 34µM 34µM 0.2mM 0.2mM Yes Yes 1h 
4 34µM 68µM 11µM 11µM Yes Yes 1h & 
overnight 
5 34µM 5mM 0.2mM 0.2mM yes Yes 1h 
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5.7.2 Spin Labelling of S4pK Using Copper Catalysed ‘Click’ chemistry 
 The buffer used throughout the purification process of the myoglobin pK mutants was 
50mM Hepes, 125mM NaCl, pH7.0 (see appendix A9), and so the conditions which 
were optimized for the peptide, at a final concentration of 34µM, were transferred onto 
the S4pK myoglobin at the same concentration. Shown in Figure 5.15 is the r.t CW EPR 
spectrum taken, of the single pK mutant S4pK. 
 
 
 
 
 
 
 
 
Figure 5.15: X-band CW EPR of the S4pK myoglobin Mutant. Spectrum taken under non-saturating 
conditions.  
The CW spectrum was taken in an aqueous buffer/ glycerol mixture which should 
increase correlation time, giving a broader EPR spectrum, however, when looking at the 
EPR line-shape it is very narrow, and indicative of a mobile, but not free, spin label.  
   Although the label is mobile, the CW EPR spectrum indicates that the pK containing 
myoglobin is spin labelled. The UV-Vis absorption spectrum was recorded for the pK 
myoglobin following the labelling reaction, confirming the protein to be oxy-
myoglobin. The double pK myoglobin mutant was then spin labelled in the same 
manner as the single mutant. 
 
5.7.3 Spin Labelling of S4pKS118pK Using Copper Catalysed ‘Click’ chemistry 
   The purified S4pKS118pK was labelled under the same conditions as for the singly 
labelled pK myoglobin. There was no need to adjust the concentrations of label or the 
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other reagents, as these were already present in excess, when compared to protein 
concentration. Figure 5.16 shows the r.t CW EPR spectrum of the doubly labelled pK 
mutant. 
 
 
 
 
 
 
 
Figure 5.16: X-band CW EPR of the S4pKS118pK myoglobin Mutant. Spectrum taken under non-
saturating conditions.  
   Although CW EPR will give some information as to whether or not the protein is 
labelled, mass spectrometry was used to confirm if one or both of the pK amino acids 
were labelled, before the DEER experiments could be performed. 
5.8 Confirmation of Spin Labelling of the S4pKS118pK mutant using 
Mass Spectrometry 
   A sample of the double pK myoglobin mutant was taken before labelling and after, 
and mass spectrometry (LCT LC-MS) carried out to estimate the accurate mass of both 
the labelled and unlabelled samples. Figure 5.17 shows the LCT LC-MS analyses of 
both samples, processed over a narrow mass range to 0.1 Da (Performed at the 
University of St Andrews). For the unlabelled the expected mass is 18601Da, measured 
18602.4Da and for the labelled the expected mass is 18991, measured 18992.5Da. This 
high degree of correlation seemed to confirm successful incorporation of two pK UAAs 
and their labelling. 
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Figure 5.17:  LCT LC Mass Spectrometry analysis of the double pK myoglobin mutant 
S4pKS118pK. (A) analysis of the unlabeled sampled and (B), analysis of the doubly spin labelled 
sample. 
5.9 DEER Experiments 
  DEER was performed at Q-band for both the doubly labelled cysteine myoglobin 
mutant and the doubly labelled pK mutant. The results of the DEER and the MMM 
modelling for the MTS label are shown in Figure 5.18 which also shows the final SDS-
PAGE analysis of the double pK labelled mutant. 
   Looking at the distance distributions obtained for the S4CS118C mutant (MTSSL 
labelled), these overlap well with the distributions simulated using MMM. However, the 
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S4pKS118pK result is much broader and shows a shorter distance. This is not entirely 
unexpected given the much longer amino acid side chain the label is attached to and the 
much larger degree of flexibility the label has at room temperature according to the CW 
EPR. This conformational freedom is likely to have been frozen in and results in a 
distribution of distances. More of a concern is the smaller modulation depth of the 
DEER time trace which brings the labelling efficiency of the click reaction into question 
since modulation depth is related to the number of pairs of interacting labels. 
A                     B                                            C 
 
 
 
  
 
Figure 5.18: Comparisons of the Background Corrected EPR Time-Traces and Distance 
Distributions, of the S4CS118C and S4pKS118pK doubly spin-labelled mutants, shown alongside 
MMM simulation. (A) sample of the doubly labelled S4pKS118pK mutant analysed by SDS-PAGE 
following coupling to the azide spin label. (B) DEER time traces for the doubly labelled cysteine and pK 
mutants, overlaid with the MMM simulation. (C) DEER distance distributions for the doubly labelled 
cysteine and pK mutants, overlaid with the MMM simulation. 
   Although Mass Spectrometry analyses of both the labelled and unlabelled samples 
suggest thorough labelling of the sample, it is implied that although the labels 
themselves have been successfully conjugated to the pK UAAs within the myoglobin, it 
is possible that the nitroxide itself is not intact. It may have been reduced to the 
hydroxylamine during the click reaction and this would only make a difference of 2Da. 
We compared the CW EPR spectrum to standards and estimate that only 60% of the 
radical is intact.  
   At this stage, further large scale expression was carried out for the double pK mutant, 
and the experiment repeated, only a desalting column was used for the removal of 
excess ascorbic acid/copper with the hope that this more efficient removal would reduce 
the chances of reduction. Expression this time of the double pK mutant was high, 
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resulting in a final yield of ~1.8mg from 1L of culture. (Yield comparable to that 
suggested by Nguyen et al, 2009 for a single UAA mutant). 
   The click reaction was then performed on the new S4pKS118pK sample, however 
CW EPR and MS suggest this was unsuccessful, and so was repeated. MS again 
indicates that this has not been successful, whilst the CW EPR implies otherwise, and so 
the sample was prepared for DEER, as there was not enough sample to repeat the click 
reaction. 
   The final concentration of the sample was determined to be ~100µM, in 50mM 
Hepes, 125mM NaCl pH7, in 50% deuterated glycerol. Following the DEER 
experiment, unlike the original sample, there was no signal observed. This contradicts 
that observed from the CW EPR, and so it is possible that the label is unspecifically 
binding to the protein, and is not conjugated via the ‘click’ mechanism.  
 
5.10 Outlook and Future Work 
   Contrary to what is stated in the literature (Loscha et al, 2012) (Johnson et al, 2011), 
we have successfully managed to incorporate two UAAs, namely the UAA, pK, into 
recombinant sperm whale myoglobin in response to the amber stop codon, giving final 
yields in the hundred micro-molar range, without the need for modified cell lines. 
   A doubly spin-labelled mutant has given EPR distance distributions comparable not 
only to a doubly spin-labelled cysteine mutant, but also to simulated distance 
distributions obtained from the published X-Ray Crystal structure. This demonstrates 
the potential for SDSL using genetic code expansion as an alternative to cysteine 
substitution mutagenesis for the purpose of DEER spectroscopy.  
   Improving final yields, incorporation efficiencies, conformational freedom of 
incorporated spin labels and the labels themselves would prove advantageous in 
improving data quality. The incorporation of the UAA, pK, into recombinant sperm 
whale myoglobin has proven to be a favourable model system, and proof of principle, 
that EPR can be performed between two spin-labelled UAAs. With slight adjustments to 
the protocols described above, the system can be optimized, to facilitate transfer from a 
model system, to a protein system where EPR would be used for structural 
characterization. 
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   Assignment of the amber stop codon to the UAA, pK, is ambiguous, as it 
simultaneously codes for the incorporation of the UAA, as well as the termination of 
protein synthesis. This is due to a direct competition between the exogenous tRNACUA 
and the endogenous release factors.  
   Eukaryotic cells typically express two release factors, RF1 and RF2, with the RF1 
terminating protein synthesis in response to the codons UAA and UAG, and RF2 
terminating at UAA and UGA. Johnson et al, 2011have developed the E. coli cell-line, 
JX33, with the gene encoding RF1 knocked out, which allows for more efficient 
incorporation of UAAs at multiple sites, with up to ten unnatural amino acids 
incorporated into a single recombinant protein, with little effect on protein yield. By 
limiting termination of the stop codon UAA to RF2 only, RF1 is completely reassigned 
to the amber stop codon.  
   It is proposed that sperm whale myoglobin could be expressed using this modified cell 
line or similar, to optimise expression and incorporation efficiency. It should be noted 
however, that switching to the specialized cell line has no guarantee of increased yields, 
as the efficiency of UAG as a sense codon depends on multiple factors.  
   The orthogonal synthetases and tRNAs, although effective, have been artificially 
mutated for the incorporation of UAAs, unlike endogenous sets that have been 
evolutionarily tuned for optimal decoding. Furthermore, local protein structure, as well 
as mRNA context can possibly affect incorporation efficiency, despite expression using 
the modified cell line (Loscha et al, 2012). Mottagui-Tabar & Isaksson (1997) found 
that the presence of a lysine residue, three positions N’ terminal to the stop codon, 
resulted in increased read-through. With this is mind, positons for UAA incorporation 
could be changed to reflect this observation, as well as adopting the modified JX33 cell-
line, or equivalent. In doing so expression and incorporation of a given UAA can be 
further optimised. 
   The UAA being incorporated is another variable which should be considered. As 
stated prior, the incorporation of aliphatic amino acids is something which should be 
further explored. The modified lysine residue in this study is efficiently incorporated, 
however, from CW EPR spectra taken at r.t for the singly spin labelled pK4 mutant, 
there is a high degree of flexibility introduced by the extended lysine residue. With this 
in mind, one could take inspiration from the bis-legged Rx spin label (Fleissner et al, 
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2011), in synthesising a bis-legged spin label, with azide and MTS functional groups, 
for spin labelling of pK, anchored by labelling of the MTS functional group to a nearby 
cysteine residue. This could potentially produce a more rigid spin label, with less 
flexibility and conformational freedom than that demonstrated for the spin-labelled 
S4pK mutant.  
   By considering different spin labels, with various functional groups, as well as the 
structure of the amino acid being incorporated, and the cell line being used for 
expression, a ‘Tool-Box’ approach can be developed for the incorporation of different 
spin labels and UAAs into recombinant proteins. 
   Optimisation of current coupling conditions, as well as testing new labels and UAAs 
in the myoglobin model system will facilitate a smoother transition from the test system 
to systems which we would like to study, but would prove difficult by EPR. 
   As stated above, there are many cysteine rich proteins which can be recombinantly 
expressed using E. coli expression systems, and so perhaps application of such methods 
to the study of these proteins, using modified cell lines, could open up a new avenue for 
the study of cysteine rich proteins, using EPR spectroscopy. 
   Furthermore, such methods using orthogonal pyrrolysyl tRNA synthetase 
/tRNACUA(Pyl) pairs are transferable to more complex expression systems, such as Pichia 
pastoris. As described in Chapter 3, when looking at the interactions of complement 
proteins fH and C3b, expression of the recombinant fH fragments proved challenging.           
   The presence of intermolecular disulphide bonds, making the proteins cysteine rich, 
significantly increased protein aggregation, and complicated the purification procedures.    
Keeping the protein in its reduced form for labelling purposes whilst ensuring the 
integrity of the disulphide bonds, and consequently protein fold, proved particularly 
challenging. Consequently, there is the potential for the incorporation of UAAs, into 
recombinant fH, using the Pichia pastoris system, which is well known for yielding 
large amounts of recombinant proteins from fermentation (often in gram quantities) 
(Macauley-Patrick et al, 2005). 
  By considering all variables mentioned above, the concept of SDSL opens up many 
avenues for exploring long range structure in biological systems which were otherwise 
out with the limits of the technique. Not only is this an exciting prospect for the EPR 
field, but for structural biology as a whole.  
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5.11 A New Generation of Spin Label 
  We are currently developing new strategies using several model protein systems for 
the incorporation of novel nitroxide spin labels for the SDSL of cysteine rich proteins. 
The new labels are specific for addition to only vicinal cysteine pairs, allowing specific 
labelling in the presence of single cysteine residues. This work is inspired by Huang et 
al, 2011 and their work on fluorescence labelling with As
III
 binding and  Smith et al, 
2010 and their work on bromo-malemides and disulphide bridging.  
   Figure 5.19 shows the chemical structure of three spin labels (synthesised by Dr. 
Bouchra Hajjaj, University of St Andrews), BMSL, POMSL and SLAsH, designed for 
the specific labelling of cysteine pairs, in the presence of single cysteines. 
   
 
 
 
Figure 5.19: Chemical Structures of novel nitroxide spin labels (A) BMSL, (B) POMSL, and (C) 
SLAsH. (visualised using ChemDraw
TM
). 
 
5.11.1 Expression and Purification of the 14-3-3 ϛ  and Vps75 Proteins 
The recombinant proteins Vps75 and 14-3-3ϛ have been expressed with vicinal cysteine 
residues as test systems. 
   14-3-3ϛ  is a dimer with each monomer containing a pair of i, i+1 (Q150C E151C) 
vicinal cysteine residues joined in a disulfide bond, whilst the Vps75 construct has 
vicinal cysteine residues incorporated at i, i+3 (L16C A19C) and i, i+4 (L16C K20C).  
   Figure 5.20 shows the XRC structure of 14-3-3ϛ, with the cysteine residues shown as 
spheres, alongside the XRC structure of Vps75 (i to i+3). 
           A                                                   B                                   C 
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Figure 5.20: XRC Structures of the (A) 14-3-3ϛ  (PDB_ID 2BTP  (Yang et al, 2006)) and (B) Vps75 
(PDB_ID 2ZD7 (Park et al, 2008)). Mutants, with vicinal cysteines shown as spheres.   
Figure 5.21 and 5.22 show the elution profiles and SDS-PAGE analysis of the model 
proteins following purification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.21: Elution profile (A) and SDS-PAGE (B) analysis of 14-3-3ϛ following the final 
purification step (SEC). 
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Figure 5.22: Elution profile (A) and SDS-PAGE (B) analysis of Vps75 following the final 
purification step (SEC). 
 
5.11.2 Spin Labelling of 14-3-3ϛ  
The 14-3-3ϛ Q150C E151C mutant was labelled with MTSSL, SLAsH and BMSL 
labels. Figure 5.23 shows the CW EPR spectra obtained. The SLAsH labelling was very 
poor and addition of it to the protein caused precipitation. Other methods for adding it 
will be investigated in the future or methods for making it more water soluble. Tests 
using varying levels of spin label together with Ellman’s and mass spectrometry 
indicated that the BMSL cannot bridge these cysteines. Preliminary tests with the Vps75 
(L16C A19C mutant) indicate that BMSL or POMSL can bridge the cysteines. Ongoing 
work will be to find conditions where the maleimide attached to one cysteine is 
selectively removed in the presence of the succinimide bridged pair of cysteines.  
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Figure 5.23: CW EPR of labelled 14-3-3 ϛ with (A) MTSSL, (B) SLAsH and (C) BMSL. Spectra 
taken at rt under non-saturating conditions. 
 
5.12   Obtaining Nanometre Scale Distances Between the Ferric Heme 
of Sperm Whale Myoglobin and Nitroxide Spin Labels Using DEER 
 
   Many proteins contain naturally occurring paramagnetic metal centres or intrinsic 
organic radicals, however, in spite of this, the number of systems with intrinsic 
paramagnetism studied using DEER is limited. By taking advantage of these intrinsic 
EPR active sites, there is potential to study proteins and complexes thereof, which 
otherwise cannot be studied using traditional methods of EPR spectroscopy, such as in 
the study of cysteine rich proteins. However, the sensitivity of pulsed EPR 
measurements on broad-line metal centres is often restricted by the available excitation 
bandwidth, and to metal centres which exhibit moderate g-anisotropy and fast 
relaxation, e.g. CuII (Narr et al, 2002, Yang et al, 2007). 
   For this reason, the field is so far restricted to the use of nitroxide spin labels, as these 
typically have only a small effect on the spectral line shape in DEER (Amsterdam et al, 
2003). Many proteins contain ferric heme groups, in which the FeIII is paramagnetic, 
however, mainly due to large g-anisotropy and the fast electronic relaxation associated 
with low spin heme centres (even at low temperatures), obtaining high quality 
measurements, comparable to published crystal structures is difficult. There are two 
examples in the literature of measurements between a low spin ferric heme and a 
nitroxide. Schiemann (Abdullin et al, 2014) showed a very nice measurement using the 
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DEER experiment and another pulsed EPR set-up called RIDME (which takes 
advantage of the very different relaxation times of the centres). However, the P450 
system is not as broad and is easier to manipulate into low spin than typical heme 
centres. Van Doorslaer (Ezhevskaya et al, 2013) measured a neuroglobin heme to 
nitroxide distance at X and Q-bands but the broadband and fast relaxing nature of the 
iron meant that the results had a poor signal to noise and an upper limit of 3nm 
distances seemed to be imposed. 
 
5.12.1 Aims of this work 
 
   High field EPR is becoming an increasingly useful tool for the exploration of spin-
labelled proteins, due to lifting of the degeneracy of the g-tensor at higher fields. The 
use of DEER at W band in the study of nitroxide-nitroxide distance measurements 
provides concentration sensitivity gains in the range of 20-30 times on commercial X-
band spectrometers, however, similar gains may not be achieved with ferric heme 
proteins, as the large g anisotropy in such systems will lead to a significant broadening 
of the linewidth, meaning few spins may be detected. By applying a set of non-standard 
pulses during the DEER experiment at W band, such imperfections can be compensated 
for, provide broadband excitation whilst compensating for substantial applied field 
inhomogeneities.  
   This work looks at incorporating cysteine residues into recombinant sperm whale 
myoglobin, generating the single mutants S4C, S118C, and the double mutant 
S4CS118C. In each case, the intrinsic ferric heme (FeIII) will be coordinated to 
imidazole, to induce low spin state, S=½, in the iron. Using broadband composite pulses 
applied to the single cysteine mutants, it should be possible to extract long range 
distance measurements between the ferric heme and the nitroxide spin label. With the 
double mutant, the nitroxide-nitroxide interaction can be independently determined 
from the nitroxide-heme interaction by appropriate spectral selection, highlighting the 
possibility for triangulation for studies involving protein-protein docking. 
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5.13 Expression and Purification of Low Spin (s= ½) Myoglobin 
Mutants 
   In order to yield low spin iron, the buffers used throughout were slightly different to 
those used in Appendix A9. Unless stated below, the purification was performed in the 
same manner, with washes and elution performed in the same volumes stated in 2.5.3. 
   Immediately following cell lysis, DTT was added to the non-cell extract at a final 
concentration of 50mM, before this was diluted to allow passage over the IMAC 
column. The protein was eluted from the column in 50mM Hepes, 125mM NaCl and 
0.5M imidazole, pH 7.0. This was treated with 10mM DTT and further purified using 
SEC with a HiLoad 16/600 Superdex S-75 column (GEHealthcare) into 50mM Hepes, 
125mM NaCl, pH 7.0. An SDS-PAGE gel with coomassie staining was used to confirm 
the purity of the monomeric species. A greater than 5 times excess of MTS spin label 
(Toronto Research Chemicals) was then added and the protein left at room temperature 
for 1 h. The protein was transferred into 50mM HEPES, 125mM NaCl, 200mM 
imidazole, pH 7.0 buffer in deuterium oxide, before 50% deuterated glycerol was added. 
   The presence of DTT throughout the purification process ensures that the myoglobin 
is maintained in its oxy-form. In a non-living system, oxymyoglobin (Fe
II
) is slowly 
converted to metmyoglobin (Fe
III
), and so the presence of a strong reducing agent 
prevents the formation of a mixed species. Full conversion of oxymyoglobin to 
metmyoglobin was monitored by the UV absorption spectra, by monitoring the position 
of the soret band and peaks in the 500-650 nm region, whilst the imidazole ligand 
coordinates to the heme, inducing a low spin state of the iron (S= ½) (Gurd et al, 1967). 
 
5.14 DEER Experiments 
   HiPER is a high power home-built W-band spectrometer which is capable of reducing 
nitroxide-nitroxide DEER measurement times from 24h to as little as 20min 
(Cruickshank et al, 2009). The use of composite pulses, or wideband optimal control 
sequences, is particularly attractive when applied to high field EPR, as sensitivity is 
often constrained by a limited excitation bandwidth and B1 inhomogeneity. A composite 
pulse emulates the effect of traditional pulses, but includes an inbuilt compensatory 
mechanism rendering it less sensitive to common experimental imperfections (Levitt, 
2011).  
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   All measurements were carried out by Miss. Claire Motion, University of St Andrews, 
using the home-built HIPER 94 GHz (W band) high power pulsed electron spin 
resonance spectrometer. The samples were tested using the standard 4 pulse DEER 
experiment and with broadband composite pulses used when measuring between the 
ferric heme and a nitroxide spin label, and standard pulses for the doubly labelled 
cysteine mutant. 
5.14.1 Nitroxide-Nitroxide DEER Measurements (S4CS118C) at W-Band 
   The ability to extract distances from a system that shows both nitroxide-nitroxide 
interactions as well as nitroxide-heme interactions shows the potential for triangulation 
and protein docking using EPR spectroscopy. Figure 5.24 shows the DEER time traces 
and distance distributions obtained using 4-pulse DEER for the double cysteine mutant 
at 50K. These are shown alongside time traces and distributions simulated using MMM. 
They show good agreement. 
 
 
 
 
 
 
 
 
 
 
Figure 5.24: DEER time traces and associated distance distributions for the S4CS118C doubly 
labelled Met-myoglobin mutant, shown alongside MMM simulation. (A) Structure of sperm whale 
myoglobin (PDB_ID: 1mBN), with cysteine residues represented as blue spheres. (B) MMM modelled 
DEER time trace and (C) Distance distributions for the S4CS118C mutant; (D) Background corrected 
DEER time trace (following DeerAnalysis) for the S4CS118C mutant measured on HiPER and (E) 
Distance distributions from DeerAnalysis for the S4CS118C mutant.  
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5.14.2 Nitroxide-Heme (Fe
III
) DEER Measurements at W-Band 
   The DEER between the single cysteine mutant spin labels and the ferric heme was 
taken using composite pulses to compensate for the increased inhomogeneity introduced 
by the metal centre at high frequency.  
  For these experiments it is highly advantageous to probe on the FeIII, and pump on the 
nitroxide. In doing so, Fe III- nitroxide DEER measurements are experimentally viable, 
despite the spectral width of the FeIII signal being 10x greater at W-band than at X-band, 
and 200x greater than the nitroxide spectral width at W band (Cruickshank et al, 2009). 
Figure 5.25 and 5.26 shows DEER time traces and distance distributions obtaining 
using composite pulse DEER (based on the 4-pulse sequence) for the S4C and S118C 
nitroxides, to the ferric heme, respectively. Measurements were taken at 6K. These are 
shown alongside time traces and distributions simulated using MMM 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.25: DEER time traces and associated distance distributions for the S4C singly labelled 
Met-myoglobin mutant to the ferric heme, shown alongside MMM simulation. (A) Structure of 
sperm whale myoglobin (PDB_ID: 1mBN), with cysteine residue represented as blue spheres. (B) DEER 
time trace and (C) Distance distributions for the S4C mutant, simulated using MMM. (D) Background 
corrected DEER time trace (following DeerAnalysis) for the S4C mutant. (E) Distance distributions from 
DeerAnalysis for the S4C mutant.  
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Figure 5.26: DEER time traces and associated distance distributions for the S118C singly labelled 
Met-myoglobin mutant to the ferric heme, shown alongside MMM simulation. (A) Structure of 
sperm whale myoglobin (PDB_ID: 1mBN), with cysteine residue represented as blue spheres. (B) DEER 
time trace and (C) Distance distributions for the S4C mutant, simulated using MMM. (D)Background 
corrected DEER time trace (following DeerAnalysis) for the S4C mutant. (E) Distance distributions from 
DeerAnalysis for the S4C mutant.  
   Looking at the experimental data for each of the singly labelled single cysteine 
mutants measured to the ferric heme centre of the met-myoglobin, and comparing this 
to simulation, the distance distributions obtained are in good agreement. The results 
reported here are very exciting since they open up the possibility of measuring many 
otherwise unmeasurable systems. Measurements are underway for the S4C S118C 
doubly labelled mutant with ferric heme to investigate whether triangulation can be 
directly applied in this system. Preliminary results are promising. 
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5.15 Beyond MTSSL - Outlook and Future Work 
  The diversity of protein function is made possible because almost half of all enzymes 
require the incorporation of cofactors, such as metal atoms, to function (Finkelstein, 
2009), whilst metal binding sites on proteins are responsible for catalyzing some of the 
most physiologically relevant reactions (Yeung et al, 2009).  This development opens up 
the potential to study a full range of metalloproteins, or proteins with native accessible 
paramagnetic centres, that otherwise would be out with the remit of DEER.  
   The MTSSL spin label is effective for the study of many biologically relevant systems 
using EPR spectroscopy however, it is not without limitation. EPR is a highly specific 
technique which can be used to explore long range structure in systems which cannot be 
explored by other high resolution structural techniques. However, the main caveat of 
EPR is that it works best in its simple form, when looking at the interactions of two 
radicals.  
   This is simple enough when specifically introducing cysteine residues into proteins 
which do not have any or have few native cysteine residues. The problem of specificity 
arises when studying proteins which have many free cysteine residues, which, in order 
to maintain structural integrity, cannot be exchanged. In such instances, the 
development of new methods of spin-labelling and new labels themselves can only 
progress the field of SDSL, and open avenues of structural exploration that otherwise 
would not be possible. 
   The inspiration behind investigating new labelling strategies was the protein Nitric 
Oxide Synthase (NOS) (Structure and Mechanisms reviewed by (Daff, 2010). NOS is 
found in the human body in several different isoforms and is a major signalling 
molecule, and is consequently tightly regulated. It exists as a 160kDa homodimer which 
binds Calmodulin to exert its function. Until 2014 the structure of the homodimer was 
not known (Campbell et al, 2014) and while many aspects of the system were suitable 
for investigation by EPR distance measurements the presence of 30 free cysteine 
residues made site-directed spin labelling impossible.  
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   Consequently it was proposed that NOS structure was explored by utilising its binding 
partner calmodulin (CaM) for SDSL. Figure 5.27 is a schematic representation of the 
NOS domains, with calcium bound. 
 
 
 
 
 
 
 
 
Figure 5.27: Schematic representation of the NOS homodimer with NOS CaM bound. 
By spin-labelling the calmodulin, one could use EPR to extract a range of distances 
between mutants on each monomer, which could give further insight into the entire 
heterodimer. This, however, does little to shed insight into structural changes that occur 
as a result of activity. Ideally one would like to explore NOS structure when CaM is 
bound, however, the cysteine residues prove problematic. 
   NOS contains within its domains up to four paramagnetic centres, a FMN, FAD, heme 
and proteins (Rakowsky et al, 1998). Measuring distances from these to spin labels 
would be valuable for determining structure. Following the work done in 5.3, it was 
possible to measure accurately distances between spin labelled cysteine residues and the 
ferric heme of sperm whale myoglobin, using high field EPR, and composite pulses. 
Consequently, the same methodologies could be employed, to measure distances 
between the native paramagnetic centres of NOS (heme and flavin radicals), and local 
affects in NOS structure by the addition of CaM. 
Appendices  
 
213 
 
Appendices 
Appendix A: Stock Solutions, Buffers, and Media Compositions 
A1: Stock Solutions 
10x YNB: 34g YNB, 100g (NH4)2SO4, adjusted to 1000mL with ddH2O, filter sterilised 
500x B: 20mg biotin adjusted to 100mL with ddH2O, filter sterilised 
10x M: 5mL MeOH, 95mL ddH2O, filter sterilised 
10x GY: 100mL glycerol, 900mL ddH2O, autoclave for 20min 
10x D: 200g D-glucose, adjusted to 1000mL with ddH2O, autoclave 20min 
0.5m EDTA: 76.06g EDTA, pH8.2, adjusted to 500mL with ddH2O 
1M K2HPO4: 87.09g K2HPO4, adjusted to 500mL with ddH2O 
1M KH2PO4: 136.09g KH2PO4, adjusted to 500mL with ddH2O 
1M Potassium Phospahte Buffer: 132mL of 1MK2HPO4, 868mL of KH2PO4, pH6.0 
4M NaCl: 233.76g NaCl, adjusted to 1000mL with ddH2O 
1M DTT: 0.154g DTT, adjusted to 1000µL with ddH2O 
1M TCEP: 0.286g TCEP, adjusted to 1000µL with ddH20  
Coomassie Stain: 1.00g Coomassie R250, 100mL glacial acetic acid, 400mL MeOH, 
adjusted to 1000mL with ddH2O 
Coomassie Destain Solution: 200mL MeOH, 100mL glacial acetic acid, adjusted to 
1000mL with ddH2O 
 
A2: Buffers 
10x PBS: 80g NaCl, 2.0g KCl, 14.4g Na2HPO4, 2.4g KH2PO4, adjusted to 1000mL 
with ddH2O (pH7.4) 
10X TBE: 108g Trizma® base, 55g boric acid, 7.5g EDTA, disodium salt, adjust to 
1000ml with ddH2O 
 
 
Appendices  
 
214 
 
A3: fH1-4 Preparations 
The gene for full length fH was purchased from GeneArt, and fH fragments cloned into 
the pPICZαB vector (both provided by Prof Paul N. Barlow, University of Edinburgh, 
Scotland, UK). 
IMAC – Ni-NTA Superflow Cartridge 5mL 
Equilibration Buffer: 20mM Potassium Phosphate, 0.5M NaCl, pH7.0                            
Wash Buffer: 20mM Potassium Phosphate, 0.5M NaCl, 20mM Imidazole, pH7.0  
Elution Buffer: 20mM Potassium Phosphate, 0.5M NaCl, 500mM Imidazole, pH7.0 
Anion Exchange Chromatography – TricornTM Mono Q 4.6/100 PE 
Equilibration Buffer: 20mM Sodium Carbonate, 1mM EDTA, pH9.0                         
Elution Buffer: 20mM Sodium Carbonate, 1mM EDTA, 1M NaCl, pH9.0 
SEC: HiLoad
TM
 16/600 Superdex
TM
 S-75  
Equilibration/Elution Buffer: 1X PBS, pH7.4 
 
A4: fH19-20 Preparations 
The gene for full length fH was purchased from GeneArt, and fH fragments cloned into 
the pPICZαB vector (both provided by Prof Paul N. Barlow, University of Edinburgh, 
Scotland, UK). 
Cation Exchange Chromatography - SP-Sepharose FastFlow
TM
 Resin 
Equilibration/Wash Buffer: 20mM Potassium Phosphate, pH6.6 
Elution Buffer: 20mM Potassium Phosphate, 1M NaCl, pH6.6 
Cation Exchange Chromatography – Resource 15STM 
Equilibration/Wash Buffer: 20mM Potassium Phosphate, pH6.6 
Elution Buffer: 20mM Potassium Phosphate, 1M NaCl, pH6.6 
SEC: HiLoad
TM
 16/600 Superdex
TM
 S-75  
Equilibration/Elution Buffer: 1X PBS, pH7.4 
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A5: C3 Preparations 
Anion Exchange Chromatography - Q-Sepharose FastFlow
TM 
Resin 
Equilibration/Wash Buffer: 90% 20mM Tris, 50mM εACA, 5mM EDTA, 0.2mM 
PMSF, 10% Elution Buffer 
Elution Buffer: 20mM Tris, 50mM εACA, 5mM EDTA, 0.2mM PMSF, 1M NaCl 
Anion Exchange Chromatography – TricornTM Mono Q 4.6/100 PE 
Equilibration/Wash Buffer: 95% 20mM Tris, 50mM εACA, 5mM EDTA, 0.2mM 
PMSF, 5% Elution Buffer 
Elution Buffer: 20mM Tris, 50mM εACA, 5mM EDTA, 0.2mM PMSF, 1M NaCl 
 
A6: C3b/C3(N) Preparations 
Anion Exchange Chromatography – TricornTM Mono Q 4.6/100 PE 
Equilibration/Wash Buffer: 20mM Tris, 50mM εACA, 5mM EDTA, 0.2mM PMSF 
Elution Buffer: 20mM Tris, 50mM εACA, 5mM EDTA, 0.2mM PMSF, 1M NaCl 
SEC: HiLoad
TM
 16/600 Superdex
TM
 S-75  
Equilibration/Elution Buffer: 1X PBS, pH7.4 
 
A7: MiniHMM/RLC and cMyBP-C Domain C0 Preparations 
The plasmids for expression of the MiniHMM fragment, cardiac RLC and cMyBP-C 
Domain C0 were provided by Dr Mark Pfuhl, Kings College, London, UK. 
IMAC – Ni-NTA Superflow Cartridge 5mL 
Lysis Buffer: 25mM Hepes, 125mM NaCl, 10% Glycerol, 1mM PMSF, 2 
SigmaFAST
TM
 Protease Inhibitor Cocktail Tablets, EDTA-Free (per 100mL of Lysis 
Buffer),pH6.8                                                                                                           
Equilibration Buffer: 25mM Hepes, 125mM NaCl, 20mM Imidazole, 10% Glycerol, 
pH6.8                                                                                                                            
Wash Buffer: 25mM Hepes, 125mM NaCl, 40mM Imidazole, 10% Glycerol, pH6.8       
Elution Buffer: 25mM Hepes, 125mM NaCl, 500mM Imidazole, 10% Glycerol, pH6.8 
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SEC: HiLoad
TM
 16/600 Superdex
TM
 S-75  
Equilibration/Elution Buffer: 25mM Hepes, 125mM NaCl, 10% Glycerol, pH6.8 
 
A8: 6xhis TEV Protease Preparations 
   A glycerol stock containing Rosetta
TM
 2(DE3) cells successfully transformed with the 
recombinant 6xHIS TEV protease was kindly donated by Dr Huanting Liu and Prof. 
James H. Naismith, University of St Andrews, Scotland, UK.  
Lysis Buffer: 1xPBS, 0.3M NaCl, 10mM Imidazole, 1mM PMSF, 1mM Benzamidine, 
pH7.4 
Equilibration/Wash Buffer: 1xPBS, 0.3M NaCl, 30mM Imidazole, 1mM PMSF, 
1mM Benzamidine, pH7.4 
Elution Buffer: 1xPBS, 0.3M NaCl, 250mM Imidazole, 1mM PMSF, 1mM 
Benzamidine, pH7.4 
Dialysis Buffer 1: 50mM Tris-HCl, 0.3M NaCl, 1mM PMSF, pH7.4 
Dialysis Buffer 2: 50mM Tris-HCl, 0.3M NaCl, 50% Glycerol, pH7.4 
 
A9: Myoglobin Preparations 
   The plasmids pBk-Pyls and pMyo4-TAG-PylT used throughout this work were kindly 
supplied by Prof. Jason Chin. The pBk-Pyls plasmid contains the pyrrolysyl tRNA 
synthetase / tRNACUA(Pyl) pair whilst the pMyo4-TAG-PylT contains the gene for 
recombinant myoglobin expression. 
IMAC – Ni-NTA Superflow Cartridge 5mL 
Lysis Buffer: 50mM Hepes, 125mM NaCl, 10mM Imidazole, 1mM PMSF, 2 
SigmaFAST
TM
 Protease Inhibitor Cocktail Tablets, EDTA-Free (per 100mL Lysis 
Buffer), pH7.0   
 
Equilibration/Wash Buffer: 50mM Hepes, 125mM NaCl, 25mM Imidazole, pH7.0                                      
 
Elution Buffer: 50mM Hepes, 125mM NaCl, 500mM Imidazole, pH7.0 
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SEC: HiLoad
TM
 16/600 Superdex
TM
 S-75  
Equilibration/Elution Buffer: 50mM Hepes, 125mM NaCl, pH7.0 
 
A10: 14-3-3 ϛ Preparations 
Agar plates from the successful transformation of the recombinant 14-3-3 ϛ  proteins 
into Rosetta
TM
 2(DE3) were kindly provided by Dr David Norman, University of 
Dundee, Scotland, UK. From these glycerol stocks were made for subsequent 
expression. 
IMAC: Ni-NTA Superflow Cartridge 5mL 
Lysis Buffer: 50mM Tris-HCl, 100mM NaCl, 1mM PMSF, 2 SigmaFAST
TM
 Protease 
Inhibitor Cocktail Tablets, EDTA-Free (per 100mL of Lysis Buffer), pH7.5                                                                                                        
Equilibration/Wash Buffer: 50mM Tris-HCl, 100mM NaCl, 20mM Imidazole, pH7.5 
Elution Buffer: 50mM Tris-HCl, 100mM NaCl, 500mM Imidazole, pH7.5 
SEC: HiLoad
TM
 16/600 Superdex
TM
 S-75 
Equilibration/Elution Buffer: 50mM Tris-HCl, 100mM NaCl, pH7.5 
 
A11: Vps75 Preparations 
Agar plates from the successful transformation of the recombinant Vps75 proteins into 
Rosetta
TM
 2(DE3) were kindly provided by Dr David Norman, University of Dundee, 
Scotland, UK. From these glycerol stocks were made for subsequent expression. 
IMAC: Ni-NTA Superflow Cartridge 5mL 
Lysis Buffer: 20mM Tris, 500mM NaCl, 1mM PMSF, 2 SigmaFAST
TM
 Protease 
Inhibitor Cocktail Tablets, EDTA-Free (per 100mL of Lysis Buffer), pH7.5 
Equilibration Buffer: 20mM Tris, 500mM NaCl, pH7.5 
Wash Buffer: 20mM Tris, 500mM NaCl, 5mM Imidazole, pH7.5 
Elution Buffer: 20mM Tris, 500mM NaCl, 400mM Imidazole, pH7.5 
SEC: HiLoad
TM
 16/600 Superdex
TM
 S-75 
Equilibration/Elution Buffer: 20mM Tris, 500mM NaCl, pH7.5 
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A12: Media 
LB Broth: 10g Bacto-tryptone, 5g Yeast Extract, 10g NaCl, adjusted to 1000mL with 
ddH2O, pH7.5 
LB Agar: 10g Bacto-tryptone, 5g Yeast Extract, 10g NaCl, 15g agar, adjusted to 
1000mL with ddH2O, pH7.5 
LSLB Broth: 10g Bacto-tryptone, 5g Yeast Extract, 5g NaCl, adjusted to 1000mL with 
ddH2O, pH7.5 
LSLB Agar: 10g Bacto-tryptone, 5g Yeast Extract, 5g NaCl, 15g agar, adjusted to 
1000mL with ddH2O, pH7.5 
BMG Media: Autoclave 700mL ddH2O, cool to r.t before the addition of 100mL 1M 
potassium phosphate buffer, pH6.0, 100mL 10X YNB, 2mL 500X B and 100mL of 10X 
GY. 
BMGY Media: As BMG, but supplemented with 10g Yeast Extract and 20g Bacto-
peptone before autoclaving (20min). 
BMM Media: Autoclave 700mL ddH2O, cool to r.t before the addition of 100mL 1M 
potassium phosphate buffer, pH6.0, 100mL 10X YNB, 2mL 500X B and 100mL of 10X 
M. 
BMMY Media: As BMM, but supplemented with 10g Yeast Extract and 20g Bacto-
peptone before autoclaving (20min). 
YPD Broth: Dissolve 10g Yeast Extract and 20g of Bacto-peptone in 900mL ddH2O. 
Autoclave for 20 min before the addition of 100mL 10X D. 
YPD Agar: As YPD Broth, but supplemented with 20g of agar before autoclaving 
(20min). 
YPDS Broth: Dissolve 10g Yeast Extract, 20g of Bacto-peptone and 182.2g sorbitol in 
900mL ddH2O. Autoclave for 20 min before the addition of 100mL 10X D. 
YPDS Agar: As YPDS Broth, but supplemented with 20g of agar before autoclaving 
(20min). 
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A13: Primers  
Amplification of fH1-4 from full length fH gene  
 
FOR: 5’ gaggattgtaacgagttgccaccaag 3’ 
 
REV: 5’ cttctcttcacaggatggcaatggtc 3’ 
 
 
K247C FOR: 5’ catgatctgcaggagaggattgtaacgagttgccaccaag 3’ 
 
K247C REV: 5’ taataatctagactactaacactcttcacaggatggcaatggtc 3’ 
 
K247CHistag FOR: 5’ catgatctgcaggagaggattgtaacgagttgccaccaag 3’ 
 
K247CHistag REV: 5’ taataatctagactactaatgatgatgatgatgatgacactcttcacaggatggcaatggtc 
3’ 
 
 
Amplification of fH1920 from full length fH gene  
 
FOR: 5’ ggggtccactggtaagtgtggtccacctcc 3’ 
REV: 5’ cccctctcttagcacaagttgggtactcc 3’ 
 
RLC Mutagenesis Primers 
K30C FOR: 5’ ccaggaattttgtgaggccttcactatcatgg 3’ 
K30C REV: 5’ ccatgatagtgaaggcctcacaaaattcctgg 3’ 
E88C FOR: 5’ cctcacaatgtttgggtgtaaacttaagggagcgg 3’ 
E88C REV: 5’ ccgctcccttaagtttacacccaaacattgtgagg 3’ 
E97C FOR: 5’ gcggaccctgaggaatgtattctcaacgcattc 3’ 
E97C REV: 5’ gaatgcgttgagaatacattcctcagggtccgt 3’ 
D117C FOR: 5’ ggggtgctgaaggcttgttacgttcgggaaatgc 3’ 
D117C REV: 5’ gcatttcccgaacgtaacaagccttcagcacccc 3’ 
T125C FOR: 5’ cgggaaatgctgacctgtcaggcggagagg 3’ 
T125C REV: 5’ cctctccgcctgacaggtcagcatttcccg 3’ 
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Sperm Whale Myoglobin Mutagenesis Primers 
S118C FOR: 5’ catgttctgcattgtagacatccagg 3’ 
S118C REV: 5’ cctggatgtctacaatgcagaacatg 3’ 
S4C FOR: 5’ accatggttctgtgtgaaggtgaatgg 
S4C REV: 5’ ccattcaccttcacacagaaccatggt 3’ 
TAG4S FOR: 5’ accatggttctgtctgaaggtgaatgg 
TAG4S REV: 5’ ccattcaccttcagacagaaccatggt 3’ 
S118TAG FOR: 5’ catgttctgcattagagacatccaggt 
S118TAG REV: 5’acctggatgtctctaatgcagaacatg 3’ 
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Appendix B: Protein Sequences (Wild Type) 
B1: Full Length fH, Codon Optimised for Expression in Pichia pastoris 
        10         20         30         40         50         60 
MRLLAKIICL MLWAICVAED CNELPPRRNT EILTGSWSDQ TYPEGTQAIY KCRPGYRSLG  
        70         80         90        100        110        120  
NVIMVCRKGE WVALNPLRKC QKRPCGHPGD TPFGTFTLTG GNVFEYGVKA VYTCNEGYQL 
       130        140        150        160        170        180  
LGEINYRECD TDGWTNDIPI CEVVKCLPVT APENGKIVSS AMEPDREYHF GQAVRFVCNS 
       190        200        210        220        230        240  
GYKIEGDEEM HCSDDGFWSK EKPKCVEISC KSPDVINGSP ISQKIIYKEN ERFQYKCNMG 
       250        260        270        280        290        300  
YEYSERGDAV CTESGWRPLP SCEEKSCDNP YIPNGDYSPL RIKHRTGDEI TYQCRNGFYP 
       310        320        330        340        350        360  
ATRGNTAKCT STGWIPAPRC TLKPCDYPDI KHGGLYHENM RRPYFPVAVG KYYSYYCDEH 
       370        380        390        400        410        420 
FETPSGSYWD HIHCTQDGWS PAVPCLRKCY FPYLENGYNQ NYGRKFVQGK SIDVACHPGY 
       430        440        450        460        470        480 
ALPKAQTTVT CMENGWSPTP RCIRVKTCSK SSIDIENGFI SESQYTYALK EKAKYQCKLG 
       490        500        510        520        530        540  
YVTADGETSG SITCGKDGWS AQPTCIKSCD IPVFMNARTK NDFTWFKLND TLDYECHDGY  
       550        560        570        580        590        600  
ESNTGSTTGS IVCGYNGWSD LPICYERECE LPKIDVHLVP DRKKDQYKVG EVLKFSCKPG  
       610        620        630        640        650        660  
FTIVGPNSVQ CYHFGLSPDL PICKEQVQSC GPPPELLNGN VKEKTKEEYG HSEVVEYYCN  
       670        680        690        700        710        720  
PRFLMKGPNK IQCVDGEWTT LPVCIVEEST CGDIPELEHG WAQLSSPPYY YGDSVEFNCS  
       730        740        750        760        770        780  
ESFTMIGHRS ITCIHGVWTQ LPQCVAIDKL KKCKSSNLII LEEHLKNKKE FDHNSNIRYR  
       790        800        810        820        830        840  
CRGKEGWIHT VCINGRWDPE VNCSMAQIQL CPPPPQIPNS HNMTTTLNYR DGEKVSVLCQ  
       850        860        870        880        890        900  
ENYLIQEGEE ITCKDGRWQS IPLCVEKIPC SQPPQIEHGT INSSRSSQES YAHGTKLSYT  
       910        920        930        940        950        960  
CEGGFRISEE NETTCYMGKW SSPPQCEGLP CKSPPEISHG VVAHMSDSYQ YGEEVTYKCF  
       970        980        990       1000       1010       1020  
EGFGIDGPAI AKCLGEKWSH PPSCIKTDCL SLPSFENAIP MGEKKDVYKA GEQVTYTCAT  
      1030       1040       1050       1060       1070       1080  
YYKMDGASNV TCINSRWTGR PTCRDTSCVN PPTVQNAYIV SRQMSKYPSG ERVRYQCRSP  
      1090       1100       1110       1120       1130       1140  
YEMFGDEEVM CLNGNWTEPP QCKDSTGKCG PPPPIDNGDI TSFPLSVYAP ASSVEYQCQN  
      1150       1160       1170       1180       1190       1200  
LYQLEGNKRI TCRNGQWSEP PKCLHPCVIS REIMENYNIA LRWTAKQKLY SRTGESVEFV  
      1210       1220       1230  
CKRGYRLSSR SHTLRTTCWD GKLEYPTCAK R  
 
 
Molecular weight: 13,9096.3 (actual molecular weight ~155kDa due to glycosylation) 
Theoretical pI: 6.2 
Extinction Coefficient (A280): 247,300 
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B2: fH 1-4 Fragment, Codon Optimised for Expression in Pichia pastoris 
        10         20         30         40         50 
MRLLAKIICL MLWAICVAED CNELPPRRNT EILTGSWSDQ TYPEGTQAIY  
        60         70         80         90        100 
KCRPGYRSLG NVIMVCRKGE WVALNPLRKC QKRPCGHPGD TPFGTFTLTG  
       110        120        130        140        150 
GNVFEYGVKA VYTCNEGYQL LGEINYRECD TDGWTNDIPI CEVVKCLPVT  
       160        170        180        190        200 
APENGKIVSS AMEPDREYHF GQAVRFVCNS GYKIEGDEEM HCSDDGFWSK  
       210        220        230        240        250 
EKPKCVEISC KSPDVINGSP ISQKIIYKEN ERFQYKCNMG YEYSERGDAV  
       260         
CTESGWRPLP SCEEK 
 
 
Molecular weight: 29,972.1 
Theoretical pI: 5.32 
Extinction Coefficient (A280): 52,370  
 
 
B3: fH19-20 Fragment, Codon Optimised for Expression in Pichia pastoris 
      1110       1120       1130       1140       1150 
GKCG PPPPIDNGDI TSFPLSVYAP ASSVEYQCQN LYQLEGNKRI  
      1160       1170       1180       1190       1200 
TCRNGQWSEP PKCLHPCVIS REIMENYNIA LRWTAKQKLY SRTGESVEFV  
      1210       1220       1230  
CKRGYRLSSR SHTLRTTCWD GKLEYPTCAK R    
 
 
Molecular weight: 14,277.2 
Theoretical pI: 9.08 
Extinction Coefficient (A280): 26,930 
 
B4: Complement C3 
   10         20         30         40         50         60  
SPMYSIITPN ILRLESEETM VLEAHDAQGD VPVTVTVHDF PGKKLVLSSE KTVLTPATNH  
 
        70         80         90        100        110        120  
MGNVTFTIPA NREFKSEKGR NKFVTVQATF GTQVVEKVVL VSLQSGYLFI QTDKTIYTPG  
 
       130        140        150        160        170        180  
STVLYRIFTV NHKLLPVGRT VMVNIENPEG IPVKQDSLSS QNQLGVLPLS WDIPELVNMG  
 
       190        200        210        220        230        240  
QWKIRAYYEN SPQQVFSTEF EVKEYVLPSF EVIVEPTEKF YYIYNEKGLE VTITARFLYG  
 
       250        260        270        280        290        300  
KKVEGTAFVI FGIQDGEQRI SLPESLKRIP IEDGSGEVVL SRKVLLDGVQ NPRAEDLVGK  
 
       310        320        330        340        350        360  
SLYVSATVIL HSGSDMVQAE RSGIPIVTSP YQIHFTKTPK YFKPGMPFDL MVFVTNPDGS  
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       370        380        390        400        410        420  
PAYRVPVAVQ GEDTVQSLTQ GDGVAKLSIN THPSQKPLSI TVRTKKQELS EAEQATRTMQ  
 
       430        440        450        460        470        480  
ALPYSTVGNS NNYLHLSVLR TELRPGETLN VNFLLRMDRA HEAKIRYYTY LIMNKGRLLK  
 
       490        500        510        520        530        540  
AGRQVREPGQ DLVVLPLSIT TDFIPSFRLV AYYTLIGASG QREVVADSVW VDVKDSCVGS  
 
       550        560        570        580        590        600  
LVVKSGQSED RQPVPGQQMT LKIEGDHGAR VVLVAVDKGV FVLNKKNKLT QSKIWDVVEK  
 
       610        620        630        640        650        660  
ADIGCTPGSG KDYAGVFSDA GLTFTSSSGQ QTAQRAELQC PQPAASVQLT EKRMDKVGKY  
 
       670        680        690        700        710        720  
PKELRKCCED GMRENPMRFS CQRRTRFISL GEACKKVFLD CCNYITELRR QHARASHLGL  
 
       730        740        750        760        770        780  
ARSNLDEDII AEENIVSRSE FPESWLWNVE DLKEPPKNGI STKLMNIFLK DSITTWEILA  
 
       790        800        810        820        830        840  
VSMSDKKGIC VADPFEVTVM QDFFIDLRLP YSVVRNEQVE IRAVLYNYRQ NQELKVRVEL  
 
       850        860        870        880        890        900  
LHNPAFCSLA TTKRRHQQTV TIPPKSSLSV PYVIVPLKTG LQEVEVKAAV YHHFISDGVR  
 
       910        920        930        940        950        960  
KSLKVVPEGI RMNKTVAVRT LDPERLGREG VQKEDIPPAD LSDQVPDTES ETRILLQGTP  
 
       970        980        990       1000       1010       1020  
VAQMTEDAVD AERLKHLIVT PSGCGEQNMI GMTPTVIAVH YLDETEQWEK FGLEKRQGAL  
 
      1030       1040       1050       1060       1070       1080  
ELIKKGYTQQ LAFRQPSSAF AAFVKRAPST WLTAYVVKVF SLAVNLIAID SQVLCGAVKW  
 
      1090       1100       1110       1120       1130       1140  
LILEKQKPDG VFQEDAPVIH QEMIGGLRNN NEKDMALTAF VLISLQEAKD ICEEQVNSLP  
 
      1150       1160       1170       1180       1190       1200  
GSITKAGDFL EANYMNLQRS YTVAIAGYAL AQMGRLKGPL LNKFLTTAKD KNRWEDPGKQ  
 
      1210       1220       1230       1240       1250       1260  
LYNVEATSYA LLALLQLKDF DFVPPVVRWL NEQRYYGGGY GSTQATFMVF QALAQYQKDA  
 
      1270       1280       1290       1300       1310       1320  
PDHQELNLDV SLQLPSRSSK ITHRIHWESA SLLRSEETKE NEGFTVTAEG KGQGTLSVVT  
 
      1330       1340       1350       1360       1370       1380  
MYHAKAKDQL TCNKFDLKVT IKPAPETEKR PQDAKNTMIL EICTRYRGDQ DATMSILDIS  
 
      1390       1400       1410       1420       1430       1440  
MMTGFAPDTD DLKQLANGVD RYISKYELDK AFSDRNTLII YLDKVSHSED DCLAFKVHQY  
 
      1450       1460       1470       1480       1490       1500  
FNVELIQPGA VKVYAYYNLE ESCTRFYHPE KEDGKLNKLC RDELCRCAEE NCFIQKSDDK  
 
      1510       1520       1530       1540       1550       1560  
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VTLEERLDKA CEPGVDYVYK TRLVKVQLSN DFDEYIMAIE QTIKSGSDEV QVGQQRTFIS  
 
      1570       1580       1590       1600       1610       1620  
PIKCREALKL EEKKHYLMWG LSSDFWGEKP NLSYIIGKDT WVEHWPEEDE CQDEENQKQC  
 
      1630  
QDLGAFTESM VVFGCPN  
 
Molecular weight: 184,326.5 
Theoretical pI: 5.85 
Extinction Coefficient (A280): 180,550 
 
B5: Complement C3b 
10         20         30         40         50         60  
SPMYSIITPN ILRLESEETM VLEAHDAQGD VPVTVTVHDF PGKKLVLSSE KTVLTPATNH  
 
        70         80         90        100        110        120  
MGNVTFTIPA NREFKSEKGR NKFVTVQATF GTQVVEKVVL VSLQSGYLFI QTDKTIYTPG  
 
       130        140        150        160        170        180  
STVLYRIFTV NHKLLPVGRT VMVNIENPEG IPVKQDSLSS QNQLGVLPLS WDIPELVNMG  
 
       190        200        210        220        230        240  
QWKIRAYYEN SPQQVFSTEF EVKEYVLPSF EVIVEPTEKF YYIYNEKGLE VTITARFLYG  
 
       250        260        270        280        290        300  
KKVEGTAFVI FGIQDGEQRI SLPESLKRIP IEDGSGEVVL SRKVLLDGVQ NPRAEDLVGK  
 
       310        320        330        340        350        360  
SLYVSATVIL HSGSDMVQAE RSGIPIVTSP YQIHFTKTPK YFKPGMPFDL MVFVTNPDGS  
 
       370        380        390        400        410        420  
PAYRVPVAVQ GEDTVQSLTQ GDGVAKLSIN THPSQKPLSI TVRTKKQELS EAEQATRTMQ  
 
       430        440        450        460        470        480  
ALPYSTVGNS NNYLHLSVLR TELRPGETLN VNFLLRMDRA HEAKIRYYTY LIMNKGRLLK  
 
       490        500        510        520        530        540  
AGRQVREPGQ DLVVLPLSIT TDFIPSFRLV AYYTLIGASG QREVVADSVW VDVKDSCVGS  
 
       550        560        570        580        590        600  
LVVKSGQSED RQPVPGQQMT LKIEGDHGAR VVLVAVDKGV FVLNKKNKLT QSKIWDVVEK  
 
       610        620        630        640        650        660  
ADIGCTPGSG KDYAGVFSDA GLTFTSSSGQ QTAQRAELQC PQPAARRRRS NLDEDIIAEE  
 
       670        680        690        700        710        720  
NIVSRSEFPE SWLWNVEDLK EPPKNGISTK LMNIFLKDSI TTWEILAVSM SDKKGICVAD  
 
       730        740        750        760        770        780  
PFEVTVMQDF FIDLRLPYSV VRNEQVEIRA VLYNYRQNQE LKVRVELLHN PAFCSLATTK  
 
       790        800        810        820        830        840  
RRHQQTVTIP PKSSLSVPYV IVPLKTGLQE VEVKAAVYHH FISDGVRKSL KVVPEGIRMN  
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       850        860        870        880        890        900  
KTVAVRTLDP ERLGREGVQK EDIPPADLSD QVPDTESETR ILLQGTPVAQ MTEDAVDAER  
 
       910        920        930        940        950        960  
LKHLIVTPSG CGEQNMIGMT PTVIAVHYLD ETEQWEKFGL EKRQGALELI KKGYTQQLAF  
 
       970        980        990       1000       1010       1020  
RQPSSAFAAF VKRAPSTWLT AYVVKVFSLA VNLIAIDSQV LCGAVKWLIL EKQKPDGVFQ  
 
      1030       1040       1050       1060       1070       1080  
EDAPVIHQEM IGGLRNNNEK DMALTAFVLI SLQEAKDICE EQVNSLPGSI TKAGDFLEAN  
 
      1090       1100       1110       1120       1130       1140  
YMNLQRSYTV AIAGYALAQM GRLKGPLLNK FLTTAKDKNR WEDPGKQLYN VEATSYALLA  
 
      1150       1160       1170       1180       1190       1200  
LLQLKDFDFV PPVVRWLNEQ RYYGGGYGST QATFMVFQAL AQYQKDAPDH QELNLDVSLQ  
 
      1210       1220       1230       1240       1250       1260  
LPSRSSKITH RIHWESASLL RSEETKENEG FTVTAEGKGQ GTLSVVTMYH AKAKDQLTCN  
 
      1270       1280       1290       1300       1310       1320  
KFDLKVTIKP APETEKRPQD AKNTMILEIC TRYRGDQDAT MSILDISMMT GFAPDTDDLK  
 
      1330       1340       1350       1360       1370       1380  
QLANGVDRYI SKYELDKAFS DRNTLIIYLD KVSHSEDDCL AFKVHQYFNV ELIQPGAVKV  
 
      1390       1400       1410       1420       1430       1440  
YAYYNLEESC TRFYHPEKED GKLNKLCRDE LCRCAEENCF IQKSDDKVTL EERLDKACEP  
 
      1450       1460       1470       1480       1490       1500  
GVDYVYKTRL VKVQLSNDFD EYIMAIEQTI KSGSDEVQVG QQRTFISPIK CREALKLEEK  
 
      1510       1520       1530       1540       1550       1560  
KHYLMWGLSS DFWGEKPNLS YIIGKDTWVE HWPEEDECQD EENQKQCQDL GAFTESMVVF  
 
 
GCPN  
 
 
Molecular weight: 176,774.7 
Theoretical pI: 5.64 
Extinction Coefficient (A280): 176,700 
 
B6: 14-3-3 ϛ 
        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MDKNELVQKA KLAEQAERYD DMAAAMKSVT EQGAELSNEE  
        70         80         90        100        110        120  
RNLLSVAYKN VVGARRSSWR VVSSIEQKTE GAEKKQQMAR EYREKIETEL RDIANDVLSL  
       130        140        150        160        170        180  
LEKFLIPNAS QAESKVFYLK MKGDYYRYLA EVAAGDDKKG IVDQSQQAYC CAFEISKKEM  
       190        200        210        220        230        240  
QPTHPIRLGL ALNFSVFYYE ILNSPEKAAS LAKTAFDEAI AELDTLSEES YKDSTLIMQL  
       250  
LRDNLTLWTS  
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Molecular weight: 28,300.9 
Theoretical pI: 5.81 
Extinction Coefficient (A280): 27,390 
 
 
B7: Vps75 
        10         20         30         40         50         60  
MSYYHHHHHH DYDIPTTENL YFQGAMADIG SMMSDQENEN EHAKAFLGLA KAEEEVDAIE  
        70         80         90        100        110        120  
REVELYRLNK MKPVYEKRDA YIDEIAEFWK IVLSQHVSFA NYIRASDFKY IDTIDKIKVE  
       130        140        150        160        170        180  
WLALESEMYD TRDFSITFHF HGIEGDFKEQ QVTKVFQIKK GKDDQEDGIL TSEPVPIEWP  
       190        200        210        220        230        240  
QSYDSINPDL IKDKRSPEGK KKYRQGMKTI FGWFRWTGLK PGKEFPHGDS LASLFSEEIY  
       250        260        270  
PFAVKYYAEA QRDLEDEEGE SGLSADGDSE G  
 
 
Molecular weight: 31581.0 
Theoretical pI: 4.82 
Extinction Coefficient (A280): 49,850 
 
 
B8: Myoglobin 
       10         20         30         40         50         60  
MVLSEGEWQL VLHVWAKVEA DVAGHGQDIL IRLFKSHPET LEKFDRFKHL KTEAEMKASE  
        70         80         90        100        110        120  
DLKKHGVTVL TALGAILKKK GHHEAELKPL AQSHATKHKI PIKYLEFISE AIIHVLHSRH  
       130        140        150        160  
PGDFGADAQG AMNKALELFR KDIAAKYKEL GYQGGSGHHH HHH  
 
Molecular weight: 18355.1 
Theoretical pI: 8.70 
Extinction Coefficient (A280): 15,470 (A409): 125,000 
 
B9: Myosin Regulatory Light Chain 
        10         20         30         40         50         60  
MAPKKAKKRA GGANSNVFSM FEQTQIQEFK EAFTIMDQNR DGFIDKNDLR DTFAALGRVN  
        70         80         90        100        110        120  
VKNEEIDEMI KEAPGPINFT VFLTMFGEKL KGADPEETIL NAFKVFDPEG KGVLKADYVR  
       130        140        150        160  
EMLTTQAERF SKEEVDQMFA AFPPDVTGNL DYKNLVHIIT GEEKD  
 
Molecular weight: 18,652.1 
Theoretical pI: 4.82 
Extinction Coefficient (A280):  This protein does not contain any Trp residues.  
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As the RLC makes a complex with MiniHMM this is taken into consideration when 
calculating the Extinction Coefficient. 
 
 
B10: MiniHMM 
        10         20         30         40         50         60  
MHHHHHHSTE NLYFQGSSER RDSLLVIQWN IRAFMGVKNW PWMKLYFKIK PLLKSAEREK  
        70         80         90        100        110        120  
EMASMKEEFT RLKEALEKSE ARRELEEKMV SLLQEKNDLQ LQVQAEQDNL ADAEERCDQL  
       130        140        150        160        170  
IKNKIQLEAK VKEMNERLED EEEMNAELTA KKRKLEDECS ELKRDIDDLE LTLAK 
 
 
Molecular weight: 20,939.8 
Theoretical pI: 5.41 
Extinction Coefficient (A280): 19,480 
 
For the RLC/MiniHMM complex, which are co-expressed, the Extinction Coefficient 
(A280) used is 20,970. This is for half of the complex (one heavy chain + one rMLC). 
Molecular weight without of Histag is 37785.1. 
 
B11: cMyBP-C Domain C0 
        10         20         30         40         50         60  
MHHHHHHSSG VDLGTENLYF QSMPEPGKKP VSAFSKKPRS VEVAAGSPAV FEAETERAGV  
        70         80         90        100        110        120  
KVRWQRGGSD ISASNKYGLA TEGTRHTLTV REVGPADQGS YAVIAGSSKV KFDLKVIEGS  
 
TREEF 
 
Molecular weight: 13,520.0 
Theoretical pI: 8.07 
Extinction Coefficient (A280): 9,970 
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Appendix C: Making Chemically Competent Cells 
For the preparation of Top 10, BL21, BL21 (*) and DH10β E. coli cells 
 
Table B.1 Media and Buffers for Cell Preparation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An aliquot of each cell line (purchased from Invitrogen Technologies) was used to 
streak some working material onto SOB agar and cells were grown at r.t to obtain single 
colonies. A single colony was used to inoculate 2ml of SOB-medium and the culture 
shaken overnight at r.t. To 250 mL of fresh SOB-medium, 1mL of the overnight culture 
was added and cells grown until an OD600 of 0.3 was reached. 
Media/Buffer Composition 
SOB 1.25g yeast extract 
 5g tryptone 
 150mg NaCl 
 50mg KCl 
 60mg MgSO4 
 ad 250mL ddH2O 
 Adjust pH 7.5 with 1 M NaOH 
For agar add 15 g agar per 1000mL 
SOC As above supplemented with 20mM glucose 
CCMB80 Buffer 10 ml 1M KOAc pH 7.0 
 80 mM CaCl2.2H2O 
 20 mM MnCl2.4H2O 
 10 mM MgCl2.6H2O 
 100 mL sterile glycerol 
 adjusted to 1000mL with ddH2O 
 and adjust pH 6.4 with 0.1 M HCl 
 Sterile filter – store 4oC 
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Cells were spun at 3000g at 4
o
C for 10 min to pellet cells. Cells were resuspended in 80 
mL of ice cold CCMB80 Buffer and incubated on ice for 20 min. Cells were spun again 
and resuspended in 10 ml of ice-cold CCMB80 Buffer. The OD600 of 50µL of the 
resuspended cells mixed with 200µL of SOC was taken, and all cells diluted to yield a 
final OD600 with this test of between 1.0 and 1.5. Cells were incubated on ice for 20 min 
and aliquoted into 50µL volumes and stored at -80
o
C. 
Efficiency of cells was tested by transforming cells with 1µL of standard pUC19 control 
plasmid (Life Technologies). 
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Appendix D: Protein Sequence Analysis by Mass Spectrometry 
Sample Preparation for Trypsin Digest 
Using standard methods, the protein sample being tested was run on SDS-PAGE in high 
enough quantity to produce a clean sharp band and the gel stained with GelCode Blue 
(Pierce ) for 1hr and de-stained in ddH2O for a further hour. Any tryptic mapping was 
done for the C3b protein sample which is shown as 2 separate bands on SDS PAGE.     
   Each band was excised separately and tightly avoiding excess acrylamide. Bands were 
incubated separately in 300µL of 200mM NH4HCO3 (ABC) in 50% Acetonitrile 
(ACN) at r.t for 30 min. This step was repeated twice, changing solutions in between to 
remove excess SDS. Gel pieces were the incubated in 300µL of 20mM DTT, 200mM 
ABC, 50% ACN at 32
o
C for 1hr to reduce disulphides in the protein.  
   Three washes each with 300µL of 200mM ABC.50% CAN were carried out and 
100µL of 50mM iodoacetamide , 200mM ABC.50%ACN added and left at r.t in the 
dark for 20 min. The gel pieces were then washed in 500µL of 20mM ABC.50%ACN 
three times and bands cut into pieces of approximately 2mm x 1mm in size. Gel pieces 
were spun at 13,000rpm for 2min and gel pieces covered in ACN, turning gel pieces 
white. ACN was decanted gel pieces allowed to dry.  
   To a vial of Promega mass spectrometry grade trypsin, 50µL of 50mM ABC was 
added, and gel pieces swollen in a mix of 58µL 50mM ABC and 2µL Trypsin at 4
o
C. 
After visible swelling of the gel pieces, the tubes were sealed with Nesco-film
TM
 and 
incubated at 32
o
C for 24hr. Samples were then sonicated using a sonicating water bath 
and given to the SIRCAMS facility to run. (University of Edinburgh). 
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Appendix E: Forms in Support of Ethics Application PA10837 
E1: Participant Information Sheet 
 
Participant Information  
Sheet 
 
Project Title  
Isolation and purification of complement protein C3b from human blood/plasma 
What is the study about?  
 
We invite you to participate in a research project where we extract human blood for the 
purpose of purifying proteins of interest (namely complement protein C3b) for use in 
structural analysis. 
 
This study is being conducted as part of my PhD Thesis in the School of Physics & Astronomy. 
 
Do I have to take Part? 
 
This information sheet has been written to help you decide if you would like to take part.   It is 
up to you and you alone whether or not to take part.   If you do decide to take part you will be 
free to withdraw at any time without providing a reason.    
 
What would I be required to do? 
 
You will be invited to the medical school at the North Haugh where a trained individual will 
extract ~20ml of blood from you. This will be done in sterile conditions, similar to those used 
when extracting blood for medical purposes or for donation.  
 
Will my participation be Anonymous and Confidential? 
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Your participation will be entirely anonymous, as it will not be possible to identify any 
participants from their samples as all samples will be pooled, before purifying the desired 
proteins from the pool. Any data generated as a result will be used in PhD thesis and potential 
future publications but again I stress that your sample will not be identifiable in publication, or 
to the researcher working on the project. 
 
Storage and Destruction of Data Collected 
 
No ‘data’ as such is generated from the project. There will be basic assays carried out in order 
to assess the quality of protein purified and to determine whether we need to adjust our 
purification protocols. Any methods used in doing so will be published in future publication as 
well as included in the final PhD thesis. Again though, no information on any specific 
participant will be stored, as the desired end product is purified from a pooled blood sample 
from multiple participants. 
 
What will happen to the results of the research study? 
 
The results will be finalised by 2015 and written up as part of my PhD Thesis. 
 
 
 
 
 
Are there any potential risks to taking part? 
 
There are no potential risks in taking part, though the subject may experience brief discomfort 
during the blood extraction due to the use of needles. There are no risks involved with the 
procedure as all participants have blood taken from a trained individual. The technique is done 
in sterile conditions with new sharps used for each participant, and used sharps disposed of 
immediately and safely. Used sharps are then incinerated departmentally. 
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Questions 
 
You will have the opportunity to ask any questions in relation to this project before completing 
a Consent Form. 
 
Consent and Approval 
 
 
This research proposal has been scrutinised and been granted Ethical Approval through the 
University ethical approval process. 
 
 
What should I do if I have concerns about this study? 
 
A full outline of the procedures governed by the University Teaching and Research Ethical 
Committee is available at http://www.st-andrews.ac.uk/utrec/Guidelines/complaints/ 
 
Contact Details  
 
Researcher:  Stacey Bell  
Contact Details:         sb258@st-andrews.ac.uk 
Supervisor:  Graham Smith 
Contact Details:         GMS@st-andrews.ac.uk            01334 462669 
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E2: Supervisor  Statement in Support of Ethics Application PA10837 
(gms@st-andrews.ac.uk – Graham Smith)                                  
Project : Isolation and Purification of Complement Protein C3b from human 
blood/plasma.                                       
Researcher : Stacey Bell (sb258@st-andrews.ac.uk)                                                                                                       
School of Physics and Astronomy 
 
Having reviewed all aspects of this project and the associated risks involved, I can 
approve this application. Potential risks have been identified, and how these will be 
addressed is covered extensively throughout the submitted application. This particular 
protein cannot be made using recombinant methods, and so must be purified directly 
from source, which in this instance is human blood/plasma. This coupled with our 
interest in studying the human protein, means that there is no alternative other than 
purification from blood extracted from human participants.  
Submitted with this application is the relevant documentation outlining the nature of 
the procedure to the participants, alongside relevant consent form. The participants 
are under no obligation to proceed, and are assured they can withdraw at any time. 
Blood is being taken by a trained individual from willing and informed donors, with 
volumes of blood not exceeding levels which could detrimentally affect the wellbeing 
of the participant. For these reasons I see no reason why this application should not be 
granted ethical approval. 
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E3: Participant Consent Form 
 
Participant Consent Form 
Anonymous Data 
 
 
Project Title  
Isolation and Purification of Complement Protein C3b from human blood/plasma. 
 
Researcher(s) Name(s)  
Stacey Bell (sb258@st-andrews.ac.uk) 
Supervisors Names 
Janet E Lovett 
(janet.lovett@ed.ac.uk) 
Graham Smith (gms@st-
andrews.ac.uk) 
 
The University of St Andrews attaches high priority to the ethical conduct of research.  We 
therefore ask you to consider the following points before signing this form. Your signature 
confirms that you are happy to participate in the study. 
 
What is Anonymous Data? 
 
The term ‘Anonymous Data’ refers to data collected by a researcher that has no identifier 
markers so that even the researcher cannot identify any participant.  Consent is still 
required by the researcher, however no link between the participant’s signed consent and 
the data collected can be made. 
 
Consent 
 
The purpose of this form is to ensure that you are willing to take part in this study and to let 
you understand what it entails.   Signing this form does not commit you to anything you do 
not wish to do. 
 
Material gathered during this research will be anonymous, so it is impossible to trace back 
to you. Blood will be taken from multiple participants and pooled together, and so it is 
impossible to identify any one participant from the pooled samples. After the desired protein 
has been isolated by multiple purification methods, it is necessary to assess the success of 
these purification protocols using basic lab techniques. Any data gathered from these 
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techniques will definitely be used outlining our methods in PhD theses, as well as potential 
usage in future publication. It is important to state however, that at no time is any one 
individual’s sample identifiable from any other. 
 
I have read and understood the information sheet.   
I have been given the opportunity to ask questions about the study.   
I have had my questions answered satisfactorily.   
I understand that I can withdraw from the study without having to give an explanation.   
I understand that my data once processed will be anonymous and that only the 
researcher(s) (and supervisors) will have access to the raw data which will be kept 
confidentially. 
  
I agree to my data (in line with conditions outlined above) being kept by the researcher and 
being archived and used for further research projects / by other bona fide researchers.   
  
I have been made fully aware of the potential risks associated with this research and am 
satisfied with the information provided. 
  
I agree to take part in the study   
   
 
 
Participation in this research is completely voluntary and your consent is required before 
you can participate in this research.   
 
 
 
 
 
Name in Block 
Capitals 
 
Signature 
 
Date 
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Appendix F: Record of Personal Development  
CONFERENCES ATTENDED  
- Annual Meeting of the St Andrews Centre of Magnetic Resonance (2012, 2013, 2014, 2015). 
-Annual International Meeting of the ESR Spectroscopy Group of the Royal Society of 
Chemistry (Warwick 2012, Dundee 2014, Southampton 2015).  
- IXth EF-EPR 2014 conference (Marseille 2014). 
 
PRESENTATIONS  
- Annual Meeting of the St Andrews Centre of Magnetic Resonance (2014, 2015 – poster 
presentations).  
- Annual International Meeting of the ESR Spectroscopy Group of the Royal Society of 
Chemistry (Warwick 2012, Dundee 2014, Southampton 2015 – poster presentations).  
- IXth EF-EPR 2014 conference (Marseille 2014 – poster presentation).  
- University of Edinburgh, Departmental Talk – Using EPR Spectroscopy as a tool to study the 
protein – protein interactions in large biomacromolecular complexes (2011, 2012).  
- University of St Andrews, Departmental Talk – Using EPR Spectroscopy as a tool to study the 
protein - protein interaction in large biomacromolecular complexes (2015). 
 - University of Edinburgh, School of Chemistry (organic section) conference, Firbush Outdoor 
Retreat Centre, (2013). 
 
PRIZES AWARDED  
- Annual Meeting of the St Andrews Centre of Magnetic Resonance, 2014 poster prize.  
 
‘Site-Directed Spin-Labelling : Cysteine Substitution Mutagenesis V.S. Genetic Code Expansion’ 
PUBLIC ENGAGEMENT & OUTREACH  
- Volunteer at the Edinburgh International Science Festival for two consecutive years, 
representing the University of Edinburgh, The Royal Society of Chemistry, and the BBC.  
- Volunteer for the Solar Sparks, which involved visiting schools in Fife, teaching children from 
4-11 about sustainability and renewable energy. 
 
SCIENCE WRITING & COMMUNICATION  
- Contributions to the University of St Andrews ‘Sci@StAnd’ science publication. 
 
TEACHING & MENTORING  
- During my PhD, I have been fortunate to be employed by the University of Edinburgh as a 
part-time demonstrator to undergraduate students in both the schools of Biology and Chemistry.  
- I have been responsible for the supervision and mentoring of three final year undergraduate 
students, each for a period of 4 months, in a research project on which their dissertations are 
based, and which contributes significantly to their final degree.  
- I have also been the mentor to a visiting scholar at the University of St Andrews, from ETH in 
Zurich for a period of 6 months, introducing him to the field of molecular biology.  
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